**COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS**

This section provides the terms and conditions under which prescription services will be paid by the Medicaid program and a description of the authorized benefits for eligible beneficiaries.

**Terms and Conditions**

**Licensed Prescribers**

Payment will be made for prescription services only when issued by a licensed prescribing practitioner who has an active Medicaid prescriber number. (Refer to Section 37.5.6 - Prescribers for detailed information about prescribers).

**Eligible Beneficiaries**

The Medicaid program will only reimburse pharmacy claims when the beneficiary is eligible on the date of service. Pharmacy claims submitted with a date of service after a beneficiary’s date of death are not allowed. (Refer to Chapter 1 – General Information and Administration of the *Medicaid Services Manual* for additional information on Medicaid eligibility).

**Rebate Agreements**

In accordance with Section 4401 of the Omnibus Budget Reconciliation Act of 1990 (OBRA ‘90), the Medicaid program will pay only for those drug products for which the pharmaceutical company has entered into a federal rebate agreement withthe U.S. Department of Health and Human Services (DHHS).

**NOTE**: The listing of Medicaid drug federal rebate participating pharmaceutical companies can be accessed at: [[www.lamedicaid.com/Provweb1/Forms/Drug\_appendices/APNDC.pdf](http://www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDC.pdf)](http://www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDC.pdf). This listing is updated periodically and is posted on the Louisiana Medicaid website. **Providers should take note of the effective dates of the labeler codes.**

Coverage will be provided for those drug products labeled by the pharmaceutical companies that have entered into a rebate agreement. As new pharmaceutical companies enter into rebate agreements, labeler codes will be added.

The therapeutic categories, e.g., cough and cold preparations, anorexics and cosmetic drugs, will remain non-payable.The *Medicaid Drug Federal Rebate Participation Pharmaceutical Companies* listing and additional information can be accessed at: [[www.lamedicaid.com/Provweb1/Forms/Drug\_appendices/APNDC.pdf](http://www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDC.pdf)](http://www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDC.pdf) or by visiting Section 37.5.1 of this manual chapter.

**Medically Accepted Indications**

A drug must be medically necessary and prescribed for medically accepted indications to be eligible for reimbursement.

As defined by Section 1927(k)(6) of the Social Security , the term “medically accepted indication” means any use for a covered outpatient drug which is approved by the Food and Drug Administration (FDA) under the Federal Food, Drug and Cosmetic Act or the use of which is supported by one or more citations included or approved for inclusion in any of the following compendia: *American Hospital Formulary Service Drug Information, United States Pharmacopeia – Drug Information* (or its successor publications),and *DRUGDEX Information System.*

**Drug Utilization Review**

OBRA ‘90 also requires that states have a Drug Utilization Review (DUR) program in place and that this program assures that prescriptions are appropriate, are medically necessary and not likely to result in adverse medical results. The DUR program must include prospective drug review, retrospective drug review, and an educational program. (Refer to Section 37.5.12 - Patient Counseling, DUR for detailed information regarding DUR).

**Patient Counseling Requirement**

The Louisiana Board of Pharmacy’s regulations require patient counseling, patient profiles, and prospective drug review, in accordance with OBRA ‘90.

**Patient Counseling Documentation**

Section 1927(g)(2)(ii)(I) of OBRA ‘90 requires that the pharmacist offer to discuss with each Medicaid beneficiary or a caregiver, in person whenever practicable, or by toll-free telephone for long distance calls, matters which, in their professional judgment, the pharmacist deems significant. Such counseling is subject to standards for counseling in accordance with the Louisiana Board of Pharmacy Regulations at LAC, 46:LIII, §517. Such counseling is to be provided unless refused by the beneficiary or caregiver. The Pharmacy Program will require counseling documentation for all prescriptions reimbursed by Louisiana Medicaid. According to the patient counseling standards in the OBRA’90, patient counseling begins with, and focuses on providing information related to the immediately prescribed drug. The only documentation required is a “yes” or “no” checked on the form next to the patient’s signature to indicate whether they accepted the offer to provide this information. Counseling records must be retained in the pharmacy for five years from the date of payment and must be readily retrievable upon audit.

**NOTE:** Refer to Section 37.5.12 of this manual chapter for detailed information.

**Pharmacy Signature and Delivery Logs**

Pharmacy providers must obtain a signature from the patient or caregiver confirming the receipt of the prescription(s). This applies to all prescription pick-ups, home and facility deliveries. Claim submission is not proof that the prescription(s) or prescription order was actually furnished.

**Pharmacy Pick-up**

1. Signature log documentation should include the prescription number(s) and the date the prescription was picked up. If multiple prescriptions are being picked up at one time, a single signature will be sufficient for all of the patient’s prescriptions;
2. Electronic signatures for receipt are permitted only if retrievable upon audit and kept on file by the pharmacy;
3. Obtaining a signature to confirm receipt of prescription(s) can be part of a counseling log; and
4. Signature confirmation must be maintained by the dispensing pharmacy for five years from the date of payment and must be retrievable upon audit.

**Facility Delivery/Mail Order/Specialty**

1. A signature is required at the time of delivery;
2. Signature documentation must also include the list of prescription number(s) and date the medication(s) was/were delivered. A single signature will be sufficient for all the medication in the delivery;
3. Electronic signatures for receipt or electronic tracking slips for delivery are permitted only if retrievable on audit;
4. A waiver signature form is not an acceptable practice and such forms will not serve as confirmation of delivery; and
5. Confirmation of the delivery must be maintained by the pharmacy for five years from the date of payment and must be retrievable on audit. Delivery industry tracking receipts that contain a signature (e.g., FedEx, UPS, and USPS) qualify as a signature for receipt of delivery.

**Home Delivery**

1. If a pharmacy provider chooses to have a pharmacy representative deliver prescription(s) to a beneficiary’ s home, the pharmacy should inform the beneficiary or designee of the pharmacy’s delivery schedule, verify the date and location for the delivery, and notify the beneficiary or designee that a signature will be required at the time of delivery; and
2. The pharmacy representative will obtain a signature from the beneficiary or their designee confirming the delivery. A waiver signature form is not an acceptable practice, and such forms will not serve as confirmation of delivery. Delivery confirmation must be maintained by the pharmacy for five years from the date of payment and must be retrievable upon audit. Electronic signatures for receipt are permitted only if retrievable and kept on file by the pharmacy.

**Prescription Duration**

Scheduled narcotic prescriptions must be filled within six (6) months of the date issued, excluding Schedule II narcotic prescriptions. Schedule II narcotic prescriptions will expire 90 days after the date of issue in accordance with the Louisiana Board of Pharmacy regulations. Prescriptions for non-controlled substances expire after 11 authorized refills or one year after the date prescribed, whichever occurs first.

**Prescription Transfers**

The transfer of prescriptions, including those for Schedule III-V narcotics, must be in accordance with the Louisiana Board of Pharmacy regulations.

**Date of Service**

The date of service is based on the adjudication process. The pharmacy staff should evaluate any prospective warnings or alerts based on internal software, or the Louisiana Program response generated during the claim submission. Based on this clinical review, the date the prescription was adjudicated is the service date except when long-term care eligibility determination is delayed.

**Prescription Refills**

Prescription refills can be provided if they are authorized specifically by the prescribing practitioner. Prescriptions for non-controlled substances have a one-year expiration and an 11-refill maximum from the date prescribed, whichever occurs first.

Refills for Scheduled III-V narcotics have a six (6) month expiration and a five refill maximum from the date prescribed, whichever occurs first.

**No refills are allowed on Schedule II prescriptions.**

**National Drug Code**

In order to be reimbursed for a pharmacy claim, prescribed items must have an assigned National Drug Code (NDC).

**Prescriptions Received via Telecommunication**

Most prescriptions are acceptable when received by telephone or other telecommunication device in accordance with state and federal regulations. Providers must file and log prescriptions received via telecommunication as they would any other written or electronic prescriptions.

**Tamper Resistant Prescription Policy**

Written, non-electronic prescriptions for Medicaid beneficiaries are required to be written on tamper-resistant pads.

The “Transitional Medical Assistance (TMA), Abstinence Education and QI Program Extension Act of 2007” (H.R. 3668) and the “U.S. Troop Readiness, Veterans’ Health Care, Katrina Recovery and Iraq Accountability Appropriations Act of 2007” (H.R. 2206) states that all handwritten prescriptions or those printed from an electronic medical record (EMR), or an ePrescribing application must contain all three characteristics listed below. Exceeding these guidelines is permissible if:

1. One or more industry-recognized features designed to prevent unauthorized copying of a completed or blank prescription form;
2. One or more industry-recognized features designed to prevent the erasure or modification of information written on the prescription by the prescriber; and
3. One or more industry-recognized features designed to prevent the use of counterfeit prescription forms.

This provision applies to all written (non-electronic) prescriptions for outpatient drugs including over-the-counter drugs reimbursed by Pharmacy Program, regardless of whether Medicaid is the primary or secondary payer.

It is the responsibility of the prescriber to obtain and purchase tamper-resistant prescription pads.

**NOTE**: The *Table of Tamper Resistant Prescription Criteria and Examples* can be accessed in Section 37.5.12 at: [www.lamedicaid.com/Provweb1/manuals/App\_L\_Tamper\_Res\_Prescription.pdf](http://www.lamedicaid.com/Provweb1/manuals/App_L_Tamper_Res_Prescription.pdf)

**Excluded Prescriptions**

The tamper-resistant requirement does not apply to prescriptions which are communicated by the prescriber to the pharmacy electronically, verbally or by facsimile.

**Confirming Non-Compliant Prescriptions**

If a prescription does not meet the requirements for tamper-resistance, pharmacies may obtain verbal confirmation and document appropriately. The pharmacy does not need to speak with the prescriber directly. They may receive confirmation from a nurse or administrative staff person who has authority to act on behalf of the prescriber.

**Emergency Fills**

Emergency fills with non-compliant written prescriptions are permissible as long as the prescriber provides a verbal, faxed, electronic or compliant written prescription within 72 hours after the date on which the prescription was filled. If an emergency fill is confirmed with a verbal order, the pharmacist must document the call on the face of the written prescription.

**Authorized Benefits**

Provided below are the authorized medications and/or supplies which are payable under Louisiana Medicaid.

**NOTE**: Refer to “Quantity Limitations” in this section and Section 37.3 - Reimbursement Services for detailed information regarding authorized benefits.

**Legend Drugs**

Legend drugs are drugs that require a prescription or that have the following statement on the label, “Caution: Federal law prohibits dispensing without a prescription.” Medicaid reimbursement is available for most legend drugs that are dispensed in outpatient settings.

**NOTE**: Refer to “Non-Covered Services” in this section for detailed information regarding legend drugs.

**Legend Vitamin and Mineral Products**

Only the following legend vitamin and mineral products will be reimbursed by the Pharmacy Program:

|  |  |  |
| --- | --- | --- |
| Vitamin B 12 preparations | Vitamin E preparations | Pediatric vitamin preparations |
| Vitamin A preparations | Vitamin K preparations | Legend prenatal vitamins for pregnant and lactating beneficiaries |
| Vitamin B preparations | Calcium replacement | Magnesium salt replacement |
| Vitamin B1 preparations | Folic Acid preparation | Prescription strength fluoride as a single entity |
| Vitamin B6 preparations | Geriatric vitamin preparations | Urinary pH modifiers (Phosphorus) |
| Vitamin C preparations | Multivitamin preparations |  |
| Vitamin D preparations | Niacin preparations |  |

Select multivitamins may be subject to clinical/prior authorization (PA) and Point of Sale (POS) edits. Multivitamins DermacinRX (Davimet TM) and DermacinRx (MultitamTM) have a clinical authorization and quantity limit requirement.

**Injectable Drugs**

Reimbursement is provided for most injectable drugs for outpatient beneficiaries when supplied by community pharmacies, long-term care (LTC) pharmacies, and home infusion pharmacies that are enrolled as Medicaid providers.

Some antibiotic and oncologic injections administered in practitioners offices and clinics are reimbursed through the Professional Services Program.

**Non-Legend Drugs**

Only a limited number of non-legend or over-the-counter (OTC) drugs can be reimbursed by the Louisiana Medicaid program. For Medicaid reimbursement, these drugs must be prescribed by licensed practitioners. **Providers must bill the NDC from the actual package dispensed**. **Also, the drug manufacturer must participate in the federal rebate program.**

The following non-legend drugs are covered when an authorized prescriber has written a prescription:

1. Insulin;
2. Sodium chloride solution for inhalation therapy;
3. Contraceptives, topical;
4. Urinary pH modifiers; and
5. Other non-legend drugs that have Pharmacy Program approval.

**Non-Legend Items and Supplies**

Only a limited number of non-legend items and supplies can be reimbursed by the Medicaid Program. In order to receive Medicaid reimbursement, these items and supplies must be prescribed by licensed practitioners. (**Providers must bill the NDC from the actual package dispensed):**

1. OTC Vitamin D preparations;
2. OTC Vitamin E preparations;
3. OTC Niacin preparations;
4. OTC Calcium replacement agents;
5. OTC Magnesium replacement agents;
6. OTC Phosphate replacement agents;
7. OTC Iron replacement agents;
8. Normal saline and heparin flushes;
9. Disposable needles and syringes used to administer insulin;
10. Test strips for determining blood glucose levels;
11. Lancets;
12. Urine test strips (e.g., Clinitest® and Clinistix®);
13. Family planning items; and
14. Other non-legend items and supplies that have Pharmacy Program approval.

**Total Parenteral Nutrition**

Total Parenteral Nutrition (TPN) and associated supplies and equipment are covered services in the Pharmacy Program. (Refer to Section 37.5.10 - Total Parenteral Nutrition for additional information).

**Medication Administration**

Enrolled pharmacies may be reimbursed for the administration of select adult vaccines and the COVID vaccine. Pharmacists who have the “Authority to Administer” authorized by the Louisiana Board of Pharmacy may administer vaccines. (Refer to Section 37.5.11 - Medication Administration for detailed information).

**Non-Covered Services**

**Drugs Excluded From Coverage**

The following drugs and/or therapeutic categories are excluded from Medicaid coverage:

1. Select agents when used for anorexia, weight loss, or weight gain with the exception of orlistat (Xenical);
2. Select agents when used to promote fertility except vaginal progesterone when used for high-risk pregnancy to prevent premature births;
3. Select agents when used for symptomatic relief of cough and colds except prescription antihistamine and antihistamine/decongestant combination products;
4. Select prescription vitamins and mineral products except:

|  |  |  |
| --- | --- | --- |
| Vitamin B 12 preparations | Vitamin E preparations | Pediatric vitamin preparations |
| Vitamin A preparations | Vitamin K preparations | Legend prenatal vitamins for pregnant and lactating beneficiaries |
| Vitamin B preparations | Calcium replacement | Magnesium salt replacement |
| Vitamin B1 preparations | Folic Acid preparation | Prescription strength fluoride as a single entity |
| Vitamin B6 preparations | Geriatric vitamin preparations | Urinary pH modifiers (Phosphorus) |
| Vitamin C preparations | Multivitamin preparations |  |
| Vitamin D preparations | Niacin preparations |  |

1. Select nonprescription drugs except OTC antihistamines and antihistamine/decongestant combinations, OTC naloxone, polyethylene glycol 3350, and OTC medications listed in the U.S. Preventive Service Task Force A and B Recommendations.

Otherwise Restricted Drugs include the following:

1. The state will cover agents when used for cosmetic purposes or hair growth only when the state has determined that use to be medically necessary;
2. Select drugs for erectile dysfunction except when used for the treatment of conditions, or indications approved by the FDA, other than erectile dysfunction;
3. Compound prescriptions (mixtures of two or moe ingredients; the individual drugs will continue to be reimbursed);
4. Drug Efficacy Study Implementation (DESI) Drugs (refer to those drugs that the FDA has proposed to withdraw from the market because they lack substantial evidence of effectiveness);
5. Experimental drugs;
6. Medications which are included in the reimbursement to a facility, i.e. hospitals, skilled nursing facility for beneficiaries receiving benefits under Part A of Title XVIII, mental hospitals, or some other nursing facilities; and
7. Vaccines covered in other programs. The state will cover select adult vaccines in the pharmacy program.

**Durable Medical Equipment**

The Medicaid Pharmacy Program will reimburse continuous glucose monitors and other diabetic supplies as a pharmacy benefit. Preferred products and PA criteria for continuous glucose monitors will be posted on the Single Preferred Drug List (PDL).

The following diabetic supplies with be reimbursed as a pharmacy benefit only:

1. Diabetes glucose meters;
2. Diabetic test strips;
3. Continuous glucose meters;
4. Transmitters and sensors;
5. External insulin pumps (i.e. Omnipod and V-Go);
6. Control solution;
7. Ketone test strips
8. Lancets and devices;
9. Pen needles;
10. Re-usable insulin pens; and
11. Syringes.

**Prior Authorization and Single Preferred Drug List**

The Medicaid Program administers a PA process for pharmacy services. This process utilizes a single PDL for selected therapeutic classes. Drugs included on the PDL are preferred. Drugs in these classes that are not included on the PDL require prescribers to obtain PA.

**Preferred Drug List Provider Notification**

Lists of covered drug products, including those that require PA, will be posted on the Louisiana Medicaid website.

**Prior Authorization Process General Information**

The PA process provides for a turn-around responseby eithertelephone or other telecommunications device within 24 hours ofa PA request. In emergency situations, providers may dispense a minimum of a 72 hour or a three day supply of medication**.**

**Prior Authorization and Single PDL Information Site**

The *Louisiana Medicaid Single PDL/Non-Preferred Drug List (NPDL)* and the *Louisiana Uniform Prescription Drug Prior Authorization Form* and its instructions can be accessed at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> or by visiting Section 37.5.5 of this manual chapter.

**Who Can Obtain Prior Authorization**

The prescribing practitioner is responsible for obtaining PA for non-preferred agents, agents which require clinical PA or where PAs are otherwise required.Pharmacist or beneficiary calls/requests will not be accepted. The prescribing practitioner must have and provide their valid individual Louisiana Medicaid prescribing provider number to obtain PA. Only individual provider numbers will be accepted.

The prescribing practitioner may obtain the PA by one of the following:

1. Electronic prior authorization (E-PA);
2. Telephone;
3. Facsimile; or
4. Mail.

**NOTE:** Refer to the Section 37.5.4 – Contact Information for access to additional information on PA. In addition, refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

The Prior Authorization Unit’s (PAU’s) hours of operation are 8:00 am to 6:00 pm Central Time, Monday through Saturday.

**NOTE: National Provider Identifier (NPI) numbers that are assigned to a group are not allowed to prescribe or obtain a PA.** If a prescribing practitioner does not have an individual prescriber number, refer to Section 37.5.6 - Prescribers for detailed information.

**Prior Authorization Request Form**

The Louisiana Uniform Prescription Drug PA Form must be used by the prescriber to request a PA. The form and its instructions can be accessed at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> or by visiting Section 37.5.5 of this manual chapter.

**Emergency Procedures**

Prescriptions indicating emergency situations shall be dispensed in a minimum quantity of a three day supply. **Refills for the dispensing of the non-preferred products in these emergency situations are not permitted.** The beneficiary’s practitioner must contact the PAU (RxPA) to request authorization to continue the medication past the emergency supply, and a new prescription must be issued.

This process may be used when the RxPA Unit is closed (Sundays; Monday – Saturday before 8:00 am and after 6:00 pm) or when the PA system is unavailable. The pharmacist may also use professional judgment in situations that would necessitate an emergency supply.

**The prescribing practitioner must indicate that the prescription is an emergency Rx on the face of the prescription if hard copy, or if the prescription is called in to the pharmacy, the emergency status of the prescription must be communicated to the pharmacist who must indicate “Emergency Rx” on the hard copy prescription. When the pharmacist determines the prescription is an emergency, the pharmacist must indicate “Emergency by Pharmacist” on the hard copy prescription.**

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)or by visiting Section 37.5.1 for detailed claim submission and processing information.

Beneficiaries are exempt from paying co-payments for emergency situations.

Monitoring of emergency prescriptions/beneficiaries is conducted on an ongoing basis through management reports, pharmacy provider audits, and other monitoring programs to review the number of and the reasons for these prescriptions.

**Hospital Discharge Prescriptions for Atypical Antipsychotic Agents**

When a beneficiary is discharged from a hospital with a prescription for an atypical antipsychotic prescription, the prescribing practitioner must indicate on the face of the prescription, if it is a hard copy, that the prescription is a “Hospital Discharge”. If the prescription is called in to the pharmacy, the “Hospital Discharge” status of the prescription must be communicated to the pharmacist who must indicate “Hospital Discharge” on the hard copy prescription.

In situations where the prescribing practitioner is unavailable and the pharmacist determines the prescription is a “Hospital Discharge” prescription, the pharmacist must indicate “Hospital Discharge on the hard copy prescription.

Claims for “Hospital Discharge” prescriptions needing PA will be submitted using the same process used for an emergency override.

**Prescriptions for “Hospital Discharge” products shall be dispensed in a minimum quantity of a three-day supply, and refills for the dispensing of the non-preferred products are not permitted.** The beneficiary’s practitioner mustcontact the RxPA Unit to request authorization to continue the medication past the “Hospital Discharge” supply, and a new prescription must be issued.

**Prescriptions Issued Prior to the Effective Dates of Prior Authorization**

The PA process does not impact original prescriptions (or refills) issued by a prescribing practitioner prior to a drug’s effective date of PA.

**Beneficiaries with Retroactive Eligibility**

Drugs that are not on the PDL are sometimes dispensed to patients who are awaiting Medicaid eligibility determinations. Pharmacy providers will be reimbursed for these claims when the date of service falls within the beneficiaries’ retroactive time period. The retroactive time period is defined as the time period between the first date of eligibility and the date that the beneficiary’s eligibility is placed on the beneficiary file. Pharmacy providers shall submit these claims electronically.

**Important Facts**

When a beneficiary elects to self-pay for an original prescription which requires PA, attempts to have Medicaid pay for the refill of this prescription will result in the pharmacy claim being denied.

If an approved PA exists in the system, the pharmacy claim will bypass the PA edit and continue with existing POS edits. If an approved PA does not exist, the pharmacy claim will be denied through the POS system.

An approved PA does not guarantee payment of the claim by Medicaid. It only indicates that the drug has been approved as a course of treatment within the Medicaid Program. All existing POS claim edits will continue to be applied.

The PA process does not verify a beneficiary’s Medicaid eligibility. It only verifies that the beneficiary is “on file” (i.e., has a valid Medicaid ID number on file – not that the beneficiary is eligible on the date of service). Beneficiary eligibility will continue to be verified by the Pharmacy POS subsystem or through the Medicaid Eligibility Verification System (MEVS) or Recipient Eligibility Verification System (REVS) automated beneficiary eligibility systems.

Only practitioners’ individual prescriber numbers are accepted to request PA of a non-preferred drug. Any provider number other than an individual prescribing provider number **WILL NOT** be accepted to prior authorize non-preferred drugs.

**Clinical Authorization**

There are certain medications that require clinical authorization. Clinical authorization is a prescriber initiated request for authorization on a selected number of drugs.

**Prescribers must complete the *Louisiana Uniform Prescription Drug Prior Authorization Form* in full. The clinical authorization criteria can be used as a reference when completing the form. Clinical authorization requests should be faxed or mailed to the RxPA Unit.** (Refer to Section 37.5.4 – Contact Information in this manual chapter for contact information).

**NOTE:** Refer to the Single PDL to access the clinical authorization drug list, forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Monthly Service Limit**

**Limit**

Medicaid reimburses up to four prescriptions per calendar month per beneficiary. Claims including those for emergency prescriptions and PA prescriptions that are in excess of four per calendar month per beneficiary will be denied.

**Exceptions to Limit**

The following federally mandated beneficiary groups are exempt from the 4 prescriptions per calendar month limitations:

1. Persons under 21 years of age;
2. Persons who are residents of long-term care institutions, such as nursing homes and Individuals with Intellectual Disabilities (ICF/IID) facilities; and
3. Beneficiaries who are pregnant.

**Limit Override Procedures**

The four prescriptions per month limit can be exceeded when the prescriber determines an additional prescription is medically necessary and communicates the following information to the pharmacist on the hard prescription, by telephone or other telecommunications device:

1. “Medically necessary override; and
2. Valid diagnosis code that directly relates to each drug prescribed that is over the four prescription limit (an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM, or its successor) literal description is not acceptable).

The prescriber should use the Electronic Clinical Drug Inquiry (e-CDI) in their clinical assessment of the beneficiary’s disease state or medical condition and the current drug regimen before making a determination that more than four prescriptions per calendar month is required by the beneficiary. (Refer to Section 37.5.4 for details on how to access the e-CDI).

Printed statements without the prescribing practitioner’s signature, check-off boxes or stamped signatures are not acceptable documentation.

An acceptable statement and diagnosis code are required for each prescription in excess of four for each calendar month.

Pharmacists and prescribers are required to maintain documentation to support the override of a prescription limitation.

**NOTE:** Refer to Section 37.5.1 to access the *POS User Guide* to obtain detailed billing instructions and override procedures at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Drugs with Special Payment Criteria/Limitations**

Coverage of some drugs is limited to special criteria being met. These are explained below.

**NOTE:** Refer to Section 37.5.8 - Claim Submission for detailed override information as well as Section 37.5.1 to access the *POS User Guide* for detailed billing instructions, where applicable, at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Age and Gender Restricted Drugs**

Certain drugs have age and gender restrictions placed on them. For further assistance, providers should contact the Gainwell Provider Helpdesk (Refer to Section 37.5.4 for contact information).

**Acne Agents**

Pharmacy claims for select acne agents have a quantity limit, age requirements, and/or clinical authorization requirement.

Clinical information (acne severity) is required for all topical acne agents.

All agents are limited to use in beneficiaries who are younger than 21 years of age when used for acne. Trifarotene (Aklief®) is limited to beneficiaries who are at least 9 years of age.

Pharmacy claims submitted with a diagnosis code for psoriasis (L40\*) will bypass the age restriction and clinical authorization requirement for tazarotene cream or tazarotene gel.

*\* Any number or letter or combination of* ***UP TO 4*** *numbers and letters of an assigned ICD-10-CM diagnosis code*

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Acoramidis (AttrubyTM)**

Pharmacy claims for acoramidis (Attruby™) will be subject to the following:

1. Clinical authorization; and
2. Quantity limit.

The quantity limit for acoramidis (Attruby™) is listed in the following chart.

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Quantity Limit** |
| Acoramidis (Attruby™) | Four (4) tablets per day |

**Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder Agents**

Prescriptions forAttention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD) agents may be subject to the following:

1. Age requirement;
2. Behavioral health clinical information recipients under 7 years;
3. Concurrent use;
4. Diagnosis code requirement;
5. Therapeutic duplication; and
6. Quantity limit.

The numeric diagnosis code must be documented on the hardcopy prescription or in the pharmacy’s electronic record keeping system. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis code is required for the claim submission.

Pharmacy claims for ADD and ADHD medications that have a missing or invalid diagnosis code will deny at POS.

When beneficiaries are established on ADD/ADHD medications, but the diagnosis codes submitted are not included in the table of covered diagnoses, prescribing providers may call the RxPA Unit (Refer to Section 37.5.4 for contact information).

**Therapeutic Duplication**

Pharmacy claims for ADD/ADHD medications will be subject to a therapeutic duplication.

An incoming pharmacy claim for a short-acting ADD/ADHD medication will deny when there is an active claim on file for another short-acting ADD/ADHD medication. An incoming claim for a long-acting ADD/ADHD medication will deny when there is an active claim on file for another long-acting ADD/ADHD medication.

An incoming pharmacy claim for an ADD/ADHD medication will deny when there is an active claim on file for another ADD/ADHD medication written by a different prescriber.

**Therapeutic Duplication of Serdexmethylphenidate/ Dexmethylphenidate (Azstarys™) with Another Long-Acting ADD/ADHD Medication**

An incoming pharmacy claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) will deny with a therapeutic duplication if there is an active claim for another long-acting ADD/ADHD medication on file. Conversely, a claim for long-acting ADD/ADHD medication will deny with a therapeutic duplication if there is an active claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) on file.

**Therapeutic Duplication of Serdexmethylphenidate/ Dexmethylphenidate (Azstarys™) with Another Short-Acting ADD/ADHD Medication**

An incoming pharmacy claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) will deny with a therapeutic duplication if there is an active claim for another short-acting ADD/ADHD medication on file. Conversely, a claim for short-acting ADD/ADHD medication will deny with a therapeutic duplication if there is an active claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) on file.

**Therapeutic Duplication of Xelstrym™ with another Long-Acting Stimulant or Related Medication for ADHD**

Pharmacy claims for dextroamphetamine (Xelstrym™) will deny if there is an active claim on the beneficiary’s file for any other long-acting stimulant and related medication for ADHD and vice versa.

**Behavioral Health Medications for Beneficiaries 7 Years of Age and Younger**

Pharmacy claims for behavioral health medications for beneficiaries 7 years of age and younger require an approved clinical authorization for reimbursement.

**Clinical Authorization for ADD/ADHD Medications for Beneficiaries Less Than 7 years of Age**

Pharmacy claims for ADD/ADHD medications for beneficiaries less than 7 years of age require an approved clinical authorization for reimbursement.

 **NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Allergy Treatment Agents: Allergen Extracts, Antihistamines, and Rhinitis Agents (Nasal)**

**Allergen Extracts**

Pharmacy claims for allergen extracts may be subject to clinical authorization/PA, physician prescriber requirements, age requirements, diagnosis code requirements, and an auto-injectable epinephrine prescription requirement for reimbursement.

Select allergen extracts are listed in the following chart:

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Grass Pollen Allergen Extract (Timothy Grass) Sublingual Tablet (Grastek®) |
| House Dust Mite Allergen Extract Sublingual Tablet (Odactra™) |
| Mixed Grass Allergen Extracts Sublingual Tablet (Oralair®) |
| Peanut (*Arachis hypogaea*) Allergen Powder Capsule; Packet (Palforzia®) |
| Ragweed Pollen Allergen Extract Sublingual Tablet (Ragwitek®) |

**Physician Prescriber Requirements for Allergen Extracts**

Prescribers of allergen extracts must have a specialty of 1) Allergy, 2) Otology, Laryngology, Rhinology, or 3) Ophthalmology, Otology, Laryngology, Rhinology for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Auto-Injectable Epinephrine Requirement for Allergen Extracts**

Pharmacy claims for allergen extracts require a pharmacy claim for an auto-injectable epinephrine product within the last year for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Antihistamines**

Antihistamine and antihistamine/decongestant products may require a PA for reimbursement.

Antihistamine and antihistamine/decongestant products are subject to a therapeutic duplication with each other and with other sedating antihistamines at POS.

The program, in accordance with the Social Security Act Section 1927 (d)(2), excludes drugs or classes of drugs containing cough and cold agents when those products are prescribed for the treatment of cough and cold.

Pharmacy claims for carbinoxamine maleate (Ryvent™) have a prior drug use requirement.

An incoming pharmacy claim for carbinoxamine maleate 6mg (Ryvent™) or generic carbinoxamine 6mg will deny if there is no evidence in paid pharmacy claims of at least a 60-day supply of generic carbinoxamine 4mg tablets in the previous 180-day period.

**Exclusions**

Claims for diphenhydramine, hydroxyzine HCL, and hydroxyzine pamoate are excluded from the therapeutic duplication.

After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system the following:

1. The reason the prescribing provider chose to override the therapeutic duplication; and
2. The National Council for Prescription Drug Program (NCPDP) DUR override codes used in submitting the claim.

**NOTE:** Refer to “Prospective Drug Utilization Policies/Limits/Edits” in this section for policy regarding first and second generation antihistamines and combination agents included in the therapeutic duplication edit.

**Rhinitis Agents (Nasal)**

Pharmacy claims for rhinitis agents (nasal) may require a PA.

Select rhinitis agents have a quantity limit as listed in the following chart.

|  |  |
| --- | --- |
| **Generic (Brand)** | **Quantity Limit** |
| Azelastine Nasal Spray (Astepro®) | 1 bottle (200 sprays) per 25 days |
| Azelastine Nasal Spray (Astelin®) | 1 bottle (200 sprays) per 25 days |
| Azelastine/Fluticasone Nasal Spray (Dymista®) | 1 bottle (120 sprays) per 30 days |
| Beclomethasone Nasal Spray (Beconase AQ®; Qnasl 40®; Qnasl 80®) | 1 bottle (120 sprays) per 30 days |
| Ciclesonide Nasal Spray (Omnaris®; Zetonna®) | 1 bottle (60 sprays) per 30 days |
| Flunisolide Nasal Spray | 1 bottle (200 sprays) per 25 days |
| Fluticasone Propionate Nasal Spray (Flonase®) | 1 bottle (120 sprays) per 30 days |
| Fluticasone Propionate Nasal Spray (Xhance®) | 2 bottles (240 sprays) per 30 days |
| Ipratropium Bromide Nasal Spray | 1 bottle (345 sprays) per 28 day |
| Mometasone Nasal Spray | 1 bottle (120 sprays) per 30 days |
| Olopatadine Nasal Spray (Patanase®) | 1 bottle (240 sprays) per 30 days |
| Olopatadine/Mometasone Nasal Spray (Ryaltris®) | 1 bottle (240 sprays) per 30 days |

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Alzheimer’s Agents**

Select agents for the treatment of Alzheimers disease require clinical authorization or PA. The following chart lists select agents for the treatment of Alzheimer’s disease.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Aducanumab-avwa (Aduhelm™)\* |
| Donepezil ODT, Tablet (Aricept®) |
| Donepezil Transdermal Patch (Adlarity®) |
| Galantamine ER Capsule, Solution, Tablet |
| Lecanemab-irmb (Leqembi™)\* |
| Memantine Solution, Tablet, Dose Pack (Namenda®, Namenda®Titration Pack) |
| Memantine ER Capsule, Dose Pack (Namenda XR®, Namenda XR® Titration Pack) |
| Memantine/Donepezil ER Capsule (Namzaric®) |
| Rivastigmine Capsule |
| Rivastigmine Transdermal Patch (Exelon®) |

\* Aducanumab-avwa (Aduhelm™) and lecanemab-irmb (Leqembi™) require a drug specific clinical authorization form.

**Analeptics: Armodafinil (Nuvigil®), Modafinil (Provigil®), Pitolisant (Wakix®), and Solriamfetol (Sunosi®)**

Pharmacy claims for analeptics are subject to the following:

1. Age Requirement;
2. Diagnosis Code;
3. Therapeutic Duplication;
4. Quantity Limit; and
5. Concurrent use.

**Age Restriction**

Pharmacy claims for analeptics have the following minimum age requirements.

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Minimum Age** |
| Armodafinil (Nuvigil) | 17 years |
| Modafinil (Provigil) | 17 years |
| Pitolisant (Wakix) | 6 years |
| Solriamfetol (Sunosi) | 18 years |

**Diagnosis Code Requirements**

Pharmacy claims for analeptics require and appropriate diagnosis code.

**NOTE:** Refer to the Diagnosis Code Policy chart at: <https://ldh.la.gov/assets/HealthyLa/PDL/7.30.2020/Louisiana.Medicaid.ICD-10.Chart.docx>

**Therapeutic Duplication**

A therapeutic duplication is monitored at POS for the following:

1. Armodafinil, modafinil, pitolisant and solriamfetol with each other; and
2. Armodafinil, modafinil, pitolisant and solriamfetol with any other stimulant or related agent.

**Quantity Limit**

Pharmacy claims for analeptics have the following quantity limits.

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Quantity Limit** |
| Armodafinil (Nuvigil) | 30 tablets per 30 days |
| Modafinil (Provigil) | 30 tablets per 30 days |

**Concurrent Use with Sedative Hypnotics**

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) will deny atPOS when there is an active claim on the beneficiary’s file for a sedative hypnotic.

If in the professional judgment of the prescriber a determination is made which necessitates therapy with modafinil (Provigil®) or armodafinil (Nuvigil®) and a sedative hypnotic, the pharmacist may override this edit. After consultation with the prescriber to verify the necessity of both agents, the pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic record keeping system the prescriber’s reason for concurrent therapy. The reason for service code, professional service code and result of service code used in submitting the claim must also be documented on the hardcopy prescription or in the pharmacy’ electronic recordkeeping system.

Pharmacy claims for solriamfetol (Sunosi®) or pitolisant (Wakix®) will deny if there is an active claim on the beneficiary’s file for a sedative hypnotic. Pharmacy claims for a sedative hypnotic will deny if there is an active claim on the beneficiary’s file for solriamfetol (Sunosi®) or pitolisant (Wakix®).

**Androgenic Agents**

Pharmacy claims for androgenic agents may require a PA. A valid diagnosis code is required for recipients younger than 18 years of age.

**NOTE:** Refer to the Diagnosis Code Policy Chart at: <https://ldh.la.gov/assets/HealthyLa/PDL/7.30.2020/Louisiana.Medicaid.ICD-10.Chart.docx>

**AND**

Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Anthelmintics**

Pharmacy claims for anthelmintics may require a PA. Pharmacy claims for oral ivermectin (Stromectol®) must be submitted with a valid diagnosis code.

**NOTE:** Refer to the Diagnosis Code Policy Chart at: <https://ldh.la.gov/assets/HealthyLa/PDL/7.30.2020/Louisiana.Medicaid.ICD-10.Chart.docx>

**AND**

Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Antiemetic/Antivertigo Agents**

Pharmacy claims for select antiemtic/antivertigo agents may be subject to the following:

1. Clinical authorization/PA;
2. Behavioral health clinical authorization for ages less than 7 years (for prochlorperazine);
3. Diagnosis code requirement; and
4. Quantity limit.

The following bypass conditions apply for antiemtic/antivertigo agents:

1. Prochlorperazine pharmacy claims that are submitted with a diagnosis code for severe nausea or vomiting will bypass the Behavioral Health Clinical Authorization requirement for children younger than 7 years of age; and

1. Ondansetron ODT and ondansetron tablet pharmacy claims that are submitted with a diagnosis code for cancer or palliative end-of-life care will bypass the quantity limit.

Select antiemetic/antivertigo agents are listed in the following chart.

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Generic Name (Brand Name Example)** |
| Amisulpride Vial (Barhemsys®) | Metoclopramide Solution, Tablet, Vial (Reglan®) |
| Aprepitant Capsule, Pack, Powder for Oral Suspension (Emend®) | Metoclopramide Nasal (Gimoti®) |
| Aprepitant Vial (Aponvie®, Cinvanti®) | Netupitant/Palonosetron HCl Capsule (Akynzeo®) |
| Dimenhydrinate Vial | Ondansetron ODT, Solution, Tablet, Vial  |
| Dolasetron Mesylate (Anzemet®) | Ondansetron Oral Film (Zuplenz®) |
| Doxylamine/Pyridoxine Tablet (Bonjesta®, Diclegis®) | Ondansetron Ampule, Syringe |
| Dronabinol Oral (Marinol®) | Palonosetron Vial (Aloxi®) |
| Fosaprepitant Dimeglumine Vial (Emend® | Prochlorperazine Rectal, Tablet, Vial (Compro®) |
| Fosnetupitant/Palonosetron Vial (Akynzeo®) | Promethazine Ampule, Rectal, Suppository, Syrup, Tablet, Vial (Phenergan®) |
| Granisetron ER Syringe, Tablet, Vial (Sustol®) | Rolapitant Tablet (Varubi®) |
| Granisetron Transdermal Patch (Sancuso® ) | Scopolamine Transdermal (Transderm-Scop®) |
| Meclizine Tablet (Antivert®) | Trimethobenzamide Capsule, Vial (Tigan®) |

The following **antiemetic/antivertigo** agent will be subject to a quantity limit as listed in the chart.

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Quantity Limit** |
| Ondansetron (Zofran**®**) ODT, Tablet (solid oral dosage forms) | 30 tablets/30 days |

**Amifampridine (Firdapse®)**

Pharmacy claims for amifampridine (Firdapse®) are subject to the following:

1. Diagnosis code requirement; and
2. Maximum daily dose.

The maximum daily dose for amifampridine (Firdapse®) is listed in the chart below.

|  |  |
| --- | --- |
| **Generic Name (Brand Name)** | **Maximum Daily Dose** |
| Amifampridine (Firdapse®) | 80 mg/day |

**Amyotrophic Lateral Sclerosis**

Pharmacy claims for amyotrophic lateral sclerosis (ALS) agents require an appropriate diagnosis code entered at POS.

Select amyotrophic lateral sclerosis (ALS) agents are listed in the following chart.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Edaravone (Radicava®; Radicava ORS®) |
| Riluzole (Rilutek®; Tiglutik™; Exservan™) |
|  |
| Toferson (Qalsody™) |

**NOTE:** Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

|  |
| --- |
|  |
|  |
|  |
|  |
|  |
|  |
|  |

**Anti-Anxiety Drugs**

Select anti-anxiety drugs may be subject to the following POS edits:

1. PA;
2. Age limit;
3. Behavioral health clinical authorization for age less than 7 years;
4. Quantity limit;
5. Concurrent use;
6. Prior use;
7. Therapeutic duplication; and
8. Diagnosis code requirements.

Select anti-anxiety drugs may require PA.

|  |
| --- |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |

**Age Requirement**

The following anti-anxiety agents are limited for use in beneficiaries who meet specific age requirements as listed in the chart.

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Age Limit** |
| Alprazolam XR tablet (Xanax XR®) |  > or = 18 years  |
| Alprazolam ODT (Niravam®) |  > or = 18 years |
| Lorazepam ER capsule (Loreev XR®) |  > or = 18 years |

**Behavioral Health Clinical Authorization For Ages Less Than 7 Years**

Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for all agents, EXCEPT meprobamate, when requested for beneficiaries who are younger than 7 years of age.

**Quantity Limit**

The following anti-anxiety agents will be subject to a quantity limit as listed in the chart.

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Quantity Limit Per Rolling 30 Days** |
| Alprazolam (Xanax®) | 90 units |
| Alprazolam ER (Xanax XR®) | 30 units |
| Alprazolam ODT (Niravam ™) | 90 units |
| Chlordiazepoxide  | 90 units |
| Clorazepate (Tranxene T-Tab®) | 90 units |
| Diazepam (Valium®) | 90 units |
| Lorazepam (Ativan®) | 90 units |
| Lorazepam ER (Loreev XR™) | 90 units |
| Oxazepam (Serax®) | 90 units |

Quantity limits will be bypassed for clonazepam (Klonopin®), clorazepate (Tranxene®), and diazepam (Valium®) when an acceptable diagnosis code is submitted.

Acceptable diagnosis codes that will bypass the edit are:

|  |  |
| --- | --- |
| **ICD-10-CM Diagnosis Code** | **Description** |
| P90 | Convulsions in Newborn |
| G40.\* | Epilepsy, Seizures |
| R56.\* | Other Convulsions |

**Concurrent Use**

Incoming benzodiazepine pharmacy claims will deny when the beneficiary has an active prescription (a prescription in which the days’ supply has not expired) for a buprenorphine-containing product used to treat opioid dependence.

Incoming benzodiazepine pharmacy claims will deny when the beneficiary has an active prescription for an opioid analgesic

Pharmacy claims for selected anxiolytics, when submitted with a seizure-related diagnosis code will bypass the behavioral-health clinical authorization requirement, the restriction on concurrent use with opioids, and quantity limits.

Pharmacy claims submitted with a diagnosis code for cancer or palliative end-of-life care will bypass the restriction on concurrent use of benzodiazepines with opioids.

**Prior Use**

An incoming pharmacy claim for lorazepam (Loreev XR™) will deny if there is no evidence of a pharmacy claim for **ONE** of the following in the most recent 30-day period:

1. A quantity of at least 90 lorazepam immediate-release tablets; **OR**
2. Any quantity of lorazepam (Loreev XR™).

**Therapeutic Duplication**

Pharmacy claims for anti-anxiety agents will deny at POS with a therapeutic duplication if there is an active claim for another anti-anxiety agent, with oxybate ((Xyrem®) and with oxybate salts (Xywav™).

**Diagnosis Code Requirements**

Pharmacy claims for alprazolam ER and alprazolam ODT require an appropriate diagnosis code.

**NOTE:** Refer to the Diagnosis Code Policy chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  |  |  |
|  |  |
|  |  |
|  |  |  |
|  |  |
|  |  |  |

**Antibiotic-Otic Agents**

Select antibiotic- otic agents are listed in the following chart.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Ciprofloxacin Solution |
| Ciprofloxacin/Dexamethasone Susp (Ciprodex®) |
| Ciprofloxacin/Fluocinolone Acetonide Solution (Otovel®) |
| Ciprofloxacin/Hydrocortisone Suspension (Cipro HC Otic®) |
| Colistin/Neomycin/Thonzonium/Hydrocortisone Suspension (Cortisporin® TC)  |
| Neomycin/Polymyxin B/Hydrocortisone Solution, Suspension |
| Ofloxacin Solution |

Pharmacy claims for select antibiotic otic agents may be subject to the following:

1. PA; and
2. Quantity limit.

Select antibiotic-otic agents are listed in the following chart.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Ciprofloxacin Solution |
| Ciprofloxacin/Dexamethasone Susp (Ciprodex®) |
| Ciprofloxacin/Fluocinolone Acetonide Solution (Otovel®) |
| Ciprofloxacin/Hydrocortisone Suspension (Cipro HC Otic®) |
| Colistin/Neomycin/Thonzonium/Hydrocortisone Suspension (Cortisporin® TC)  |
| Neomycin/Polymyxin B/Hydrocortisone Solution, Suspension |
| Ofloxacin Solution |

Pharmacy claims for the following **antibiotic-otic** agent will be subject to a quantity limit as listed in the chart.

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Quantity Limit** |
| Ciprofloxacin HCl 0.2% Otic Solution | 2 packs of 14 single-use containers per 30 days |

**Anticoagulants**

Prescriptions for select anticoagulants are subject to the following clinical edits for reimbursement:

1. Quantity limits; and
2. Duration of therapy.

**Quantity Limits**

The quantity limits for anticoagulant agents are listed in the chart below:

| **Generic** | **Representative Brand** | **Dosage Form** | **Quantity Limit** |
| --- | --- | --- | --- |
| Apixaban  | Eliquis® | Tablet | 2 tablets/day(Initial 4 tablets/day for 7 days when treating DVT/PE) |
| Apixaban Starter Pack | Eliquis® Starter Pack | Tablet Dose Pack | 1 unit/365 days |
| Dabigatran Etexilate Mesylate  | Pradaxa® | Capsule | 2 capsules/day |
| Dalteparin Sodium  | Fragmin® | Vial/Syringe | 2 syringes or vials/day |
| Edoxaban Tosylate  | Savaysa® | Tablet | 1 tablet/day |
| Enoxaparin Sodium  | Lovenox® | Vial/Syringe | 2 syringes or vials/day |
| Fondaparinux Sodium  | Arixtra® | Syringe | 1 syringe/day |
| Rivaroxaban 2.5mg | Xarelto® | Tablet | 2 tablets/day |
| Rivaroxaban 10mg, 15mg & 20mg | Xarelto® | Tablet | 1 tablet/day |
| Rivaroxaban Starter Pack  | Xarelto® Starter Pack | Tablet Dose Pack | 1 pack (51 tablets)/365 days |
| Rivaroxaban | Xarelto® Oral Suspension | Suspension | 4 bottles (155ml each)/31 days |

**Duration of Therapy**

The duration of therapy for select anticoagulant agents are listed in the chart below:

|  |  |  |
| --- | --- | --- |
| **Generic** | **Representative Brand** | **Maximum Duration of Therapy** |
| Dalteparin  | Fragmin® | 35 days per rolling 90 days |
| Enoxaparin | Lovenox® | 35 days per rolling 90 days |
| Fondaparinux Sodium | Arixtra® | 35 days per rolling 90 days |

**Anticonvulsants**

Pharmacy claims for anticonvulsants may be subject to the following:

1. Age requirement;
2. Behavioral Health [carbamazepine (Equetro®)];
3. Concurrent use;
4. Diagnosis code requirement;
5. Maximum daily dose;
6. PA;
7. Prior use;
8. Quantity limit; and
9. Therapeutic duplication.

**Age Requirement**

The following select anticonvulsants have an age requirement:

1. Perampanel (Fycompa®) is limited to use in beneficiaries who are at least four years old; and
2. Phenobarbital sodium (Sezaby®) is limited to use in beneficiaries who are younger than one year old.

**Behavioral Health**

Behavioral health clinical information required for carbamazepine (Equetro®) and clonazepam when requested for a behavioral health diagnosis for beneficiaries who are younger than seven years of age.

**Diagnosis Code Requirement**

Pharmacy claims for ganaxolone (Ztalmy®) or phenobarbital sodium (Sezaby®) must be submitted with an appropriate diagnosis code.

Pharmacy claims for selected anxiolytics, when submitted with a seizure-related diagnosis code will bypass the behavioral-health clinical authorization requirement, the restriction on concurrent use with opioids, and quantity limits.

Pharmacy claims for selected anxiolytics, when submitted with a cancer or palliative care diagnosis will bypass the restriction on concurrent use with opioids.

**Concurrent Use**

Benzodiazepines are monitored at POS for concurrent use with opioids and buprenorphine-containing products.

**Maximum Daily Dose**

Select agents have a maximum daily dose as listed in the following chart.

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Maximum Daily Dose** |
| Clobazam (Onfi®, Sympazan®) | 40mg per day |
| Eslicarbazepine (Aptiom®) | 1600mg per day |

**Prior Use**

Pharmacy claims for cannabidiol (Epidiolex®) have a prior use requirement (in a previous 365-day period) of the following:

1. **ONE** paid claim for cannabidiol (Epidiolex®);

**OR**

1. A paid claim in the previous 365 days for at least **TWO** of the following agents (brand/generic or preferred/non-preferred formulations) below:
2. Clobazam;
3. Felbamate;
4. Lamotrigine;
5. Levetiracetam;
6. Rufinamide;
7. Topiramate; and
8. Valproate derivatives.

Pharmacy claims for ganaxolone (Ztalmy®) have a prior use requirement (in a previous 365-day period) of the following:

1. At least **TWO** different anticonvulsant medications (preferred or non-preferred); **OR**
2. Ganaxolone (Ztalmy®).

**Quantity Limit**

Select agents have quantity limits as listed in the following chart.

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Quantity Limit** |
| Clonazepam (Klonopin®) | 90 units per 30 days |
| Midazolam (Nayzilam®) | 5 boxes (10 doses) per 30 days |

**Therapeutic Duplication**

Clonazepam is monitored for therapeutic duplication with other benzodiazepines, with oxybate (Xyrem®), and with oxybate salts (Xywav™).

**NOTE:** Refer to the Diagnosis Code Policy Chart at: <https://ldh.la.gov/assets/HealthyLa/PDL/7.30.2020/Louisiana.Medicaid.ICD-10.Chart.docx>

**AND**

Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

**Antidepressant Medications**

Pharmacy claims for select antidepressant medications may be subject to the following:

1. PA;
2. Diagnosis Code Requirement;
3. Behavioral Health clinical information for beneficiaries under 7 years of age;
4. Quantity Limit; and
5. Therapeutic Duplication.

The following quantity limit will apply for zuranolone (ZurzuvaeTM).

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Quantity Limit** |
| Zuranolone (ZurzuvaeTM) 20 mg | 28 capsules per 14 days |
| Zuranolone (ZurzuvaeTM) 25 mg | 28 capsules per 14 days |
| Zuranolone (ZurzuvaeTM) 30 mg | 14 capsules per 14 days |

Additional clinical information is required for brexanolone (Zulresso™), esketamine (Spravato®) and zuranolone (Zurzuvae™).

**Therapeutic Duplication**

Pharmacy claims for a tricyclic antidepressant will deny if there is an active claim on the beneficiary’s file for a tricyclic antidepressant.

Pharmacy claims for selective serotonin reuptake inhibitors (SSRIs) will deny if there is an active claim on the beneficiary’s file for a SSRI.

|  |
| --- |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |

**Anti-Fungals, Oral and Topical**

Pharmacy claims for select oral antifungal agents will be subject to the following:

1. Prior or clinical authorization; and
2. Quantity limit.

|  |
| --- |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |

**Anti-Infective, Anti-Fungal, and Corticosteroids**

Pharmacy claims for select anti-infective, anti-fungal, and corticosteroids have quantity limits.

|  |  |  |
| --- | --- | --- |
| **Medication** | **Dosage Form** | **Quantity Limit** |
| Ciclopirox Olamine 0.77% | Suspension | 60ml/30 days |
| Ciprofloxacin HCl 0.2% | Otic Solution | 2 packs of 14 singles/30 days |
| Clobetasol Propionate 0.05% | Cream  | 100gm/30 days |
| Clobetasol Propionate 0.05% | Ointment | 120gm/30 days |
| Clobetasol Propionate 0.05% | Solution | 100ml/30 days |
| Doxycycline Hyclate / Monohydrate | Capsule | 60 caps of any strength/30 days |
| Econazole Nitrate 1% | Cream  | 85gm/30 days |
| Gentamicin Sulfate 0.3%  | Ophthalmic Ointment | 3.5gm/30 days |
| Gentamicin Sulfate 0.3%  | Ophthalmic Solution | 5ml/30 days |
| Gentamicin Sulfate 0.1% | Cream  | 30gm/30 days |
| Gentamicin Sulfate 0.1% | Ointment | 30gm/30 days |
| Itraconazole 100mg | Capsule | 120 caps/30 days |
| Itraconazole 100mg  | Capsule Pulsepak | 1 pack (28 caps) / 28 days |
| Itraconazole 65mg | Capsule | 120 caps/30 days |
| Ketoconazole 2% | Shampoo | 120ml/30 days |
| Ketoconazole 2% | Cream  | 60gm/30 days |
| Mupirocin 2% | Cream  | 30gm/30 days |
| Mupirocin 2% | Ointment | 22gm/30 days |
| Nystatin 100,000 units/gm | Cream  | 60gm/30 days |
| Nystatin 100,000 units/gm | External Powder | 120mg (Two 60mg bottles)/30 days |
| Nystatin 100,000 units/gm | Ointment | 60gm/30 days |

**Antimigraine Agents- CGRP Antagonists**

Pharmacy claims for select antimigraine agents-CGRP antagonists may be subject to clinical or PA and quantity limits.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

The quantity limits for select CGRP antagonists are listed in the following chart:

|  |  |
| --- | --- |
| **Medication-Generic (Brand)**  | **Quantity Limit**  |
| Atogepant (Qulipta) | 30 tablets/30 days |
| Eptinezumab-jjmr (Vyepti™)  | 3 single dose vials (300mg)/90 days  |
| Erenumab-aooe (Aimovig®) - 70mg, 140mg single dose syringe  | 3 single dose syringes/90 days  |
| Fremanezumab-vfrm (Ajovy®) - 225mg single dose syringe  | 3 single dose syringes/90 days  |
| Galcanezumab-gnlm (Emgality®) - 100mg single dose syringe  | 3 single dose syringes/30 days  |
| Galcanezumab-gnlm (Emgality®) - 120mg single dose pen/syringe  | 7 single dose syringes/180 days  |
| Rimegepant (Nurtec® ODT)  | 16 tablets/30 days  |
| Ubrogepant (Ubrelvy™)  | 16 tablets/30 days  |

**Antimigraine Agents - Ergotamine**

Pharmacy claims for select antimigraine agents-ergotamine may be subject to PA.

**Antiparkinson Agents: Anticholinergics and Other**

Pharmacy claims for select Antiparkinson’s agents (Anticholinergics and other) may require a clinical or PA.

**Antiretroviral Agents – HIV/AIDS**

Pharmacy claims for select antiretroviral agents – HIV/AIDS require a diagnosis code and are monitored for therapeutic duplication.

**NOTE**: Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Antipsychotic Agents**

Pharmacy claims for select antipsychotic medications are subject to the following:

1. Diagnosis Code Requirement;
2. Age Requirements;
3. Quantity limits;
4. Maximum daily dose;
5. Prior use; and
6. Therapeutic Duplication.

**Diagnosis Code Requirement on All Antipsychotic Medications**

Prescriptions for antipsychotic agents require appropriate diagnosis codes.

The numeric diagnosis code must be documented on the hardcopy prescription or in the pharmacy’s electronic record keeping system. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis code is required for the claim submission.

Pharmacy claims for antipsychotic medications that have a missing or invalid diagnosis code will deny at POS.

**NOTE**: Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

If the prescriber does not indicate a diagnosis code, and the pharmacist determines the beneficiary cannot wait to receive the medication, the pharmacy provider may override the denial. The pharmacist must document “Emergency” on the hard copy prescription or in the pharmacy’s electronic recordkeeping system and the reason for the emergency.

Antipsychotic agents are also subject to prospective DURs when a third antipsychotic agent is submitted for payment.

**Age Requirements for Antipsychotic Medications**

Select antipsychotic agents have age requirements. Pharmacy claims for pimavanserin (Nuplazid®) is limited to use in beneficiaries who are at least 18 years old.

**Maximum Daily Dose for Antipsychotic Medications**

The following antipsychotic agents are subject to a maximum daily dose limit as listed in the chart below.

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Maximum Daily Dose** |
| **Age (Years)** |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Younger than 5** | **5** | **6-9** | **10-12** | **13-15** | **16-17** | **18 and older** |
| Aripiprazole (Abilify®) | 5mg | 20mg | 20mg | 20mg | 30mg | 30mg | 30mg |
| Aripiprazole (Abilify® Mycite®) | 0mg | 0mg | 0mg | 0mg | 0mg | 0mg | 30mg |
| Asenapine (Saphris®) | 0mg | 0mg | 0mg | 20mg | 20mg | 20mg | 20mg |
| Asenapine Transdermal Patch (Secuado®) | 0mg | 0mg | 0mg | 0mg | 0mg | 0mg | 7.6mg |
| Brexpiprazole (Rexulti®) | 0mg | 0mg | 0mg | 0mg | 4mg | 4mg | 4mg |
| Cariprazine (Vraylar®) | 0mg | 0mg | 0mg | 0mg | 0mg | 4.5mg | 6mg |
| Cariprazine Therapy Pack (Vraylar®) | 0mg | 4.5mg | 6mg |
| Clozapine (Clozaril®, FazaClo®, Versacloz®) | 0mg | 0mg | 0mg | 0mg | 0mg | 0mg | 900mg |
| Iloperidone (Fanapt®) | 0mg | 0mg | 0mg | 0mg | 0mg | 16mg | 24mg |
| Lumateperone (Caplyta™) | 0mg | 0mg | 0mg | 0mg | 0mg | 0mg | 42mg |
| Lurasidone (Latuda®) | 0mg | 0mg | 0mg | 80mg | 80mg | 80mg | 160mg |
| Olanzapine (Zyprexa®) | 10mg | 20mg | 20mg | 20mg | 30mg | 30mg | 40mg |
| Olanzapine/Fluoxetine (Symbyax®) | 0mg | 0mg | 0mg | 12mg/50mg | 12mg/50mg | 12mg/50mg | 18mg/75mg |
| Paliperidone (Invega®) | 3mg | 6mg | 6mg | 6mg | 9mg | 9mg | 12mg |
| Quetiapine (Seroquel®) | 100mg | 600mg | 600mg | 600mg | 1000mg | 1000mg | 1200mg |
| Risperidone (Risperdal®) | 3mg | 6mg | 6mg | 6mg | 8mg | 8mg | 16mg |
| Ziprasidone (Geodon®) | 30mg | 60mg | 60mg | 60mg | 120mg | 120mg | 200mg |

**Quantity Limits**

Pharmacy claims for selected antipsychotic medications have quantity limits.

**Antipsychotic Oral/Transdermal Agents Quantity Limit Chart**

The following antipsychotic oral/transdermal agents are subject to a quantity limit as listed in the chart below.

|  |  |
| --- | --- |
| **Medication –Generic (Brand)** | **Quantity Limit**  |
| Asenapine (Secuado®)  | 30 patches per 30 days  |
| Brexpiprazole (Rexulti®) | 30 tablets per 30 days |
| Cariprazine (Vraylar™) | 30 capsules per 30 days |
| Lurasidone (Latuda®) Tablet 20mg, 40mg, 60mg & 120mg | 30 tablets per 30 days |
| Lurasidone (Latuda®) Tablet 80mg | 60 tablets per 30 days |
| Olanzapine/Samidorphan (Lybalvi) | 30 tablets per 30 days |
| Pimavanserin (Nuplazid™) 10 mg  | 30 tablets per 30 days |
| Pimavanserin (Nuplazid™) 34 mg  | 30 capsules per 30 days  |

**Antipsychotic Injectable Agents Quantity Limit Chart**

The following antipsychotic injectable agents are subject to quantity limit as listed in the chart below.

|  |  |
| --- | --- |
| **Medication-Generic (Brand)**  | **Quantity Limit**  |
| Aripiprazole (Abilify Asimtufii®) | 1 unit every 56 days |
| Aripiprazole (Abilify Maintena®)  | 1 unit every 28 days  |
| Aripiprazole Lauroxil (Aristada® ) 441 mg; 662 mg; 882 mg syringe  | 1 unit every 28 days  |
| Aripiprazole Lauroxil (Aristada®) 1064mg syringe  | 1 unit every 56 days  |
| Aripiprazole Lauroxil (Aristada® Initio™ ) 675mg syringe  | Limited to 1 unit per 18-month period  |
| Olanzapine (Zyprexa Relprevv®) 210mg & 300mg60 tablets per 30 days | 2 units every 28 days |
| Olanzapine (Zyprexa Relprevv®) 405mg | 1 unit every 28 days |
| Paliperidone Palmitate (Invega Hafyera®) | 1 unit every 180 days |
| Paliperidone Palmitate (Invega Sustenna®)  | Initiation: 2 units in 14 days;Maintenance: 1 unit every 28 days  |
| Paliperidone Palmitate (Invega Trinza®)  | 1 unit every 84 days  |
| Risperidone (Perseris™)  | 1 unit every 28 days  |
| Risperidone (Risperdal Consta®)  | 2 units every 28 days  |
| Risperidone Microspheres (Rykindo®) | 2 units every 28 days |
| Risperidone (Uzedy™) 50mg; 75mg; 100mg; 125mg syringe | 1 unit every 28 days |
| Risperidone (Uzedy™) 150mg; 200mg; 250mg syringe | 1 unit every 56 days |

**NOTE**:  Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Therapeutic Duplication**

Pharmacy claims for a beneficiary with an active oral antipsychotic prescription on file will deny when an additional pharmacy claim for a second oral antipsychotic prescription is submitted.

Pharmacy claims for a beneficiary with an active injectable antipsychotic prescription on file will deny when an additional pharmacy claim for a second injectable antipsychotic prescription is submitted.

**Therapeutic Duplication of Olanzapine/Samidorphan (Lybalvi™) with Another Oral Antipsychotic Medication**

An incoming pharmacy claim for olanzapine/samidorphan (Lybalvi™) will deny with a therapeutic duplication if there is an active claim for another oral antipsychotic medication on file. Conversely, a claim for another oral antipsychotic medication will deny with a therapeutic duplication if there is an active claim for olanzapine/samidorphan (Lybalvi™) on file.

**Therapeutic Duplication of** **Paliperidone Palmitate (Invega Hafyera™) with Another Injectable Antipsychotic Medication**

An incoming pharmacy claim for paliperidone palmitate (Invega Hafyera™) will deny with a therapeutic duplication, if there is an active claim for another injectable antipsychotic medication on file. Conversely, a claim for another injectable antipsychotic medication will deny with a therapeutic duplication, if there is an active claim for paliperidone palmitate (Invega Hafyera™) on file.

**Prior Use Requirement Antipsychotic Agents**

Select antipsychotic agents have a prior use requirement at POS.

Pharmacy claims for cariprazine (Vraylar®) have a prior use requirement of a previous claim for cariprazine **OR** a preferred generic oral antipsychotic within the previous 365 days.

Pharmacy claims for lurasidone (Latuda®) have a prior use requirement of a previous claim for lurasidone **OR** a preferred generic oral antipsychotic within the previous 365 days.

An incoming pharmacy claim for paliperidone palmitate (Invega Hafyera™) will require a previous claim for any **ONE** of the medications listed below including the requested medication:

1. Four claims for Invega Sustenna® in the previous 120-day period; **OR**
2. One claim for Invega Trinza® in the previous 90-day period; **OR**
3. One claim for Invega Hafyera™ in the previous 365 days.

**Prior Use Requirement Antipsychotic Injectables Chart**

These agents require evidence in pharmacy claims indicating established tolerance with previous use of an oral or injectable form.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Antivirals, Oral**

Pharmacy claims for select oral antiviral agents require PA.

**Asthma/COPD- Immunomodulators**

Pharmacy claims for select immunomodulators require PA.

**Atidarsagene Autotemcel (LenmeldyTM)**

Pharmacy claims for atidarsagene autotemcel (LenmeldyTM) require a clinical authorization.

**Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD) Agents**

Prescriptions forAttention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD agents will require an appropriate diagnosis code for reimbursement. Pharmacy claims for select ADD/ADHD medications will be subject to quantity limits. ADD/ADHD will be checked for therapeutic duplication.

The numeric diagnosis code must be documented on the hardcopy prescription or in the pharmacy’s electronic record keeping system. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis code is required for the claim submission.

Pharmacy claims for ADD and ADHD medications that have a missing or invalid diagnosis code will deny at POS.

When beneficiaries are established on ADD/ADHD medications, but the diagnosis codes submitted are not included in the table of covered diagnoses, prescribing providers may call the RxPA Unit (Refer to Section 37.5.4 for contact information.)

**NOTE:** Refer to the link to access the *POS User Guide* for detailed billing instructions at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Therapeutic Duplication**

Pharmacy claims for ADD/ADHD medications will be subject to a therapeutic duplication.

An incoming pharmacy claim for a short-acting ADD/ADHD medication will deny when there is an active claim on file for another short-acting ADD/ADHD medication. An incoming claim for a long-acting ADD/ADHD medication will deny when there is an active claim on file for another long-acting ADD/ADHD medication.

An incoming pharmacy claim for an ADD/ADHD medication will deny when there is an active claim on file for another ADD/ADHD medication written by a different prescriber.

**Therapeutic Duplication of Serdexmethylphenidate/ Dexmethylphenidate (Azstarys™) with Another Long-Acting ADD/ADHD Medication**

An incoming pharmacy claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) will deny with a therapeutic duplication if there is an active claim for another long-acting ADD/ADHD medication on file. Conversely, a claim for long-acting ADD/ADHD medication will deny with a therapeutic duplication if there is an active claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) on file.

**Therapeutic Duplication of Serdexmethylphenidate/ Dexmethylphenidate (Azstarys™) with Another Short-Acting ADD/ADHD Medication**

An incoming pharmacy claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) will deny with a therapeutic duplication if there is an active claim for another short-acting ADD/ADHD medication on file. Conversely, a claim for short-acting ADD/ADHD medication will deny with a therapeutic duplication if there is an active claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) on file.

**Therapeutic Duplication of Xelstrym™ with another Long-Acting Stimulant or Related Medication for ADHD**

Pharmacy claims for dextroamphetamine (Xelstrym™) will deny if there is an active claim on the beneficiary’s file for any other long-acting stimulant and related medication for ADHD and vice versa.

**Behavioral Health Medications for Beneficiaries 7 Years of Age and Younger**

Pharmacy claims for behavioral health medications for beneficiaries 7 years of age and younger require an approved clinical authorization for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Clinical Authorization for ADD/ADHD Medications for Beneficiaries Less Than 7 years of Age**

Pharmacy claims for ADD/ADHD medications for beneficiaries less than 7 years of age require an approved clinical authorization for reimbursement.

**Benign Prostatic Hyperplasia (BPH) Treatment Agents**

Pharmacy claims for benign prostatic treatment agents may be subject to the following:

1. PA;
2. Diagnosis code requirement; and
3. Duration of therapy.

Select benign prostatic treatment agents are listed in the following chart:

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Alfuzosin ER Tablet |
| Doxazosin ER Tablet, Tablet (Cardura XL®; Cardura®) |
| Dutasteride Capsule (Avodart®) |
| Dutasteride/Tamsulosin Capsule (Jalyn®) |
| Finasteride (Proscar®) |
| Finasteride/Tadalafil (Entadfi®)  |
| Silodosin Capsule (Rapaflo®) |
| Tadalafil (Cialis®) |
| Tamsulosin Capsule (Flomax®) |
| Terazosin Capsule |

Pharmacy claims for the BPH treatment agents listed in the following chart require an appropriate diagnosis code entered at POS for beneficiaries who are younger than 18 years of age.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Dutasteride (Avodart®) |
| Finasteride (Proscar®) |

Pharmacy claims for BPH treatment agents listed in the following chart require an appropriate diagnosis code for beneficiaries at any age.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Finasteride/tadalafil (Entadfi®)  |
| Tadalafil (Cialis®) |

Pharmacy claims for the following **BPH** treatment agents are limited to a duration of therapy.

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Maximum Duration of Therapy** |
| Finasteride/tadalafil (Entadfi®)  | 26 weeks |
| Tadalafil 2.5mg or 5mg (Cialis®) when used with finasteride (Proscar®) | 26 weeks |

**Beremagene geperpavec-sydt (VyjuvekTM)**

Pharmacy claims for beremagene geperpavec-sydt (VyjuvekTM) require an approved clinical authorization for reimbursement.

**NOTE:** Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Birch triterpenes (Filsuvez®)**

Pharmacy claims for birch triterpenes (Filsuvez®) require a clinical authorization for reimbursement.

**Bronchodilator, Inhaled Beta Adrenergic**

Pharmacy claims for inhaled beta adrenergic bronchodilator may be subject to the following:

1. PA; and
2. Quantity limit.

Select inhaled beta adrenergic bronchodilators have quantity limits as listed in the following chart.

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Quantity Limit** |
| Albuterol Sulfate Nebulizer Solution 0.63 mg/3 mL | 375 ml per 30 days |
| Albuterol Sulfate Nebulizer Solution 1.25 mg/3 mL | 375 ml per 30 days |
| Albuterol Sulfate Nebulizer Solution 2.5 mg/3 mL | 375 ml per 30 days |
| Albuterol Sulfate Nebulizer Solution 2.5 mg/0.5 mL | 375 ml per 30 days |
| Arformoterol Inhalation Solution (Brovana®) | 120 ml per 30 days |
| Formoterol Inhalation Solution (Perforomist®) | 120 ml per 30 days |
| Levalbuterol Nebulizer Solution | 288 ml per 30 days |
| Levalbuterol Nebulizer Solution Concentrate | 90 vials per 30 days |
| Olodaterol (Striverdi® Respimat®) | 1 inhaler per 30 days |
| Salmeterol Xinafoate (Serevent® Diskus®) | 1 inhaler per 30 days |

**Budesonide (EohiliaTM)**

Pharmacy claims for budesonide (EohiliaTM) will be subject to the following:

1. Age Requirement;
2. Diagnosis Code; and
3. Duration of Therapy Edit.

Pharmacy claims for budesonide (EohiliaTM) have diagnosis code and age requirement of 11 years of age or older on the date of service.

**NOTE**: Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

Prescriptions for budesonide (EohiliaTM) will deny when the duration of therapy exceeds 12 weeks.

**Carisoprodol**

Pharmacy claims for carisoprodol will deny when the quantity exceeds 90 tablets per rolling 90 days. The quantity limit is cumulative and applies to all strengths and combinations of carisoprodol. The pharmacy claim will deny as exceeding the program’s maximum allowed. **There are no provisions for overrides**.

**Cefiderocol (Fetroja)**

Pharmacy claims for cefiderocol (Fetroja®) have a clinical authorization requirement.

**Cenegermin-bkbj (Oxervate TM)**

Pharmacy claims for cenegermin-bkbj (OxervateTM) require an approved clinical authorization for reimbursement.

**Chorionic Gonadotropin (Novarel®, Pregnyl®)**

Pharmacy claims for chorionic gonadotropin (Novarel®, Pregnyl®) require an appropriate diagnosis code entered at POS.

**NOTE:** Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Clotting Factor Products**

Clotting factor products administered in an outpatient setting will **only** be reimbursed as a pharmacy benefit, not as a medical/professional benefit.

Select clotting factors products are reimbursed in the pharmacy program, exluding Hemlibra.

Brand name examples of clotting factor products are listed in the following chart.

|  |  |  |
| --- | --- | --- |
| Advate® | Feiba®  | Nuwiq® |
| Adynovate® | Fibryga®  | Obizur® |
| Afstyla® | Hemofil®  | Profilnine® |
| Alphanate® | Humate®  | Rebinyn® |
| Alphanine® | Idelvion ® | Recombinatetm |
| Alprolix® | Ixinity®  | Riastap Vial® |
| Altuviiio® | Jivi® | Rixubis® |
| Balfaxar® | Kcentra®  | Sevenfact® |
| Benefix® | Koate®  | Tretten® |
| Coagadex®  | Kogenate® | Vonvendi® |
| Corifact® | Kovaltry® | Wilate®  |
| Eloctate® | Novoeight® | Xyntha® |
| Esperoct®  | Novoseven® |  |

**Codeine**

Pharmacy claims for products containing codeine have an age limit for reimbursement. The acceptable age limits are listed in the chart:

|  |  |
| --- | --- |
| **Description** | **Age (Y=Year)** |
| Codeine (Single Ingredient) | >18 Y |
| Codeine Combination Product | >12 Y |

**Contraceptive Agents**

Medicaid health plans are required to allow a six month supply (180 days supply) of contraceptive drugs to be obtained at one time by the beneficiary when the beneficiary has used the same contraceptive drugs for at least 6 consecutive months prior to receiving a 6-month supply, unless the following applies:

1. The beneficiary requests a smaller supply; or
2. The prescribing provider instructs for the beneficiary to receive a smaller supply.

**Drospirenone/Ethinylestradiol/Levomefolate Calcium (Beyaz®)**

Pharmacy claims for Drospirenone/Ethinyl Estradiol/Levomefolate Calcium (Beyaz®) require an appropriate diagnosis code for reimbursement. Claims submitted with diagnosis codes for cosmetic indications will deny.

**Etonogestrel (Nexplanon®)**

Pharmacy claims for Etonogestrel (Nexplanon®) will be limited to one implant every 2 years.

If the prescriber chooses to exceed the quantity limit for Etonogestrel (Nexplanon®), the pharmacist may override the limit after consultation with the prescribing practitioner. The pharmacist must document the NCPDP override codes and reason for the override on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

**Etonogesetrel/Ethinyl Estradiol Vaginal Ring (Nuvaring®)**

Prescription claims for Etonogestrel/Ethinyl Estradiol vaginal ring (Nuvaring®) for quantities of four and greater will deny. There is no provision for override as these claims exceed the program maximum of a 100 unit doses.

In addition, there will be a valid days’ supply range dependent on the quantity billed:

1. If quantity = 1, then Days’ Supply must be 21 to 28;
2. If quantity = 2, then Days’ Supply must be 42 to 56; and
3. If quantity – 3, then Days’ Supply must be 63 to 84.

Pharmacists are allowed to override the denial on days’ supply after consultation with the prescriber.

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Oral Contraceptive Agents**

Oral contraceptive agents will have an age limit of 12-55 years of age per program policy for legacy Medicaid.

Pharmacy claims for oral contraceptive agents are subject to an **educational alert** encouraging the submission of a diagnosis code at POS. The acceptable diagnosis codes for oral contraceptives as a family planning benefit or for menstrual disorders are listed in the chart.

| **ICD-10-CM Diagnosis Code**  | **Diagnosis Description** |
| --- | --- |
| Z30\* | Encounter for oral contraceptive management |
| F32.81 | Premenstrual dysphoric disorder |
| N92\* | Excessive, frequent and irregular menstruation |

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code.

**Medroxyprogesterone Acetate Injectable**

Prescription claims for Medroxyprogesterone Acetate injectable for female beneficiaries billed with a quantity of one and a days’ supply less than 84 will deny. Quantities of two and greater will not be payable with no provision for override as they exceed the program maximum of a 100 unit doses.

Claims for Medroxyprogesterone Acetate sub-q 104 injectable for female beneficiaries, billed with a quantity of 0.65 and a days’ supply less than 84, will deny. Quantities of 1.3 and greater will not be payable, with no provision for override, as they exceed the program maximum of a 100 unit doses.

Pharmacists are allowed to override the denial on days’ supply after consultation with the prescriber.

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Norelgestromin /Ethinyl Estradiol Transdermal Patches (Ortho-Evra) ®)**

Reimbursement of these contraceptive transdermal patches when dispensed using the package size of three must be billed in multiples of three. If the quantity billed is not a multiple of three, the claim will deny. There are no provisions for override.

**Corticotropin (Acthar® Gel, CortropinTM Gel)**

Pharmacy claims for corticotropin (Acthar® Gel, CortropinTM Gel) require an approved clinical authorization for reimbursement.

**Crinecerfont (CrenessityTM)**

Pharmacy claims for crinecerfont (CrenessityTM) require an approved clinical authorization for reimbursement.

**Cytokine and Cell-Adhesion Molecule (CAM) Antagonists**

Prescriptions for cytokine and cell-adhesion molecule (CAM) antagonists may require the following for reimbursement:

1. Clinical authorization or PA; and/or
2. Quantity limit.

The quantity limits for select cytokine and CAM antagonists are listed in the chart.

|  |  |
| --- | --- |
| **Generic (Brand Example)** |  **Quantity Limit** |
| Adalimumab (Humira®) 10mg, 20mg, 40mg | 4 injections per 28 days |
| Adalimumab (Humira®) 80mg | 2 injections per 28 days |
| Etanercept (Enbrel®) | Starting Dose – 8 injections per 28 days for 3 months (if applicable) |
| Maintenance Dose – 4 injections per 28 days |

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Cystic Fibrosis Agents**

Pharmacy claims for select agents for the treatment of cystic fibrosis may require PA.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Danicopan (Voydeya®)**

Pharmacy claims for danicopan (Voydeya®) require a diagnosis code for reimbursement.

**NOTE**: Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Deferiprone (Ferriprox)**

Pharmacy claims for deferiprone (Ferriprox) will require an approved diagnosis code for chronic iron overload due to blood transfusions (E83.111) entered at POS.

**NOTE**: Refer to the Diagnosis Code Policy Chart at: https://ldh.la.gov/assets/HealthyLa/PDL/7.30.2020/Louisiana.Medicaid.ICD-10.Chart.docx

**Deferasirox (Exjade ®, Jadenu®)**

Pharmacy claims for deferasirox (Exjade®, Jadenu®) are subject to diagnosis code requirements and age limitations.

**Beneficiaries 2 years of age and less**

Pharmacy claims for deferasirox (Exjade®, Jadenu®) will deny for beneficiaries 2 years of age or less.

**Beneficiaries 2-9 years of age**

Pharmacy claims for deferasirox (Exjade®, Jadenu®) require a valid diagnosis code for reimbursement. The diagnosis code must be documented on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

**Beneficiaries 10 years of age and older**

Pharmacy claims for deferasirox (Exjade®, Jadenu®) require a valid diagnosis code for reimbursement. The diagnosis code must be documented on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

The appropriate diagnosis codes for deferasirox (Exjade®) are listed in the chart:

| **Covered Indications at POS** | **ICD-10-CM Diagnosis Code** |
| --- | --- |
| **2-9 years of age** |
| Chronic iron overload due to blood transfusion | E83.111 |
| **10 years of age and older** |
| Chronic iron overload due to blood transfusion | E83.111 |
| Chronic iron overload in non-transfusion- dependent thalassemia (NTDT) syndromes | D56.0, D56.1, D56.5, D56.8, D57.4\* |

\* - any number or letter or combination of UP TO 4 numbers and letters of an assigned ICD-10-CM diagnosis code

**Dermatology-Antipsoriatics, Topical**

Pharmacy claims for topical antipsoriatic dermatology agents may be subject to a PA.

Pharmacy claims for tapinarof (Vtama®) are subject to a prior use requirement of at least ONE paid claim in the previous 180 days for:

1. Tapinarof (Vtama);
2. Topical corticosteroid; **OR**
3. Topical calcineurin inhibitor.

**Dermatology-Atopic Dermatitis Immunodulators**

Pharmacy claims for atopic dermatitis immunodulators may require a clinical authorization or PA.

Pharmacy claims for crisaborole (Eucrisa®) have a quantity limit and prior use requirement.

Crisaborole Ointment (Eucrisa®) is subject to a quantity limit of 300 gm per rolling 365 days.

Pharmacy claims for crisaborole ointment (Eucrisa®) or ruxolitinib (OpzeluraTM), requires prior use of at least **ONE** paid claim in the previous 180 days for:

1. Drug [crisaborole ointment (Eucrisa®) or ruxolitinib cream (OpzeluraTM)];
2. Topical corticosteroid; **OR**
3. Topical calcineurin inhibitor.

**Point of Sale Bypass Diagnosis for Opzelura® (Ruxolitinib) Prior Drug Use Requirement**

Pharmacy claims submitted for ruxolitinib (Opzelura®), when submitted with a diagnosis code for nonsegmental vitiligo (L80), will bypass the POS prior drug use requirement for ruxolitinib (Opzelura®), which requires prior use of ruxolitinib (Opzelura®), a topical corticosteroid, or topical calcineurin inhibitor.

**Dermatology-Emollients**

Pharmacy claims submitted for emollients may require PA.

**Dermatology- Immunodulators, Topical**

Pharmacy claims for topical immunodulators may require a PA. Additional clinical information (age, diagnosis, etc.) is required for sirolimus (Hyftor™). Pharmacy claims for imiquimod must be submitted with an appropriate diagnosis code.

**Desmopressin (Nocdurna®)**

Pharmacy claims for desmopressin (Nocdurna®) have a quantity limit.

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Brand Name** | **Quantity Limit** |
| Desmopressin | Nocdurna® | 30 tablets/day |

**Diabetic Testing Supplies**

The Pharmacy Program reimburses claims for prescribed diabetic testing supplies. Diabetic testing supplies will have a diagnosis code requirement and quantity limit.

|  |  |  |
| --- | --- | --- |
| **Diagnosis Description** | **ICD-10-CM Diagnosis Code** | **Quantity Limit** |
| Diabetes Due to Other Conditions or Causes | E08\*, E09\*, E013\* | 100/102 Test Strips/90 days and100/102 Lancets/90 days |
| Type 2 Diabetes Mellitus | E11\* |
| Type 1 Diabetes Mellitus | E10\* | 200/204 Test Strips/30 daysand200/204 Lancets/30 days |
| Gestational Diabetes; Diabetes Mellitus in Pregnancy | O24.4\*; O24\* |
| Long-Term (Current) Use of Insulin(Insulin Treated Non-Type 1 Diabetes Mellitus) | Z79.4\* |

\*any number or letter or combination of UP TO FOUR numbers or letters of an assigned ICD-10-

CM diagnosis code.

All diabetic supply claims submitted to Medicaid will deny when beneficiaries are Medicare Part B eligible. Medicare Part B covers diabetic supplies for all diabetic beneficiaries regardless of insulin requirements. Pharmacy providers shall submit these claims to the Medicare durable medical equipment regional carrier (DMERC). These claims will then automatically cross over to the Medicaid fiscal intermediary (FI) for payment of the coinsurance and deductible amounts, where applicable.

Diabetic supplies and glucometers for long-term care beneficiaries are not covered in the Medicaid Pharmacy Program or through PA because they are covered in the nursing facility per diem rate.

It is allowable for Medicare Part B to be billed if the long-term care beneficiary is eligible for the benefit. Medicaid is not obligated to pay the coinsurance and deductible if the items are included in the Medicaid per diem. The Medicaid FI will automatically deny any crossover claims for diabetic supplies for long-term care beneficiaries.

**NOTE:** Refer to Section 37.5.7 - Medicare Prescription Drug Coverage for detailed information.

**Dextromethorphan/Quinidine (Nuedexta®)**

Pharmacy claims for dextromethorphan/quinidine (Nuedexta®) are subject to the quantity limit listed in the chart.

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Brand Name** | **Quantity Limit** |
| Dextromethorphan/Quinidine | Nuedexta® | 60 tablets/30 days |

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  |  |  |
|  |

**Dichlorphenamide** **(Keveyis®)**

Pharmacy claims for dichlorphenamide are subject to a quantity limit of 120 tablets/30 days.

**Dofetilide (Tikosyn®)**

Pharmacy claims for dofetilide (Tikosyn®) have a clinical authorization requirement.

**Doxepin Cream (Prudoxin®, Zonalon®)**

Pharmacy claims for doxepin cream will be subject to the following edits:

1. Diagnosis code requirement;
2. Age limit;
3. Quantity limit; and
4. Therapeutic duplication.

**Diagnosis Code Requirement**

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) require a diagnosis code. The acceptable diagnosis codes are listed in the chart.

|  |  |  |  |
| --- | --- | --- | --- |
| **Generic Name** | **Brand Name** | **Description of Diagnosis** | **ICD-10-CM Diagnosis Code** |
| Doxepin Cream | Prudoxin®, Zonalon® | Atopic Dermatitis | L20\* |
| Lichen Simplex Chronicus | L28.0 |

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Age Limit**

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) will deny when the beneficiary is less than 18 years old.

**Quantity Limit**

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon® will have a quantity limit of 45 grams per rolling 30 days.

**Therapeutic Duplication**

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) will deny with a therapeutic duplication if there is an active claim on the beneficiary’s file for doxepin cream (Prudoxin®, Zonalon®).

**Duchenne Muscular Dystrophy**

Pharmacy claims for select Duchenne Muscular Dystrophy agents require an approved clinical authorization.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Casimersen (Amondys 45®) |
| Delandistrogene Moxeparvovec-rokl (Elevidys™)  |
| Eteplirsen (Exondys 51®) |
| Golodirsen (Vyondys 53®) |
| Viltolarsen (Viltepso®) |

**NOTE:** Refer to <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> for the PDL, which gives drug specific clinical authorization criteria and instructions.

**Eculizumab (Soliris®)**

Pharmacy claims for eculizumab (Soliris®) require a diagnosis code for reimbursement.

|  |  |
| --- | --- |
| **ICD-10-CM Diagnosis** **Code\*** | **Diagnosis Description** |
| D59.3 | Hemolytic-uremic syndrome |
| D59.5 | Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli] |
| G36.0 | Neuromyelitis Optica Spectrum Disorder (NMOSD) |
| G70.0 | Myasthenia Gravis |

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Epinephrine Injection (Generic, EpiPen®, and EpiPen Jr®)**

Prescriptions for epinephrine injection have the following quantity limits for reimbursement.

|  |  |
| --- | --- |
| **Medication** | **Quantity Limit** |
| Epipen® (Brand and Generic)Epipen Jr® (Brand and Generic) | 4 boxes of 2 syringes (8 syringes total) per rolling 365 days |

**Esketamine Intranasal (Spravato®)**

Pharmacy claims for esketamine intranasal (Spravato®) require an approved clinical authorization for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Elagolix (Orilissa ®)**

Pharmacy claims for elagolix (Orilissa®) require an approved clinical authorization for reimbursement.

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  |  |  |
|  |  |
|  |  |
|  |  |

**Fabry (-Anderson) Disease Agents**

Pharmacy claims for Fabry (-Anderson) Disease agents will be subject to the following:

1. Diagnosis code requirement and
2. Therapeutic duplication.

Select Fabry (-Anderson) Disease agents are listed in the following chart.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Agalsidase beta (Fabrazyme®) |
| Migalastat (Galafold™) |
| Pegunigalsidase alfa-iwxj (Elfabrio®) |

**Fecal Microbiota Spores, Live-brpk (VowstTM)**

Pharmacy claims for fecal microbiota spores, live-brpk (VowstTM) require a PA.

**Fertility Agents**

Fertility preparations, when they are used solely for the treatment of infertility, are not reimbursable. The drugs include Clomiphene citrate tablets 50mg, Urofollitropin ampules 75IU, and Menotropins ampules 150IU and 75IU.

**Fidanacogene Elaparvovec-dzkt (Beqvez™)**

Pharmacy claims for fidanacogene elaparvovec-dzkt (BeqvezTM) require a PA.

**Foscarbidopa/Foslevodopa (VyalevTM)**

Pharmacy claims for foscarbidopa/foslevodopa (VyalevTM) require an approved clinical authorization for reimbursement.

**Givosiran (Givlaari®)**

Pharmacy claims for Givosiran (Givlaari®) have a clinical authorization requirement.

**Glucagon Agents**

Pharmacy claims for some glucagon agents may be subject to the following:

1. PA; and
2. Quantity limit.

Select glucagon agents have a quantity limit as listed in the following chart.

|  |  |
| --- | --- |
| **Generic (Brand)** | **Quantity Limit** |
| Dasiglucagon Auto-Injector, Syringe (Zegalogue™) | 2 units per 30 days |
| Glucagon, Human Recombinant Injection | 2 units per 30 days |
| Glucagon, Human Recombinant Injection Emergency Kit (Amphastar) | 2 units per 30 days |
| Glucagon Injection Emergency Kit (Fresenius Kabi) | 2 units per 30 days |
| Glucagon Nasal (Baqsimi®) | 2 units per 30 days |
| Glucagon Subcutaneous Pen, Syringe, Vial (Gvoke®) | 2 units per 30 days |

**Granulocyte Colony Stimulating Factor Agents (GCSF)**

Pharmacy claims for Granulocyte Colony Stimulating Factor (GCSF) agents will be subject to the following:

1. Prior or clinical authorization.

Select Granulocyte Colony Stimulating Factor (GCSF) agents are listed in the following chart.

| **Generic Name (Brand Name Example)** |
| --- |
| Eflapegrastim-xnst (Rolvedon™) |
| Filgrastim (Neupogen®) |
| Filgrastim-aafi (Nivestym®) |
| Filgrastim-ayow (Releuko®) |
| Filgrastim-sndz (Zarxio®) |
| Pegfilgrastim (Neulasta®) |
| Pegfilgrastim-apgf (Nyvepria®)  |
| Pegfilgrastim-bmez (Ziextenzo®) |
| Pegfilgrastim-cbqv (Udenyca®) |
| Pegfilgrastim-fpgk (Stimufend®) |
| Pegfilgrastim-jmdb (Fulphila®) |
| Pegfilgrastim-pbbk (Fylnetra®) |
| Sargramostim (Leukine®) |
| Tbo-filgrastim (Granix®) |

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Growth Factor Agents**

Pharmacy claims for Growth Factor agents require PA. Growth Factor agents are listed in the following chart.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Mecasermin Subcutaneous (Increlex®) |
| Tesamorelin Acetate Subcutaneous (Egrifta SV®) |
| Vosoritide Vial (Voxzogo™) |

**Growth Hormone**

Prescriptions for Growth Hormone will be reimbursed when:

1. The prescriber has obtained an approved clinical authorization; and
2. An acceptable diagnosis code has been submitted with the pharmacy claim.

**Diagnosis Code Requirement**

Pharmacy claims for Growth Hormone will require an acceptable diagnosis code for reimbursement.

**Select Growth Hormone agents are listed in the following chart:**

|  |
| --- |
| **Generic Name (Brand Name Examples)** |
| Lonapegsomatropin-tcgd (Skytrofa®) |
| Somatropin Cartridge, Syringe (Genotropin®) |
| Somatropin Pen (Norditropin® FlexPro®) |
| Somatropin Cartridge, Vial (Omnitrope®, Saizen®) |
| Somatropin Vial (Serostim®, Zomacton®, Zorbtive®) |
| Somapacitan-beco (Sogroya®) |
| Somatrogon-ghla (Ngenla®) |

**NOTE**: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Hepatitis C Virus Direct-Acting (DAA) Antiviral Agents**

Hepatitis C Direct Acting Antiviral Agent(s) may be subject to PA and quantity limits.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Hemophilia Agents**

Pharmacy claims for select hemophilia agents may be subject to the following:

1. Prior/clinical authorization; and
2. Diagnosis code requirement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/non-preferred agents, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Hereditary Angioedema (HAE) Agents**

Pharmacy claims for Hereditary Angioedema agents require an approved clinical pre-authorization for reimbursement. The select HAE agents are as follows:

1. Berotralstat Hydrochlorode (Orladeyo);
2. C1 Inhibitor, Human Injection (Berinert®);
3. C1 Inhibitor, Human Injection (Cinryze®);
4. C1 Inhibitor, Human Injection (Haegarda®);
5. C1 Inhibitor (Recombinant) Injection (Ruconest®);
6. Ecallantide Injection (Kalbitor®);
7. Icatibant Acetate Subcutaneous (Generic);
8. Icatibant Acetate Injection (Firazyr®); and
9. Lanadelumab Injection (Takhzyro®).

Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Inhaled Antibiotics**

Pharmacy claims for inhaled antibiotic agents may require the following:

1. PA; and
2. Diagnosis code requirement.

Select inhaled antibiotic agents are listed in the following chart:

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Amikacin inhalation suspension (Arikayce®) |
| Aztreonam solution (Cayston®) |
| Tobramycin nebulizer solution, inhaler (Bethkis®, Kitabis Pak®, Tobi®) |

**Imiquimod**

Pharmacy claims for imiquimod require a diagnosis code. (See chart below).

|  |  |  |
| --- | --- | --- |
| **Generic-Brand Example** | **Diagnosis** | **ICD-10-CM Diagnosis Code** |
| Imiquimod – Zyclara® 2.5%  | Actinic Keratosis | L57.0 |
| Imiquimod – Zyclara® 3.75% | Actinic Keratosis | L57.0 |
| External Genital Warts (Condylomata Acuminata) | A63.0 |
| Imiquimod – Aldara® 5% | Actinic Keratosis | L57.0 |
| External Genital Warts (Condylomata Acuminata) | A63.0 |
| Superficial Basal Cell Carcinoma | C44.•1\* |

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Immune Globulin (Human)**

Pharmacy claims for select Immune Globulin (Human) agents have a clinical authorization requirement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Immunomodulators, Lupus**

Pharmacy claims for immunomodulators for the treatment of lupus may require PA.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Immunosupressive Agents**

Pharmacy claims for immunosuppressive agents may be subject to a prior or clinical authorization.

Select immunosuppressive agents are listed in the following chart.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Avacopan Capsule (Tavneos™) |
| Azathioprine Tablet (Azasan®; Imuran®) |
| Belumosudil Tablet (Rezurock™) |
| Cyclosporine Capsule, Solution (Sandimmune®) |
| Cyclosporine Capsule, Softgel, Solution – MODIFIED (Neoral®) |
| Everolimus Tablet (Generic; Zortress®) |
| Mycophenolate Mofetil Capsule, Suspension, Tablet (CellCept®) |
| Mycophenolic Acid as Mycophenolate Sodium (Myfortic®)  |
| Sirolimus Solution, Tablet (Rapamune®) |
| Tacrolimus Capsule, Granule Packet (Prograf®) |
| Tacrolimus ER Capsule (Astagraf ® XL) |
| Tacrolimus ER Tablet (Envarus® XR) |

**Incretin Mimetic/Enhancers**

Prescriptions for incretin mimetic/enhancers may be subject to the following:

1. Age requirement;
2. Diagnosis code requirement;
3. Prior or clinical authorization;
4. Prior use [empagliflozin/linagliptin/metformin (Trijardy® XR)];
5. Quantity limits;
6. Maximum daily dose limits; and
7. Terapeutic duplication.

**Age Requirement**

The following chart list the age requirements for select incretin mimetic/enhancers.

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Minimum Age** |
| Dulaglutide (Trulicity®) | 10 years |
| Exenatide (Bydureon® BCise™) | 10 years |
| Exenatide (Byetta®) | 18 years |
| Liraglutide (Victoza®) | 10 years |
| Semaglutide (Ozempic®, Rybelsus®) | 18 years |
| Tirzepatide (Mounjaro®) | 18 years |

**Diagnosis Code Requirement**

Pharmacy claimes for select incretin mimetic/enhancers require a diagnosis code.

**NOTE:** Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Prior or Clinical Authorization**

Pharmacy claims for select incretin mimetic/enhancers may require a prior or clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Prior Use for Empagliflozin/Linagliptin/Metformin (Trijardy® XR)**

Pharmacy claims for empagliflozin/linagliptin/metformin (Trijardy® XR) will be subject to prior use verification that there has been one of the following:

1. At least a 90-day supply of **ONE** of the following in the previous 180-day period:
2. Metformin **AND either** a DPP-4 **or** an SGLT2; **OR**
3. A combination DPP-4/metformin **or** SGLT2/metformin.
4. At least a 60-day supply of empagliflozin/linagliptin/metformin (Trijardy® XR) in the previous 90-day period.

**Quantity Limit**

The quantity limits for select incretin mimetics/enhancers are listed in the chart below:

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Quantity Limit** |
| Dulaglutide (Trulicity®) | 1 syringe per week |
| Empagliflozin/Linagliptin/Metformin (Trijardy® XR) 5 mg / 2.5 mg / 1000 mg | 60 tablets per 30 days |
| Empagliflozin/Linagliptin/Metformin (Trijardy® XR) 10 mg / 5 mg / 1000 mg | 30 tablets per 30 days |
| Empagliflozin/Linagliptin/Metformin (Trijardy® XR) 12.5 mg / 2.5 mg / 1000 mg | 60 tablets per 30 days |
| Empagliflozin/Linagliptin/Metformin (Trijardy® XR) 25 mg / 5 mg / 1000 mg | 30 tablets per 30 days |
| Semaglutide (Rybelsus®) | 30 tablets per 30 days |
| Tirzepatide (Mounjaro™) | 1 syringe per week |

**Maximum Daily Dose Limit**

The maximum dose for select incretin mimetic/enhancers are listed in the chart.

|  |  |
| --- | --- |
| **Medication (Brand Name Example)** | **Maximum Dose** |
| Alogliptin (Nesina®)  | 25mg/day |
| Alogliptin/Metformin (Kazano®) | 25mg/2000mg per day |
| Alogliptin/Pioglitazone (Oseni®) | 25mg/45mg per day |
| Exenatide (Bydureon®, Bydureon® BCiseTM) | 2mg/week |
| Exenatide (Byetta®) | 20mcg/day |
| Linagliptin (Tradjenta®) | 5mg/day |
| Linagliptin/Metformin (Jentadueto®, Jentadueto XR®) | 5mg/2000mg per day |
| Liraglutide (Victoza®) | 1.8mg/day |
| Pramlintide (Symlin®) | Type 1 diabetes: 60mcg SQ immediately prior to each major meal |
| Type 2 diabetes: 120mcg SQ immediately prior to each major meal |
| Saxagliptin (Onglyza®) | 5mg/day |
| Saxagliptin/Metformin ER (Kombiglyze XR®) | 5mg/2000mg per day |
| Semaglutide (Ozempic®) | 2mg/week |
| Sitagliptin (Januvia®) | 100mg/day |
| Sitagliptin/Metformin (Janumet®, Janumet XR®) | 100mg/2000mg per day |
| Sitagliptin (Zituvio™) | 100mg/day |
| \*Authorization at POS is required to exceed maximum doses. |

**Therapeutic Duplication**

1. GLP-1 receptor agonists are monitored at the pharmacy POS for duplication of therapy with other GLP-1 receptor agonists or DPP-4 inhibitors;
2. DPP-4 inhibitors are monitored at the pharmacy POS for duplication of therapy with other DPP-4 inhibitors or GLP-1 receptor agonists;
3. Empagliflozin/Linagliptin/Metformin (Trijardy® XR) is monitored at the pharmacy POS for duplication of therapy with DPP-4 inhibitors. Conversely, DPP-4 inhibitors are monitored at the pharmacy POS for duplication of therapy with empagliflozin/linagliptin/metformin (Trijardy® XR); and
4. Empagliflozin/Linagliptin/Metformin (Trijardy® XR) is monitored at the pharmacy POS for duplication of therapy with SGLT2s. Conversely, SGLT2s are monitored at the pharmacy POS for duplication of therapy with empagliflozin/linagliptin/metformin (Trijardy® XR).

**Inotersen (Tegsedi®)**

Pharmacy claims for inotersen (Tegsedi®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

|  |  |  |  |
| --- | --- | --- | --- |
| **Generic Name** | **Brand Name** | **Diagnosis** | **ICD-10-CM Diagnosis Code** |
| Inotersen | Tegsedi®) | Polyneuropathy of hereditary transthyretin-mediated amyloidosis | E85.1 |

**Interferons**

Select interferons have a diagnosis code requirement. (See chart below).

|  |  |  |
| --- | --- | --- |
| **Generic-Brand Example** | **Diagnosis**  | **ICD-10-CM Diagnosis Code** |
| Interferon Alfa–2B Recombinant – Intron A® | AIDS–Related Kaposi's Sarcoma | C46.\* |
| Chronic Hepatitis B | B18.0, B18.1 |
| Chronic Hepatitis C | B18.2 |
| External Genital Warts (Condylomata Acuminata) | A63.0 |
| Follicular Lymphoma | C82.\* |
| Hairy Cell Leukemia | C91.4\* |
| Melanoma | C43.\* |
| Interferon Gamma–1B – Actimmune® | Chronic Granulomatous Disease | D71 |
| Malignant Osteopetrosis | Q78.2 |
| Peginterferon Alfa–2A – Pegasys® | Chronic Hepatitis B | B18.0, B18.1 |
| Chronic Hepatitis C | B18.2 |
| Peginterferon Alfa–2B – Sylatron® | Melanoma | C43.\* |

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Ivermectin (Stromectol®)**

Pharmacy claims for ivermectin (Stromectol**®**) require an approved diagnosis code for reimbursement at POS.

**Ketorolac**

Pharmacy claims for oral forms of ketorolac will deny for a quantity greater than 20 or the day supply is greater than five days as exceeding the program’s maximum allowed. The pharmacist may override the denial after consultation with the prescriber. The prescriber must supply the diagnosis code and the rationale for using greater than a five day supply of ketorolac. The diagnosis code is required for the claim submission.

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Lasmiditan (Reyvow®)**

Pharmacy claims for lasmiditan (Reyvow®) have a quantity limit of 8 tablets per 30 days.

**Lefamulin (XenletaTM)**

Pharmacy claims for lefamulin (Xenleta™) have a clinical authorization requirement.

**Leniolislab (Joenja®)**

Pharmacy claims for leniolislab (Joenja®) require an appropriate diagnosis code entered at POS.

**NOTE:** Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**L-glutamine oral powder (Endari®)**

Pharmacy claims for l-glutamine oral powder (Endari®) require an approved clinical authorization for reimbursement.

**NOTE**: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

**Lidocaine 3.88% Cream (LidotralTM)**

Pharmacy claims for lidocaine 3.88% cream (LidotralTM) require an approved clinical authorization for reimbursement.

**Lidocaine/Prilocaine 2.5%-2.5% Cream**

Pharmacy claims for lidocaine/prilocaine 2.5%-2.5% Cream have a quantity limit of 30 grams per 30 days.

**Linezolid (Zyvox®)**

Prescriptions for linezolid (Zyvox®) injections, tablets, and oral suspension will only be reimbursed when the prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Lipotropics**

Pharmacy claims for select lipotropics may require the following:

1. Clinical authorization or PA; and
2. Quantity limit.

Select lipotropics are listed in the following chart:

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Alirocumab (Praluent®) |
| Bempedoic Acid Tablet (Nexletol™) |
| Bempedoic Acid and Ezetimibe Tablet (Nexlizet™) |
| Cholestyramine/Aspartame Packet, Powder |
| Cholestyramine/Sucrose Packet, Powder (Questran®) |
| Colesevelam Powder Pack, Tablet (Welchol®) |
| Colestipol Granules, Tablet (Colestid®) |
| Evinacumab-dgnb Vial (Evkeeza®) |
| Evolocumab Auto-Injector, Catridge, Prefiled Syringe (Repatha®) |
| Ezetimibe (Zetia®) |
| Fenofibrate Capsule Micronized, Capsule, Tablet, Tablet Nanocrystallized (Tricor®) |
| Fenofibric Acid Tablet (Fibricor®) |
| Fenofibric Acid Choline Capsule (Trilipix®) |
| Gemfibrozil Tablet (Lopid®) |
| Icosapent Ethyl Capsule (Vascepa®) |
| Inclisiran Syringe (Leqvio®) |
| Lomitapide Capsule (Juxtapid®) |
| Omega-3-acid Ethyl Esters Capsule (Lovaza®) |

Select lipotropics have quantity limits as listed in the following chart:

|  |  |
| --- | --- |
| **Medication (Generic – Brand Example)** | **Quantity Limit** |
| Alirocumab (Praluent®) | 2 injections (2ml) per 28 days |
| Evolocumab (Repatha®) 140mg/ml | 2 injections (2ml) per 28 days |
| Evolocumab (Repatha®) 420mg/3.5ml | 2 injections (7ml) per 28 days |
| Inclisiran (Leqvio®) | 3 injections (4.5mls) per 365 days |
| Lomitapide (Juxtapid®) | 60 capsules per 30 days |

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Lumateperone (Caplyta™)**

Prescriptions for lumateperone (Caplyta**™**) are subject to the following edits:

1. Clinical authorization;
2. Diagnosis Code Requirement;
3. Maximum Daily Dose; and
4. Therapeutic Duplication.

**Clinical Authorization Requirement**

Pharmacy claims submitted for lumateperone (Caplyta™) will require a clinical authorization for beneficiaries 0-5 years old.

**Diagnosis Code Requirement**

Pharmacy claims for lumateperone (Caplyta™) require a valid diagnosis code at POS.

|  |  |
| --- | --- |
|  **Diagnosis**  | **ICD-10-CM Diagnosis Code** |
| Schizophrenia | F20.\* |

\* any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

**Maximum Daily Dose Limit**

Pharmacy claims submitted for lumateperone (Caplyta™) for beneficiaries 6-17 years old will deny.

Pharmacy claims submitted for lumateperone (Caplyta™) for beneficiaries 18 years old or older will deny when the dose exceeds 42mg/day.

**Therapeutic Duplication**

Pharmacy claims for lumateperone (Caplyta™) will deny if the beneficiary has an active prescription on file for a traditional or atypical oral antipsychotics. Pharmacy claims submitted for a traditional or atypical oral antipsychotic will deny if the beneficiary has an active prescription on file for lumateperone (Caplyta™).

**Myasthenia Gravis Agents**

Pharmacy claims for Myasthenia Gravis agents require a diagnosis code.

Select Myasthenia Gravis agents are listed in the following chart.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Efgartigimod alfa-fcab (Vyvgart **®**) |
| Efgartigimod alfa and hyaluronidase-qvfc (Vyvgart**®** Hytrulo) |
| Rozanolixizumab-noli (Rystiggo **®**) |

**NOTE:** Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Mavacamten (Camzyos™)**

Pharmacy claims for mavacamten (Camzyos™) will be subject to the following:

1. Clinical authorization; and
2. Quantity limit.

**Quantity Limit**

Pharmacy claims for mavacamten (Camzyos™)are subject to a quantity limit as listed in the chart.

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Quantity Limit** |
| Mavacamten (Camzyos™) | 30 capsules per 30 days |

**NOTE:** Refer to <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> for the PDL, which gives drug specific Clinical Authorization criteria and instructions.

**Mitapivat (Pyrukynd®)**

Pharmacy claims for mitapivat (Pyrukynd®) require an approved clinical authorization for reimbursement.

**Mosquito Repellents**

Prescriptions for mosquito repellents are covered to decrease the risk of exposure to the Zika virus. Mosquito repellent coverage will be limited to Medicaid beneficiaries:

1. Who are pregnant; or
2. Of childbearing years (women and men 14-44 years of age) who are trying to conceive.

A prescription will be required to cover one of the following products:

| **Product Name** | **Ounces** | **Bill As** |
| --- | --- | --- |
| Cutter Backwoods 25 percent Spray | 6 oz. | 170 g |
| Cutter Skinsations 7 percent Spray | 6 oz. | 177 mL |
| OFF! Family Care 15 percent Spray | 2.5 ounces | 71 g |
| OFF! Deep Woods Dry 25 percent Spray | 4 ounces | 113 g |
| OFF! Deep Woods 25percent Spray | 6 ounces | 170 g |
| OFF! Active 15 percent Spray | 6 ounces | 170 g |
| Repel Sportsmen 25 percent Spray | 6.5 ounces | 184 g |
| Repel Sportsmen Max 40 percent Spray | 6.5 ounces | 184 g |
| Natrapel 20 percent Picaridin | 5 ounces | 177 mL |
| Sawyer Insect Repellent 20 percent Picaridin  | 4 ounces | 118 mL |

**Quantity Limit**

One bottle of mosquito repellent will be covered every rolling 30 days.

**Age Restriction**

Pharmacy claims for mosquito repellents have an age limit of 14 to 44 (of childbearing) years of age.

**Multiple Sclerosis (MS) Treatment Agents**

Prescriptions for Multiple Sclerosis treatment agents may require the following:

1. Clinical authorization or PA; and
2. Quantity limit.

Select MS treatment agents will be subject to the quantity limit as listed in the chart below:

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Quantity Limit** |
| Diroximel fumerate (Vumerity) | 120 capsules per 30 days |

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Nedosiran (RivflozaTM)**

Pharmacy claims for nedosiran (RivflozaTM) require an approved clinical authorization.

**Naloxone**

Pharmacy claims for naloxone have a quantity limit requirement for reimbursement. Refer to the chart below.

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Quantity Limit** |
| Naloxone Nasal Spray (Narcan®)  | 4 units/30 days  |
| Naloxone Nasal Spray (Kloxxado™)  | 4 units/30 days  |
| Naloxone Injectable Solution/Cartridge 0.4mg/ml  | 4 units/30 days  |
| Naloxone Injectable Solution Syringe 1mg/ml  | 4 units/30 days  |
| Naloxone Injectable Solution (5ml, 10ml, 20ml) 1mg/ml  | 1 unit/30 days  |
| Naloxone Injectable Solution (10ml) 0.4mg/ml  | 1 unit/30 days  |
| Naloxone Injectable Solution (Zimhi™)  | 4 syringes (2ml)/30 days  |

**Nicotine Transdermal Patches, Gum and Spray**

Select nicotine transdermal patches, nicotine polacrilix gum, and nicotine spray are covered.

Nicotine transdermal patches are limited to a maximum 168-day duration of therapy in a rolling 365 day period.

Nicotine transdermal patches have a quantity limit of one patch per day.

**Nintedaib (Ofev®)**

Pharmacy claims for nintedaib (Ofev®) have a clinical authorization requirement and quantity limit of 60 capsules/30 days.

**Omaveloxolone (SkyclarysTM)**

Pharmacy claims for omaveloxolone (SkyclarysTM) will be subject to the following:

1. Clinical Authorization; and
2. Quantity Limit.

The quantity limit for omaveloxolone (SkyclarysTM) is listed in the following chart:

|  |  |
| --- | --- |
| **Generic Name (Brand Example)** | **Quantity Limit** |
| Omaveloxolone (Skyclarys™) capsule | 90 capsules/30 days |

**Orlistat**

Medicaid will provide reimbursement to outpatient pharmacies for orlistat prescriptions based on the following criteria:

1. Patient is 12 years of age or older;
2. The prescription is for a maximum of 90 capsules **and** 30 days’ supply;
3. The beneficiary has a documented current body mass index (BMI) of 27 or greater and the prescriber had identified the BMI, in their handwriting, on the dated prescription or a dated and signed attachment to the prescription or the BMI is entered by the pharmacist in the pharmacy’s electronic record keeping system after it is communicated by the prescriber;
4. The beneficiary has other risk factors warranting the use of Orlistat and the prescriber has identified an approved diagnosis code in their handwriting, on the dated prescription or a dated and signed attachment to the prescription; and
5. There are no provisions for override of the prospective drug utilization edits, i.e., early refill (ER) and duplicate drug (ID) editing.

The beneficiary has a diagnosis for other risk factors warranting the use of orlistat (Xenical®) and the prescriber has identified an approved diagnosis code.

**NOTE**: Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Onasemnogene Abeparvovec Injection (Zolgensma®)**

Pharmacy claims for onasemnogene abeparvovec injection (Zolgensma®) require a clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Oxybate Salts (Calcium, Magnesium, Potassium, and Sodium) Oral, (Xywav®)**

Pharmacy claims for oxybate salts (calcium, magnesium, potassium and sodium) oral, (XywavTM) require clinical authorization and may be subject to a therapeutic duplication.

Incoming prescriptions for oxybate salts (calcium, magnesium, potassium and sodium) oral, (XywavTM)will deny with a therapeutic duplication when there is an active prescription on the beneficiary’s file for a CNS depressant medication, whether as a single entity or as a component of a combination product. An active prescription is a prescription in which the days’ supply has not expired. Alternately, incoming prescriptions for a CNS depressant medication will deny with a therapeutic duplication when there is an active prescription on the beneficiary’s file for oxybate salts (calcium, magnesium, potassium and sodium) oral, (XywavTM).

**Palivizumab (Synagis®)**

Prescriptions for palivizumab (Synagis®) will only be reimbursed when prescriptions meet the following criteria:

1. The prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Respiratory Syncytial Virus Season**

Louisiana’s respiratory syncytial virus (RSV) activity may be followed during the RSV season by frequently accessing the Center for Disease Control’s website. (Refer to Section 37.5.4 for web address). The RSV season in Louisiana begins November 1st and ends March 31st.

**Age Restriction**

Palivizumab claims for beneficiaries who are 24 months of age or younger on November 1st of the current RSV season meet the POS age requirement.

**Early Refill**

Palivizumab claims will only process for payment every 28 days. When a pharmacy submits a claim for Synagis® and there is an active paid Synagis® claim on file, the incoming claim will deny. An active prescription is a prescription in which the days’ supply has not expired.

**Maximum Number of Doses Allowed**

Claims billed for Synagis® outside the allowable number of doses will deny, except in an extended RSV Season\*. Based upon the diagnosis code submitted, a maximum of five doses of Synagis® will be reimbursed each RSV season. If the initial dose is given in October, the fifth and final dose should be given in February. If initial dose is given in November, the fifth and final dose should be given in March.

**NOTE:** \*In an extended RSV season, the number of allowed doses reimbursable, is increased to accommodate dosing outside the usual RSV season.

**Medical Reconsideration for Palivizumab (Synagis®)**

Medical reconsideration of a denied clinical authorization decision may be requested by the prescribing practitioner. Medical reconsideration requires completion of the Palivizumab Request for Reconsideration Form.

**Palivizumab Criteria ICD-10-CM Code and Medication List**

**NOTE:** Any accepted diagnosis code listed on the Palivizumab Clinical Authorization Form must have supporting documentation attached. Supporting documentation is supplemental information submitted to support the patient meeting the criteria and may include copies of progress notes, hospital discharge notes, pediatric cardiologist consult notes, chart notes, pharmacy profiles, etc.

**NOTE**:  Refer to the Diagnosis Code Policy Chart at:

<https://ldh.la.gov/assets/HealthyLa/PDL/7.30.2020/Louisiana.Medicaid.ICD-10.Chart.docx>

**Penicillamine (Cuprimine®, Depen®)**

Pharmacy claims for penicillamine (Cuprimine®, Depen®) have quantity limits. The quantity limits are listed in the chart.

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Brand Name** | **Quantity Limit** |
| Penicillamine | Cuprimine® | 240 capsules/30 days |
| Depen® | 240 tablets/30 days |

**Pituitary Suppressive Agents**

Pharmacy claims for pituitary suppressive agents may require a PA and/or a diagnosis code at POS.

**NOTE**:  Refer to the Diagnosis Code Policy Chart at:

[www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Pompe Disease Agents**

Pharmacy claims for Pompe Disease Agents require a diagnosis code entered at POS.

**NOTE**: Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Potassium Binders**

Pharmacy claims for select potassium binder agents may require the following:

1. PA; and
2. Quantity limit.

Select Potassium binder agents are listed in the following chart:

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Patiromer (Veltassa®)\* |
| Sodium Polystyrene Sulfonate Powder |
| Sodium Zirconium Cyclosilicate (Lokelma®) |

Pharmacy claims for the following **potassium binder** agent will be subject to a quantity limit as listed in the chart.

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Quantity Limit** |
| Patiromer (Veltassa®) | 30 packets/30 days |

**Progestational Agents**

Pharmacy claims for progestational agents may be subject to the following:

1. PA;
2. Day Supply; and
3. Diagnosis code requirement.

Select progestational agents are listed in the following chart:

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Hydroxyprogesterone Caproate IM Injection\* |
| Medroxyprogesterone Acetate IM, SQ Injection (Depo-Provera®)\* |
| Medroxyprogesterone Acetate Tablet (Provera®)\* |
| Norethindrone Acetate Tablet (Aygestin®)\* |
| Progesterone Capsule, IM Injection (Prometrium®)\* |
| Progesterone, Micronized Capsule,Vaginal Gel (Crinone®) |

Select progestational agents dispensed with the following quantities are limited to specific days supply as listed in the chart:

|  |  |  |
| --- | --- | --- |
| **Generic Name (Brand Name Example)** | **Quantity Dispensed** | **Days Supply** |
| Medroxyprogesterone Acetate Injection (Depo-Provera®) | 1 ml | 84 days\* |
| Medroxyprogesterone Acetate SQ Injection (Depo-Provera®) | 0.65 ml | 84 days\*\* |

Progesterone injectable agents require a diagnosis code.

| **Medication (Brand Example)** | **Diagnosis Description** | **Diagnosis Code** |
| --- | --- | --- |
| Progesterone Injectable | A diagnosis code is required on pharmacy claims for all ages. Pharmacy claims submitted with certain age-specific diagnosis codes **will** **deny**. | Diagnosis **must** be submitted but **cannot** be: F64\* or Z87.890 if beneficiary is younger than 18 years old N97\* if beneficiary is any age |

**Pyrimethamine (Daraprim®)**

Prescriptions for pyrimethamine (Daraprim®) will be reimbursed when:

1. The prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Schedule II Narcotic Agents**

All prescriptions for Schedule II narcotic agents require a diagnosis code indicating the reason for use documented on the hardcopy prescription or in the pharmacy’s electronic record keeping system. The diagnosis code must be written on the hardcopy prescription by the prescribing practitioner or by the pharmacist in the pharmacy’s electronic record keeping system after consultation with the prescriber.

Except for methadone, when the prescribing practitioner does not indicate a diagnosis code on the prescription and when the prescriber cannot be reached, a denial for a missing diagnosis code may be overridden if the pharmacist determines that the beneficiary cannot wait to receive the medication.

Schedule II narcotic agents are also subject to prospective DURs which address quantity limits.

**NOTE:** Refer to “Prospective Drug Utilization Policies/Limits/Edits” in this section for further information.

**Fentanyl Buccal and Sublingual Agents**

Claims for fentanyl buccal and sublingual agents (Abstral®, Actiq®, Fentora® and Onsolis®) **must** contain a cancer-related diagnosis code in order for the claim to process for payment through the POS System.

Acceptable diagnosis codes are as follows:

|  |  |
| --- | --- |
| **ICD-10-CM Code Range** | **Description** |
| C00.\*-C96\* | Cancer |

Buccal and sublingual agents are subject to prospective DURs which address quantity limits.

**Diagnosis Code Requirement**

Pharmacy claims for fentanyl nasal solution (Lazanda®) and fentanyl sublingual liquid (Subsys®) require an appropriate diagnosis code documented on the hardcopy prescription by either the prescriber or pharmacist. The pharmacist may document the diagnosis code after electronic or verbal consultation with the prescribing practitioner on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

**Age Restriction**

Claims for fentanyl nasal solution (Lazanda®) and fentanyl sublingual liquid (Subsys®) will deny when the beneficiary is 17 years of age or younger.

**Methadone**

All prescriptions for methadone must have a diagnosis code for payment. There are no provisions for an override of methadone when a diagnosis code is omitted. Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs shall only be dispensed by opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

Prescriptions for methadone will be reimbursed when the prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Morphine ER (Avinza®)**

When the cumulative daily dosage for Morphine ER (Avinza®) exceeds the maximum daily dosage, the claim will deny. The maximum daily dosage for this agent is 1600mg per day. There is no provision for override through the POS system for Morphine ER (Avinza®) when the maximum daily dosage is exceeded.

**Oxycodone/Acetaminophen 7.5/325mg (Xartemis XR®)**

Prescriptions for oxycodone/acetaminophen (Xartemis XR®) require an appropriate diagnosis code documented on the hard copy prescription by the prescriber or pharmacist. The pharmacist may document the diagnosis code after electronic or verbal consultation with the prescribing practitioner on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

Pharmacy claims for oxycodone/acetaminophen (Xartemis XR®) have a quantity limit of 30 units every 15 days within a 30-day period.

**Paroxetine Mesylate (Brisdelle®)**

Pharmacy claims for paroxetine mesylate (Brisdelle®) require submission of a valid diagnosis code at POS for reimbursement. The diagnosis code must be documented on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system. The following table lists the acceptable diagnosis codes for paroxetine mesylate (Brisdelle®).

|  |  |  |
| --- | --- | --- |
| **Medication** | **ICD-10-CM****Diagnosis Code\*** | **Diagnosis Description** |
| Paroxetine Mesylate (Brisdelle®)  | E28.310  | Moderate to severe vasomotor symptoms associated with menopause |
| E89.41  |
| N95.1  |

**Patisiran (Onpattro®)**

Pharmacy claims for patisiran (Onpattro®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

|  |  |  |  |
| --- | --- | --- | --- |
| **Generic Name** | **Brand Name** | **Diagnosis** | **ICD-10-CM Diagnosis Code** |
| Patisiran | Onpattro® | Polyneuropathy of hereditary transthyretin-mediated amyloidosis | E85.1 |

**Perampanel (Fycompa®)**

**Age Limit**

Pharmacy claims for perampanel (Fycompa®) will deny for beneficiaries under four years of age.

After consultation with the prescriber to verify the necessity of prescribing perampanel (Fycompa®) for a beneficiary under four years of age, the pharmacist may override the age restriction. The reason for service code, professional service code and result of service code used in submitting the claim must be documented on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Pirfenidone (Esbriet®)**

Pharmacy claims for pirfenidone (Esbriet®) have a clinical authorization requirement and quantity limit of 90 capsules or tablets/30 days.

**Pulmonary Arterial Hypertension (PAH)**

Pharmacy claims for agents for the treatment of pulmonary arterial hypertension have the following edits:

1. Diagnosis code requirement;
2. Quantity limit; and
3. Monitoring for drug-drug interaction.

Pulmonary arterial hypertension treatment agents require an appropriate diagnosis code entered at POS.

**NOTE:** Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

The quantity limit for agents for the treatment of pulmonary arterial hypertension are listed in the chart below.

|  |  |
| --- | --- |
| **Medication** | **Quantity Limit** |
| Ambrisentan Tablet (Letairis®) | 30 tablets per 30 days |
| Bosentan Tablet for Suspension (Tracleer®) | 120 tablets per 30 days |
| Bosentan Tablet (Tracleer®) | 60 tablets per 30 days |
| Iloprost Inhalation Solution (Ventavis®) | 9 cartons per 30 days |
| Macitentan Tablet (Opsumit®) | 30 tablets per 30 days |
| Macitentan and Tadalafil (Opsynvi®) | 30 tablets per 30 days |
| Riociguat Tablet (Adempas®) | 90 tablets per 30 days |
| Selexipag Dose Pack (Uptravi®) | 1 dose pack per 365 days |
| Selexipag Tablet (Uptravi®) | 60 tablets per 30 days |
| Sildenafil Oral Suspension (Liqrev®) | 1 bottle (122ml) per 20 days |
| Sildenafil Powder for Oral Suspension (Revatio®) | 1 bottle (112ml) per 19 days |
| Sildenafil Tablet (Revatio®) | 90 tablets per 30 days |
| Sotatercept-csrk (Winrevair™) | 2 bottles (300ml) per 30 days |
| Tadalafil Tablet (Alyq™; Adcirca®) | 60 tablets per 30 days |
| Tadalafil Suspension (Tadliq®) | 2 bottles (300ml) per 30 days |
| Treprostinil ER Tablet Titration Kit (Month 1, 2, 3) (Orenitram®) | 1 of each kit per 365 days |
| Treprostinil Inhalation Solution Starter Kit with Device (Tyvaso®) | 1 starter kit per 2 years |
| Treprostinil Inhalation Solution Refill Kit (Tyvaso®) | 1 refill kit per 28 days |
| Treprostinil Inhalation Powder Titration Kit (Tyvaso DPI™)  | 1 titration kit per 365 days |
| Treprostinil Inhalation Maintenance Kit (Tyvaso DPI™) | 1 kit per 28 days |

**Drug-Drug Interaction**

Pharmacy claims for macitentan/tadalafil, sildenafil and tadalafil are monitored at the pharmacy POS for a drug-drug interaction with nitrates.

1. Incoming prescriptions for macitentan/tadalafil, sildenafil or tadalafil will deny when the beneficiary has an active prescription (a prescription in which the days’ supply has not expired) for a nitrate; and
2. Incoming prescriptions for a nitrate will deny when the beneficiary has an active prescription (a prescription in which the days’ supply has not expired) for macitentan/tadalafil, sildenafil or tadalafil.

**Quinine Sulfate**

Pharmacy claims for quinine sulfate (Qualaquin®) 324mg have a quantity limit of 42 capsules/7 day supply per 365 days.

**Ravulizumab-cwvz (Ultomiris®)**

Pharmacy claims for ravulizumab-cwvz (Ultomiris®) require an appropriate ICD-10-CM diagnosis code for reimbursement.

**NOTE**:  Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Resmetirom (Rezdiffra ™)**

Pharmacy claims for resmetirom (RezdiffraTM) require a clinical authorization.

**Risdiplam (EvrysdiTM)**

Pharmacy claims for risdiplam (EvrysdiTM) have a quantity limit and clinical authorization requirement.

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Brand Name** | **Quantity Limit** |
| Risdiplam | EvrysdiTM | 160 ml (2-80 ml bottles) |

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Ritlecitinib (LitfuloTM)**

Pharmacy claims for ritlecitinib (LitfuloTM) require an approved clinical authorization for reimbursement.

**Note:** Refer to <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> for the PDL, which gives drug specific clinical authorization criteria and instructions.

**Ropeginterferon alfa-2b-njf (Besremi®)**

Pharmacy claims for ropeginterferon alfa-2b-njf (Besremi®) require an appropriate diagnosis code for reimbursement.

**NOTE**:  Refer to the Diagnosis Code Policy Chart at:

[www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Roflumilast (Daliresp®)**

Pharmacy claims for roflumilast (Daliresp®) require an approved clinical authorization for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Selumetinib (Koselugo™)**

Pharmacy claims for selumetinib (Koselugo®) have a clinical authorization requirement and quantity limit of 120 capsules/30 days.

**Short-Acting Beta2 Agonist Inhalers and Spacers**

Prescriptions for short- acting beta2 agonist inhalers (SABAs) (i.e albuterol, levalbuterol, and pirbuterol):

1. Require an appropriate diagnosis code; and
2. Are subject to a maximum quantity of six short-acting beta2 agonist inhalers per calendar year.

**Diagnosis Code Requirement**

The diagnosis code must be documented on the hardcopy prescription or in the pharmacy’s electronic record keeping system. The diagnosis code may be communicated to the pharmacist electronically, via telephone or facsimile.

Diagnosis codes which bypass the 6 inhaler limit are noted below:

|  |  |  |
| --- | --- | --- |
| **Generic** – **Brand Example** | **Diagnosis Description** | **ICD-10-CM Diagnosis Code(s**) |
| Albuterol – ProAir HFA®, ProAir RespiClick®, ProAir Digihaler®, Proventil HFA®, Ventolin HFA® **YQ** Levalbuterol – Xopenex HFA® **YQ***Yearly Quantity Limit (YQ)* | Bronchitis, not specified | J40 |
| Chronic Airway Obstruction | J44.9 |
| Cystic Fibrosis | E84.\* |
| Emphysema | J43.\* |
| Obstructive Chronic Bronchitis, Chronic Obstructive Asthma | J44.\* |

\* – any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code.

Pharmacy claims that do not indicate a diagnosis code on the prescription and the prescriber cannot be reached; a denial for a missing diagnosis code may be overridden by the pharmacist entering the emergency override.

**Quantity Limit**

If the prescriber chooses to exceed the quantity limit, the prescriber must provide the reason why the limit needs to be exceeded. The pharmacist may override the limit after consultation with the prescriber. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic record-keeping system the following:

1. The prescriber’s reason why the limit needs to be exceeded; and
2. The NCPDP DUR override codes used in submitting the claim.

If the prescriber cannot be reached, the pharmacist may override the quantity limit by entering the emergency override. The pharmacist must document “Emergency” on the hardcopy prescription and the reason for entering the emergency override.

**Therapeutic Duplication**

Pharmacy claims billed for concurrent use of different SABAs will deny with a therapeutic duplication. After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication. This consultation is necessary to confirm that:

1. The prescriber is aware of the current active SABA claim; and
2. The addition of a different SABA is necessary (i.e., a change in therapy).

To bill concurrent therapy with different SABAs, the pharmacist must document on the hardcopy prescription or the pharmacy’s electronic recordkeeping system the following:

1. The reason why an additional SABA was requested by the prescriber; and
2. The NCPDP DUR override codes used in submitting the claim.

**NOTE:** Refer to ‘Drugs with Special Payment Criteria/Limitations’ in this section for further policy regarding short-acting beta2 agonist inhalers.

Pharmacy claims for spacers have a quantity limit of two spacers per rolling 365 days.

**Sickle Cell Anemia Treatment Agents**

The following sickle cell anemia treatment agents may require PA:

|  |
| --- |
| **Generic Name (Brand Name)** |
| Crizanlizumab-tmca Infusion (Adakveo®) |
| Exagamglogene autotemcel (Casgevy™) |
| Hydroxyurea Capsule (Generic; Droxia®) |
| Hydroxyurea Tablet (Siklos®) |
| L-glutamine Powder Pack (Generic; Endari™) |
| Lovotibeglogene autotemcel (Lyfgenia®) |

**Skeletal Muscle Relaxants**

Pharmacy claims for skeletal muscle relaxants that contain codeine (carisoprodol-aspirin-codeine) will deny at the POS if the beneficiary is less than 12 years of age.

Pharmacy claims for skeletal muscle relaxants are subject to a quantity limit. (See chart below.)

|  |  |
| --- | --- |
| **Medication** | **Quantity Limit per 30 days** |
| Baclofen 5mg | 120 Units |
| Baclofen 10mg | 120 Units |
| Baclofen 15mf | 120 Units |
| Baclofen 20mg | 120 Units |
| Cyclobenzaprine 5mg | 90 Units |
| Cyclobenzaprine 7.5mg | 90 Units |
| Cyclobenzaprine 10mg | 90 Units |
| Cyclobenzaprine 15mg | 30 Units |
| Cyclobenzaprine 30mg | 30 Units |
| Tizanidine 2mg | 90 Units |
| Tizanidine 4mg | 90 Units |
| Tizanidine 6mg | 180 Units |

**Smallpox and Monkeypox Live Vaccine (Jynneos)**

The administration of the Smallpox and Monkeypox, Live Vaccine (Jynneos) is covered in the pharmacy program. The federal government covers the ingredient cost.

**Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination Products**

Select Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors may be subject to the following:

1. PA; and
2. Quantity limit.

Select Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and combination products have a quantity limit as listed in the following chart.

|  |  |
| --- | --- |
| **Generic (Brand) Name** | **Quantity Limit** |
| Canagliflozin Tablet (Invokana®) | 1 tablet per day (all strengths) |
| Canagliflozin/Metformin Tablet (Invokamet®) | 2 tablets per day (all strengths) |
| Canagliflozin/Metformin ER Tablet (Invokamet® XR) | 2 tablets per day (all strengths) |
| Dapagliflozin Tablet (Farxiga®) | 1 tablet per day (all strengths) |
| Dapagliflozin/Metformin ER Tablet (Xigduo® XR) | 2 tablets per day (all strengths) |
| Empagliflozin Tablet (Jardiance®) | 1 tablet per day (all strengths) |
| Empagliflozin/Metformin Tablet (Synjardy®) | 2 tablets per day (all strengths) |
| Empagliflozin/Metformin ER Tablet (Synjardy® XR) | 2 tablets per day (all strengths) |
| Ertugliflozin Tablet (Steglatro®) | 1 tablet per day (all strengths) |
| Ertugliflozin/Metformin Tablet (Segluromet®) | 2 tablets per day (all strengths) |
| Sotagliflozin Tablet (Inpefa®) | 1 tablet per day (all strengths) |

**Sodium Oxybate (Xyrem®)**

**Clinical Pre-Authorization**

Pharmacy claims for sodium oxybate (Xyrem®) will be reimbursed when the prescriber has obtained an approved clinical authorization. A diagnosis of narcolepsy or cataplexy must be submitted in the clinical authorization process.

**Therapeutic Duplication**

Pharmacy claims for sodium oxybate (Xyrem®) will deny when the beneficiary has an active claim on file for a CNS depressant. Claims for CNS depressants will deny when the beneficiary has an active claim on file for sodium oxybate (Xyrem®).

CNS depressant medications include the following agents, whether given as a single entity or as a component of a combination product:

|  |  |  |  |
| --- | --- | --- | --- |
| Alprazolam | Dantrolene | Metaxalone | Quazepam |
| Baclofen | Diazepam | Methadone | Ramelteon |
| Buprenorphine | Dihydrocodeine | Methocarbamol | Remifentanil |
| Buspirone | Doxepin | Midazolam | Secobarbital |
| Butabarbital | Estazolam | Morphine | Sufentanil |
| Butalbital | Eszopiclone | Nalbuphine | Suvorexant |
| Butorphanol | Fentanyl | Opium | Tapentadol |
| Carisoprodol | Flurazepam | Orphenadrine | Tasimelteon |
| Chlordiazepoxide | Hydrocodone | Oxazepam | Temazepam |
| Chlorzoxazone | Hydromorphone | Oxycodone | Tizanidine |
| Clonazepam | Levorphanol | Oxymorphone | Tramadol |
| Clorazepate | Lorazepam | Paregoric | Triazolam |
| Codeine | Meperidine | Pentazocine | Zaleplon |
| Cyclobenzaprine | Meprobamate | Phenobarbital | Zolpidem |

The therapeutic duplication edit for sodium oxybate (Xyrem®) and CNS depressants can be overridden in emergency circumstances. These claims will require consultation and approval from the prescribing provider to override the therapeutic duplication. After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication with the emergency override. The pharmacist must document “**Emergency**” on the hardcopy prescription and the reason why the prescribing provider choose to override the therapeutic duplication.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Sofpironium (Sofdra)**

Pharmacy claims for sofpironium (Sofdra™) are subject to the following:

1. Clinical authorization; and
2. Quantity limit.

The quantity limit for sofpironium (Sofdra™) is one (1) bottle (50ml) per 30 days.

**Somatropin**

Pharmacy claims for Somatropin (Genotropin®, Humatrope®, Norditropin®, Nutropin®, Nutropin AQ®, Omnitrope®, Saizen®, Serostim®, Tev-Tropin®, and Zorbtive®) require an appropriate diagnosis code for reimbursement. The numeric code must be documented on the hardcopy prescription or in the pharmacy’s electronic record keeping system. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile.

There are no overrides for this edit. However, the pharmacist may contact the prescriber for a valid diagnosis code and resubmit the claim.

The following chart addresses acceptable diagnosis code(s) which are in accordance with the reimbursement criteria for somatropin.

| **ICD-10-CM Diagnosis Code(s)** | **Diagnoses** |
| --- | --- |

|  |  |
| --- | --- |
| N25.0 | Growth failure in children associated with:Renal insufficiency or chronic kidney disease |
| Q87.1  | Noonan Syndrome |
| Q87.1  | Prader-Willi Syndrome |
| Q96  | Turner Syndrome |
| P05.1 | Small for gestational age at birth (fetal growth retardation) who fail to manifest catch-up growth or with no catch-up growth |
| R62.52 | Short Stature in children (idiopathic or SHOX deficiency)1. Short stature
2. Lack of expected normal physiological development in childhood
 |
| E23.0 | Pituitary dwarfism |
| E23.0 | Panhypopituitarism |
| E23.1, E89.3  | Iatrogenic pituitary disorders |
| K90.2, K91.2 | (Zorbitive® only) Short Bowel Syndrome in patients receiving specialized nutritional support:1. Blind Loop Syndrome
2. Other unspecified post-surgical nonabsorption
 |
| R64  | (Serostim® only) HIV-associated cachexia or wasting |

**Spinal Muscular Atrophy Agents**

The following spinal muscular atrophy agents may require prior or clinical authorization.

|  |
| --- |
| **Generic Name (Brand Name)** |
| Nusinersen (Spinraza®)\* |
| Onasemnogene abeparvovec-xioi (Zolgensma®)  |
| Risdiplam (Evrysdi®) |

**\*** *Nusinersen (Spinraza®) has a drug specific clinical authorization form.*

**Quantity Limit**

Risdiplam (Evrysdi™) is limited to a maximum quantity of 160ml (2-80ml bottles) every 24 days.

**Statin Agents**

Pharmacy claims for select statin agents may be subject to the following:

1. PA; and
2. Therapeutic duplication.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Sulfonylurea Agents**

Pharmacy claims for sulfonylurea agents may be subject to the following:

1. PA; and
2. Therapeutic duplication.

Sulfonylurea agents may be subject to a therapeutic duplication.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Suvorexant (Belsomra®)**

Pharmacy claims for suvorexant (Belsomra®) are subject to a maximum daily dosage limit of 20 mg/day.

**Tafamidis (Vyndaqel®, Vyndamax®)**

Pharmacy claims for tafamidis (Vyndaqel®, Vyndamax®) have a quantity limit.

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Brand Name** | **Quantity Limit** |
| Tafamidis | Vyndaqel® | 120 capsules/30 days |
| Tafamidis | Vyndamax® | 30 capsules/30days |

**Tasimelteon (Hetlioz®)**

Prescription claims for tasimelteon (Hetlioz®) may be subject to the following clinical edits:

1. Clinical Authorization;
2. Quantity Limit;
3. Maximum Daily Dose; and
4. Therapeutic Duplication.

**Clinical Authorization for tasimelteon (Hetlioz®)**

Pharmacy claims for tasimelteon (Hetlioz®) will be reimbursed at POS when the prescriber has obtained an approved clinical authorization.

Override provisions should be addressed through the Clinical Authorization process.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Maximum Dose for tasimelteon (Hetlioz®)**

Pharmacy claims for tasimelteon (Hetlioz®) have a maximum daily dose of 20mg/day. There are no override provisions through the POS system using NCPDP service codes.

**Therapeutic Duplication for tasimelteon (Hetlioz®)**

Pharmacy claims for tasimelteon (Hetlioz®) will deny at POS if there is an active claim for another sedative-hypnotic agent.

After consultation with the prescriber to verify the necessity of the therapeutic duplication, the pharmacist may override the therapeutic duplication.

The pharmacist must document the override codes on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

**Quantity Limit for tasimelteon (Hetlioz LQTM)**

Pharmacy claims for tasimelteon (Hetlioz LQTM) have a maximum quantity of 158 mls per 31 days.

**Tazarotene (Tazorac®)**

Pharmacy claims for Tazarotene (Tazorac®) require an appropriate diagnosis code for reimbursement. The prescribing provider must document the diagnosis code on the hard copy prescription or may communicate the diagnosis code to the pharmacist electronically, via telephone, or facsimile.

The acceptable diagnosis codes are:

|  |  |
| --- | --- |
| **ICD-10-CM Code** | **Description** |
| L40\* | Psoriatic Arthritis |

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Pharmacy providers may direct questions to the Provider Help Desk concerning overrides for this edit. (Refer to Section 37.5.4 for contact information).

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Tedizolid Phosphate (Sivextro®)**

Prescriptions for tedizolid phosphate (Sivextro®) will be reimbursed when:

1. The prescriber has obtained an approved clinical pre-authorization.

**Teplizumab-mzwv(TzieldTM)**

Pharmacy claims for teplizumab-mzwv (TzieldTM) require an approved clinical authorization for reimbursement.

**Tesamorelin (Egrifta®)**

Pharmacy claims for tesamorelin (Egrifta®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

**Tiotropium Bromide (Spiriva Respimat®)**

Pharmacy claims for tiotropium bromide (Spiriva Respimat®) will require a diagnosis code.

|  |  |  |
| --- | --- | --- |
| **Medication** | **Description of Diagnosis** | **ICD-10 Code** |
| Spiriva Respimat® 1.25 mcg (tiotropium bromide) | Asthma | J45\* |
| Spiriva Respimat® 2.5 mcg (tiotropium bromide)  | COPD | J44\* |

\*any number or letter or combination of UP TO 4 numbers and letters of an assigned ICD-10\_CM diagnosis code.

**Tolvaptan (Samsca®)**

Pharmacy claims for tolvaptan (Samsca®) have quantity limits. The quantity limits for tolvaptan (Samsca®) are listed in the chart.

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Brand Name** | **Quantity Limit** |
| Tolvaptan | Samsca® 15mg | 30 tablets/30 days |
| Samsca® 30 mg | 60 tablets/30 days |

**Tramadol**

Pharmacy claims for tramadol–containing products have the following edits:

1. Age Limit;
2. Clinical Authorization; and
3. Maximum Daily Dose.

|  |  |
| --- | --- |
| **Description** | **Age (Y=Year)** |
| Tramadol | >12 Y |
| Tramadol Combination Product | >12 Y |

Pharmacy claims for tramadol and tramadol combination productswill deny at POS if the beneficiary is less than 12 years of age.

Pharmacy claims for tramadol-containing products submitted for beneficiaries 12-17 years of age without an approved clinical authorization will deny.

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Maximum****Dose per Day** | **Age** |
| Tramadol Immediate Release | 400 mg/day | <76 years |
| Tramadol Immediate Release | 300 mg/day | >75 years |
| Tramadol Extended Release | 300 mg/day |  |
| Tramadol/Acetaminophen | 8 tablets/day |  |

**Trientine Tetrahydrochloride (Cuvrior™)**

Pharmacy claims for trientine tetrahydrochloride (CuvriorTM) will be subject to the following:

1. Clinical authorization; and
2. Quantity limit.

The quantity limit for trientine tetrahydrochloride (CuvriorTM) is listed in the following chart.

|  |  |
| --- | --- |
| **Generic Name (Brand Example)** | **Quantity Limit** |
| Trientine Tetrahydrochloride (Cuvrior™) | 300 tablets/30 days |

**Trifarotene (Aklief®)**

Pharmacy claims for trifarotene (Aklief®) will deny at POS when the beneficiary is younger than 9 years of age or older than 20 years of age.

**Triptans**

Pharmacy claims for triptans for beneficiaries under 18 years of age will require a valid diagnosis code for reimbursement. Triptans are identified in the following chart:

| **Generic Name** | **Representative Brand(s)** |
| --- | --- |
| Almotriptan | Axert®6 |
| Eletriptan | Relpax® |
| Frovatriptan | Frova® |
| Naratriptan | Amerge® |
| Rizatriptan | Maxalt®, Maxalt MLT® |
| Sumatriptan | Alsuma®, Imitrex®, Sumavel®, Zecuity® |
| Zolmitriptan | Zomig®, Zomig ZMT® |

The acceptable ICD-10-CM diagnosis codes for triptans in beneficiaries less than 18 years of age are as follows:

|  |  |  |
| --- | --- | --- |
| **Drug-Brand Example** | **Diagnosis** | **ICD-10-CM Diagnosis Code** |
| Almotriptan – Axert®Eletriptan – Relpax®Frovatriptan – Frova®Naratriptan – Amerge®Rizatriptan – Maxalt®, Maxalt MLT®Sumatriptan [Oral, Nasal] – Imitrex®,  Onzetra Xsail®, Tosymra®Sumatriptan [Injection] – Zembrace SymTouch®Zolmitriptan – Zomig®, Zomig ZMT® | Migraine | G43.0\*, G43.1\*, G43.7\* |
| Sumatriptan [Injection] – Imitrex®, Sumavel® | Migraine | G43.0\*, G43.1\*, G43.7\* |
| Cluster Headache, Acute | G44.009 |

**Trofinetide (DaybueTM)**

Pharmacy claims for trofinetide (DaybueTM) require an appropriate diagnosis code entered at POS.

**NOTE**: Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Urea Cycle Disorder Agents**

Pharmacy claims forUrea Cycle Disorder agents may require a prior or clinical authorization.

Select Urea Cycle Disorder agents are listed in the following chart.

|  |
| --- |
| **Generic Name (Brand Example)** |
| Carglumic Acid (Carbaglu®) |
| Glycerol Phenylbutyrate (Ravicti®) |
| Sodium Phenylbutyrate Pellet (Pheburane®, Olpruva™) |
| Sodium Phenylbutyrate Powder, Tablet (Buphenyl®) |

**NOTE:** Refer to <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> for the PDL for preferred/non-preferred agents, drug specific clinical authorization criteria and instructions.

**Urology: Bladder Relaxant Preparations**

Pharmacy claims for mirabegron ER tablet (Myrbetriq®) have a quantity limit of one tablet per day.

**Vaccines (Adult)**

Louisiana Medicaid will reimburse enrolled **pharmacies** for select adult vaccines and the COVID vaccine administered by a pharmacist with the “Authority to Administer” authorized by the Louisiana Board of Pharmacy. Adult vaccine reimbursement includes reimbursement for the ingredient cost and administration fee.

**Counseling for Vaccines**

Counseling for vaccines will be reimbursed for beneficiaries less than 21 years old when the vaccine is administered and criteria has been met.

The following criteria must be followed to receive reimbursement for vaccine counseling:

1. Confirm that the patient is not currently “up-to-date” with vaccine dosing, as recommended by the Advisory Committee on Immunization Practices (ACIP) or Centers for Disease Control and Prevention (CDC);
2. Confirm vaccination status in the Louisiana Immunization Network for Kids Statewide (LINKS), whenever possible;
3. Confirm patient consent of the parent, guardian or caregiver (if appropriate) to receive the counseling and vaccine;
4. Document the type and Brand of the vaccine or booster;
5. Confirm the Medicaid beneficiary is (for counseling reimbursement):
	1. From 3-20 years old for COVID vaccine;
	2. From 3-20 years old for influenza vaccine; or
	3. From 3-20 years old for all other vaccines:

**NOTE:** PREP Act allowance for ages 3-6 years until January 1, 2030 for COVID and influenza vaccines.

1. Counsel the patient, along with their parent, guardian, or caregiver (if appropriate) on the safety and effectiveness of vaccines;
2. Answer any questions that the patient or parent, guardian, or caregiver has regarding vaccination;
3. Counsel the patient, along with their parent, guardian, or caregiver (if appropriate) for a minimum of five minutes; and
4. Administer the vaccine.

**Pharmacist Requirements**

For adult vaccine reimbursement, the pharmacist shall:

1. Be registered with the Louisiana Board of Pharmacy with the “Authority to Administer” vaccines;
2. Be registered as a Louisiana Medicaid provider;
3. Inform the individual that the administration of an immunization or vaccine is not to be construed as being in lieu of an annual preventive visit with the individual's primary care or family physician;
4. Access the Louisiana Immunization Network for Kids (LINKS) prior to immunization administration, if possible, to verify appropriate utilization according to the Advisory Committee on Immunization Practices (ACIP) to prevent duplication, unnecessary doses, inappropriate age, etc.;
5. Report each immunization to the Louisiana Department of Health (LDH), Office of Public Health's LINKS at the time of the immunization or as soon as reasonably possible, thereafter;
6. Report all adverse events observed or which are reported to the pharmacist to the Vaccine Adverse Events Reporting System, or its successor program; and further, the pharmacist shall refer the patient with an adverse event to appropriate medical care;
7. Report certain data elements to the CDC for each COVID vaccine administered within 24 hours of administration, as a vaccination Provider;
8. Ensure that pharmacy technicians and/or state-authorized pharmacy interns administering COVID vaccines meet PREP Act qualifications. The qualified pharmacy technicians and/or state-authorized pharmacy interns act under the supervision of a qualified pharmacist. The supervising qualified pharmacist of qualified pharmacy technicians and/or state-authorized interns must comply with CDC, state, and federal requirements for COVID vaccine administration; and
9. Request the name of a patient's primary care provider prior to the administering of any immunization. The pharmacist shall notify the primary care provider, by written or electronic communication, as soon as reasonably possible that the immunization was administered.

All 340B pharmacies carved-in to Medicaid may bill vaccines and the administration fee for adults (19 years and older) at POS as a pharmacy benefit.

There will be no copay assessed on adult vaccine claims. Third party billing policy will apply and Medicaid will be the payer of last resort.

Pharmacy claims for vaccines will bypass POS edits for the four prescription monthly limit and pharmacy Lock-In.

The following chart lists select adult vaccines with age limits covered when administered by a pharmacist as a pharmacy claim:

|  |  |  |
| --- | --- | --- |
| **Vaccines** | **Brand Name Examples** | **Age Limit** |
| BCG LIVE | BCG (TICE Strain) | > 19 years |
| COVID | Various Brands | \* |
| *H. influenzae* Type B Conjugate  | Hiberix | > 19 years |
| Hepatitis A Adult | Vaqta®, Havrix® | > 19 years |
| Hepatitis A – Hepatitis B Adult  | Twinrix® | > 19 years |
| Hepatitis B Adult (recombinant adjuvanted) | Heplisav-B® | > 19 years |
| Hepatitis B Adult (recombinant) | Engerix-B®, *Recombivax HB*® | > 19 years |
| Hepatitis B vaccine [trivalent (recombinant)] | PreHevbrio® | > 19 years |
| HPV – Human Papillomavirus 9-valent  | Gardasil®9 | 19-45 years |
| Influenza Vaccine | Various Brands | \* |
| Japanese Encephalitis  | Ixiaro | > 19 years |
| Measles, Mumps & Rubella  | M-M-R®II, Priorix® | > 19 years |
| Meningococcal (Groups A, B, C, W, and Y) | Penbraya | 10-25 years |
| Meningococcal Conjugate (Groups A, C, Y and W-135)  | Menveo®, Menactra®, MenQuadfi® | > 19 years |
| MENB – Meningococcal Group B  | Trumenba®, Bexsero® | > 19 years |
| Pneumococcal – 13-valent | Prevnar 13™ | > 19 years |
| Pneumococcal – 15-valent | Vaxneuvance™ | > 19 years |
| Pneumococcal – 20-valent | Prevnar 20™ | > 19 years |
| Pneumococcal Polysaccharide (23-valent) | Pneumovax®23 | > 19 years |
| Poliomyelitis  | Ipol | > 19 years |
| Rabies Vaccine | Imovax®, RabAvert® | > 19 years |
| RSV Vaccine, Pref A and Pref B | Abrysvo | > 60 years |
| RSVPREF3 Antigen  | Arexvy Kit, Arexvy Vial | > 60 years |
| Smallpox and Monkeypox | Jynneos | \* |
| Tetanus and Diphtheria Toxoids  | TDVAX®, *Tenivac*® | > 19 years |
| Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis  | Adacel®, Boostrix® | > 19 years |
| Varicella  | Varivax® | > 19 years |
| Yellow Fever  | Stamaril, YF-Vax | > 19 years |
| Zoster Vaccine Recombinant, adjuvanted | Shingrix® | > 18 years |

\*There are select age ranges for specific vaccines based on the package insert.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting

 Section 37.5.1 for detailed billing instructions and override procedures.

**COVID Vaccine**

The COVID vaccines are covered by the Louisiana Medicaid pharmacy program. The at home administration of the COVID vaccine is not a covered service effective May 12, 2023. The COVID vaccine administration by pharmacist will be covered for beneficiaries 3 years of age and older in accordance with current prescribing information and PREP ACT guidelines until January 1, 2030.

**COVID Oral Agents**

Pharmacy claims for nirmatrelvir/ritonavir (Paxlovid®) used in the treatment of COVID are covered.

Nirmatrelvir/ritonavir (Paxlovid®) is subject to the following quantity limit and age requirements.

|  |  |  |
| --- | --- | --- |
| **Drug** | **Quantity Limit** | **Age Requirement** |
| nirmatrelvir/ritonavir (Paxlovid®) | 30 tablets/5 days | >12 years  |

**COVID Over-the-Counter (OTC) At Home Tests**

COVID OTC at home diagnostic tests are not covered. Reimbursement for COVID OTC tests ended September 30, 2024.

**Ustekinumab-kfce (YesintekTM)**

Pharmacy claims for ustekinumab-kfce (YesintekTM) require an approved clinical/PA for reimbursement.

**Vanzacaftor, Tezacaftor, and Deutivacaftor (Alyftrek TM)**

Pharmacy claims for vanzacaftor, tezacaftor, and deutivacaftor (AlyftrekTM) require an approved clinical/PA for reimbursement.

**Vamorolone (Agamree®)**

Pharmacy claims for vamorolone (Agamree®) require an approved clinical authorization for reimbursement.

**Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors**

Prescriptions for Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors: deutetrabenazine (Austedo®), tetrabenazine (Xenazine®), and valbenazine (Ingrezza®) will be reimbursed when:

1. The prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Velmanase alfa-tycv (Lamzede®)**

Pharmacy claims for velmanase alfa-tycv (Lamzede®) require an appropriate diagnosis code entered at POS.

**NOTE:** Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Zoledronic Acid (Reclast®)**

Pharmacy claims for zoledronic acid (Reclast®) are subject to the quantity limit listed in the chart.

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Brand Name** | **Quantity Limit** |
| Zoledronic Acid | Reclast® | 1 vial/365 days |

**Zuranolone (ZurzuvaeTM)**

Pharmacy claims for zuranolone (Zurzuvae™) require a PA and are subject to the quantity limits listed in the chart below.

|  |  |
| --- | --- |
| **Medication (Brand Example)** | **Quantity Limit** |
| Zuranolone (Zurzuvae™) 20 mg | 28 capsules per 14 days |
| Zuranolone (Zurzuvae™) 25 mg | 28 capsules per 14 days |
| Zuranolone (Zurzuvae™) 30 mg | 14 capsules per 14 days |

**Diagnosis Code Requirement for Selected Medications**

Prescriptions for selected medications require a diagnosis code for reimbursement for both FFS Medicaid and the MCOs. The diagnosis code should be documented on the hardcopy prescription by the prescriber or pharmacist. The pharmacist may document the diagnosis code on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system after electronic or verbal consultation with the prescribing practitioner.

**NOTE**:  Refer to the Diagnosis Code Policy Chart at:

[www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Prospective Drug Utilization Policies/Limits/Edits**

Pharmacy claims are processed utilizing prospective DUR system which consists of criteria set forth by the state-established DUR board which monitors for inappropriate use of medications and identifies potential drug conflicts. It is designed to work alongside the POS claims processing and eligibility systems, displaying alert messages, based on severity level, to alert of any possible harmful effects that a medication may have on a patient. The alerts generated are caused by various combinations of interactions between a beneficiary’s condition, beneficiary’s historical drug prescription records on file and the current medications prescribed for them.

Professional judgment regarding appropriate drug use is the responsibility of the pharmacist. Improper use of DUR override codes by pharmacy staff may result in the disallowance of these override codes and administrative sanctions by Medicaid and the Board of Pharmacy.

Prospective DUR monitors:

1. Duration of therapy;
2. Early refill;
3. Duplicate drug therapy;
4. Pregnancy and FDA Category X drugs;
5. Therapeutic duplication;
6. Drug to drug interaction;
7. Unnecessary drug therapy;
8. Age and gender restrictions;
9. Maximum dosage;
10. Quantity Limits; and
11. Drugs to diagnosis.

**NOTE:** Refer to Section 37.5.12 for an overview of Patient Counseling, DUR.

**Histamine (H2 ) Antagonists**

Pharmacy claims for H2 antagonists may be subject to a PA.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single PDL, which is inclusive of the preferred/NPDL, clinical authorization list, drug specific forms, criteria, and POS edits at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Proton Pump Inhibitors (PPIs)**

Pharmacy claims for proton pump inhibitors (PPIs) may be subject to following:

1. Prior or clinical authorization;
2. Duration of therapy;
3. Quantity limit; and
4. Therapeutic duplication.

Select proton pump inhibitors (PPIs) are listed in the following chart.

|  |
| --- |
| **Generic Name (Brand Name Example)** |
| Dexlansoprazole Capsule (Dexilant®) |
| Esomeprazole Capsule, Suspension (Nexium®) |
| Lansoprazole Capsule, ODT (Prevacid®, Prevacid SoluTab®) |
| Omeprazole Capsule Rx, Granules for Suspension (Prilosec®) |
| Omeprazole/Sodium Bicarbonate Oral Suspension (Konvomep®) |
| Omeprazole/Sodium Bicarbonate Rx Capsule, Packet (Zegerid®)  |
| Pantoprazole Suspension, Tablet (Protonix®) |
| Rabeprazole Tablet (AcipHex®) |

**Duration of Therapy**

Pharmacy claims forall PPIs are subject to a duration of therapy limit of **180 days** in a rolling **365-day period**.

**Duration of Therapy Exemptions**

The following conditions are exempt from the duration of therapy limit:

1. Beneficiaries under 6 years of age; OR
2. Beneficiaries receiving pancreatic enzymes; OR
3. Pharmacy claims submitted with an appropriate bypass diagnosis code.

**Diagnosis Codes Exempt from the Duration of Therapy Limit for PPIs**

Select diagnosis codes are exempt and bypass the duration of therapy edit for PPIs. (See the following chart for the listing).

|  |  |
| --- | --- |
| **Diagnosis** | **ICD-10-CM Diagnosis Code(s)** |
| Abscess of Esophagus | K20.8 |
| Angiodysplasia of Stomach and Duodenum (with OR without Mention of Hemorrhage) | K31.81\* |
| Atrophic Gastritis with Hemorrhage | K29.41 |
| Barrett’s Esophagus | K22.7\* |
| Cerebral Palsy (*new Aug 2019)* | G80\* |
| Chronic Pancreatitis | K86.0, K86.1 |
| Congenital Tracheoesophageal Fistula | Q39.1, Q39.2 |
| Cystic Fibrosis | E84.\* |
| Eosinophilic Esophagitis | K20.0 |
| Eosinophilic Gastritis | K52.81 |
| Gastrointestinal Hemorrhage | K92.2 |
| Gastrointestinal Mucositis (Ulcerative) | K92.81 |
| Malignant Mast Cell Tumors | C96.2\* |
| Multiple Endocrine Adenomas | D44.0, D44.2, D44.9 |
| Tracheoesophageal Fistula | J86.0, J95.04 |
| Ulcer of Esophagus with OR without Bleeding | K22.1\* |
| Zollinger-Ellison Syndrome | E16.4 |

\* Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

**Quantity Limit**

Pharmacy claims for PPIs will be subject to a quantity limit as listed in the chart:

|  |  |
| --- | --- |
| **Generic Name (Brand Name Example)** | **Quantity Limit per 30 Days** |
| Dexlansoprazole Capsule (Dexilant®) | 30 capsules |
| Esomeprazole Capsule (Nexium®) | 30 capsules |
| Esomeprazole Granules for Oral Suspension (Nexium®) | 1 carton of 30 packets |
| Lansoprazole Capsule (Prevacid®) | 30 capsules |
| Lansoprazole ODT (Prevacid® SoluTab®) | 30 tablets |
| Omeprazole Capsule/Tablet (Prilosec®) | 30 capsules/tablets |
| Omeprazole Granules for Oral Suspension (Prilosec®) | 1 carton of 30 packets |
| Omeprazole/Sodium Bicarbonate Capsule (Zegerid®) | 30 capsules |
| Omeprazole/Sodium Bicarbonate Packet (Zegerid®) | 30 packets |
| Omeprazole/Sodium Bicarbonate Suspension (Konvomep™) | 600 ml |
| Pantoprazole Granules for Oral Suspension (Protonix®) | 1 carton of 30 packets |
| Pantoprazole Tablet (Protonix®) | 30 tablets |
| Rabeprazole Sprinkle Capsule (AcipHex® Sprinkle™) | 30 capsules |
| Rabeprazole Tablet (AcipHex®) | 30 tablets |

**Therapeutic Duplication**

Pharmacy claims for PPIs will deny at POS with a therapeutic duplication if there is an active claim for another PPI on the beneficiary’s file.

**Early Refill**

The Medicaid Program denies pharmacy claims for early refills if the patient has requested the same medication at the same pharmacy prior to 85 percent of medication being utilized. This translates into a five day window based on a 30-day supply.

Prescriptions for narcotic analgesics will deny for an early refill edit when less than 90 percent of the medication had been utilized. This translates into a two day window based on a 30-day supply.

Pharmacists must enter the actual days’ supply for each pharmacy claim. If the number of days is not apparent, an estimate must be given based on professional judgment.

In some cases, the pharmacist may have knowledge of dosage changes which would warrant a beneficiary’s request for medication earlier than previously reported in the estimated days’ supply.

The pharmacist must document the circumstances on the prescription hard copy.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)or by visiting

Section 37.5.1 for detailed billing instructions and override procedures.

**Duplicate Drug Therapy**

A claim denial will occur if the beneficiary attempts to obtain the same drug (form and strength) from a different pharmacy sooner than is anticipated based on the estimated days’ supply.

After consultation with the physician, beneficiary and/or the POS help desk, the provider must determine whether there are extenuating circumstances which substantiate the dispensing of a duplicate claim.

The pharmacy provider shall record documentation of circumstances and specific contacts for the override.

For those isolated instances when one pharmacy has billed a claim, and special circumstances prevented the beneficiary from receiving the prescription from the pharmacy originally billing the claim an override is allowed. An override should only be used if the second pharmacy attempting to bill a claim for the same ingredient for the same beneficiary and cannot have the first claim reversed by the original billing pharmacy. A notation to that effect must be written on the hardcopy prescription or in the pharmacy’s electronic record keeping system. Pharmacy claims submitted with an override code are subject to the pharmacy audit process.

When both duplicate drug therapy and early refill clinical events occur, reimbursement will not be made. These situations indicate multiple pharmacy shopping patterns.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting

Section 37.5.1 for detailed billing instructions and override procedures.

**Pregnancy and FDA Category X Drugs**

The Medicaid Program denies pharmacy claims with FDA Pregnancy Category for pregnant women. Pharmacy claims submitted for a drug in this category for beneficiaries with a co-payment designation of pregnancy will be denied.

The specific drugs that are currently included in FDA Pregnancy Category X are listed below. The Medicaid Program may add drugs to these lists as new drugs appear on the market or as FDA indications change.

There is no override option for these claims.

**Pregnancy and FDA Category D Drugs**

Pharmacy claims submitted with FDA Pregnancy Category D drugs will receive an educational edit in the response from the Medicaid Program. These claims will not deny.

**Prior Drug Use**

Pharmacy claims for select drugs will require prior use of other drug(s) before reimbursement.

Olmesartan/amlodipine/hydrochlorothiazide (Tribenzor®) and amlodipine/valsartan/hydrochlorothiazide (Exforge HCT®) will require prior drug use of two drug therapies from these select drug classes: calcium channel blockers, angiotensin receptor blockers, and/or diuretics. If previous claims for drugs in two of these three drug classes (calcium channel blockers, angiotensin receptor blockers, and/or diuretics) are not identified, the pharmacy claim will deny.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting

Section 37.5.1 for detailed billing instructions and override procedures.

**Therapeutic Duplication**

The Medicaid Program denies pharmacy claims for oral formulations of drugs in the following classes and specific drugs if the beneficiary has an active paid claim on file for another drug in the same therapeutic class. An active prescription is a prescription in which the days’ supply has not expired.

If an override is determined appropriate after contacting the prescriber, additional documentation of the reason for service code, professional service code and result of service code is required on the hard copy prescription or in the pharmacy’s electronic record keeping system. Additional requirements may be associated with certain drug classes or specific drugs.

**First Generation Antihistamine**

|  |  |
| --- | --- |
| Brompheniramine Maleate | Carbinoxamine Maleate |
| Clemastine Fumarate | Cyproheptadine HCL |

If a first generation antihistamine is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

**Second Generation Antihistamine**

|  |  |
| --- | --- |
| Cetirizine HCL | Desloratadine |
| Fexofenadine HCL | Levocetirizine Dihydrochloride |
| Loratadine  |  |

If a second generation antihistamine is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

**First Generation Antihistamine-Decongestant**

|  |  |
| --- | --- |
| Pseudoephedrine HCL/Brompheniramine | Psuedoephedrine HCL/Triprolidine HCL |
| Phenylephrine/Diphenhydramine | Pseudoephedrine HCL/Chlorpheniramine  |

If a first generation antihistamine-decongestant product, is given with another first and/or second generation antihistamine or antihistamine-decongestant product, he claim will deny due to a therapeutic duplication.

**Second Generation Antihistamine-Decongestant**

|  |  |
| --- | --- |
| Cetirizine HCL/Pseudoephedrine | Fexofenadine/Pseudoephedrine |
| Loratadine/Pseudoephedrine | Desloratadine/Pseudoephedrine |

If a second generation antihistamine-decongestant product, is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

Claims for diphenhydramine, hydroxyzine HCl, and hydroxyzine pamoate are not included in the antihistamine edits for therapeutic duplication.

**Angiotensin Converting Enzyme (ACE) Inhibitors and ACE Inhibitor/Diuretic Combinations**

|  |  |
| --- | --- |
| Benazepril HCl | Lisinopril/Hydrochlorothiazide |
| Benazepril HCl/Hydrochlorothiazide | Moexipril HCl |
| Captopril | Moexipril/Hydrochlorothiazide |
| Captopril/Hydrochlorothiazide | Perindopril Erbumine |
| Enalapril Maleate | Quinapril HCl |
| Enalapril/Hydrochlorothiazide | Quinapril/Hydrochlorothiazide |
| Fosinopril Sodium | Fosinopril Sodium |
| Fosinopril/Hydrochlorothiazide | Ramipril |
| Lisinopril | Trandolapril |

**ACE Inhibitors/Calcium Channel Blocker Combinations**

|  |  |
| --- | --- |
| Benazepril/Amloipine | Trandolapril/Verapamil HCl |

**Angiotensin Receptor Antagonists (ARB) and ARB/Diuretic Combinations**

|  |  |
| --- | --- |
| Candesartan Cilexetil | Losartan/Hydrochlorothiazide |
| Candesartan/Hydrochlorothiazide | Olmesartan Medoxomil |
| Eprosartan Mesylate | Olmesartan/Hydrochlorothiazide |
| Eprosartan/Hydrochlorothiazide | Telmisartan |
| Irbesartan | Telmisartan/Hydrochlorothiazide |
| Irbesartan/Hydrochlorothiazide | Valsartan |
| Losartan Potassium | Valsartan/Hydrochlorothiazide |

**ARB/Calcium Channel Blocker Combinations**

|  |  |
| --- | --- |
| Olmesartan Medoxomil/Amlodipine  | Valsartan/Amlodipine |

**Beta-Adrenergic Blocking Agents and Beta-Adrenergic Blocking Agent/Diuretic Combinations**

|  |  |
| --- | --- |
| Acebutolol HCl | Nadolol |
| Atenolol | Nadolol/Bendroflumethiazide |
| Atenolol/Chlorthalidone | Nebivolol HCl |
| Betaxolol HCl | Penbutolol Sulfate |
| Bisoprolol Fumarate | Pindolol |
| Bisoprolol/Hydrochlorothiazide | Propranolol HCl |
| Carvedilol | Propranolol/Hydrochlorothiazide |
| Carvedilol CR | Sotalol AF |
| Labetalol HCl | Sotalol HCl |
| Metoprolol ER | Timolol Maleate |
| Metoprolol Tartrate | Timolol/Hydrochlorothiazide |
| Metoprolol/Hydrochlorothiazide |  |

**Calcium Channel Blockers**

|  |  |
| --- | --- |
| Amlodipine | Nifedipine |
| Diltiazem | Nimodipine |
| Felodipine | Nisoldipine |
| Isradipine | Verapamil |
| Nicardipine |  |

**Calcium Channel Blocker/Antihyperlipemia Agent Combination**

Amlodipine/Atorvastatin Calcium

**Potassium Replacement**

|  |  |
| --- | --- |
| Potassium Acetate | Potassium Bicarbonate/Citric Acid |
| Potassium Chloride | Potassium Citrate  |

**Tricyclic Antidepressants**

|  |  |
| --- | --- |
| Amitriptyline HCl | Imipramine Pamoate |
| Amoxapine | Maprotiline HCl |
| Clomipramine HCl | Nortriptyline HCl |
| Desipramine HCl | Protriptyline HCl |
| Doxepin HCl | Trimipramine Maleate |
| Imipramine HCl |  |

**Selective Serotonin Reuptake Inhibitors**

|  |  |
| --- | --- |
| Citalopram HBr | Paroxetine HCl |
| Escitalopram Oxalate | Paroxetine Mesylate |
| Fluoxetine HCl | Sertraline HCl |
| Fluvoxamine Maleate |  |

**Antipsychotic Agents (Typical and Atypical)**

Prescriptions for antipsychotic agents will deny for therapeutic duplication when the beneficiary has two active antipsychotic prescriptions on their file. The pharmacist must document on the hard copy prescription the reason the prescriber required the beneficiary to receive a third antipsychotic agent.

**Note:** Refer to “Drugs with Special Payment Criteria/Limitations” in this section for further policy regarding antipsychotic agents.

**Typical Antipsychotic Agents**

|  |  |
| --- | --- |
| Chlorpromazine | Pimozide |
| Fluphenazine | Thioridazine |
| Haloperidol | Thiothixene |
| Loxapine | Trifluoperazine |
| Molindone |  |
| Perphenazine |  |

**Atypical Antipsychotic Agents**

|  |  |
| --- | --- |
| Aripiprazole | Lurasidone |
| Asenapine | Olanzapine |
| Brexpiprazole | Paliperidone |
| Cariprazine | Quetiapine |
| Clozapine | Risperidone |
| Iloperidone | Ziprasidone |

**Antipsychotic /Selective Serotonin Reuptake Inhibitor Combinations**

Pharmacy claims for olanzapine/fluoxetine will deny when there are two active prescriptions for antipsychotic agents on the beneficiary’s file or when there is one active prescription for a selective serotonin reuptake inhibitor (SSRI) on the beneficiary’s history file.

Olanzapine**/**Fluoxetine

**Anti-Anxiety Agents**

|  |  |
| --- | --- |
| Alprazolam | Hydroxyzine |
| Buspirone | Lorazepam, Lorazepam XR |
| Chlordiazepoxide | Meprobamate |
| Chlorazepate | Oxazepam |
| Diazepam |  |

The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic recod keeping system the reason an additional anti-anxiety agent was requested by the prescriber.

An additional anti-anxiety agent may be submitted without a therapeutic duplication when the beneficiary has a diagnosis of seizures. The diagnosis code must be documented on the hardcopy prescription or in the pharmacy’s electronic record keeping system, after written or verbal consultation with the prescriber and submitted electronically for the override.

Acceptable diagnosis codes are:

|  |  |
| --- | --- |
| **ICD-10-CM Diagnosis Code(s)** | **Description** |
| P90 | Convulsions in Newborn |
| G40.\* | Epilepsy, Seizures |
| R56.\* | Other Convulsions |

**Sedative Hypnotic Agents**

|  |  |
| --- | --- |
| Estazolam | Temazepam |
| Eszopiclone | Triazolam |
| Flurazepam HCl | Zaleplon |
| Quazepam | Zolpidem Tartrate |

**Attention Deficit Disorder (ADD) Agents**

|  |  |
| --- | --- |
| Armodafinil | Guanfacine |
| Atomoxetine | Lisdexamfetamine |
| Dexmethylphenidate | Methylphenidate |
| Dextroamphetamine | Modafinil |
| Dextroamphentamine/amphetamine |  |

An incoming pharmacy claim for any of the above ADD agents will deny when there is an active paid claim for any of these agents on the beneficiary’s file written by a different prescriber.

**Non-Steroidal Anti-Inflammatory Agents**

|  |  |  |
| --- | --- | --- |
| Celecoxib | Ibuprofen | Meloxicam |
| Diclofenac Potassium | Ibuprofen/Hydrocodone Bitartrate | Nabumetone |
| Diclofenac Sodium | Ibuprofen/Oxycodone | Naproxen |
| Diclofenac Sodium/Misoprostol | Indomethacin | Naproxen Sodium |
| Diflunisal | Ketoprofen | Naproxen/Lansoprazole |
| Etodolac | Ketorolac Tromethamine | Oxaprozin |
| Fenoprofen Calcium | Meclofenamate Sodium | Piroxicam |
| Flurbiprofen | Mefenamic Acid | Tolmetin Sodium |

**Short-Acting Beta2 Agonist Inhalers**

|  |  |
| --- | --- |
| Albuterol  | Pirbuterol |
| Levalbuterol |  |

Pharmacy claims billed for concurrent use of different short-acting beta2 agonist inhalers (SABAs) will deny with a therapeutic duplication.

**NOTE:** Refer to ‘Drugs with Special Payment Criteria/Limitations’ in this section for further policy regarding short-acting beta2 agonist inhalers.

**Short-Acting Opiate Agents**

|  |  |
| --- | --- |
| Buprenorphine\* | Hydrocodone/APAP |
| Buprenorphine/Naloxone\* | Hydrocodone/Ibuprofen |
| Butorphanol Tartrate | Hydromorphone HCl IR |
| Codeine Phosphate | Levorphanol Tartrate |
| Codeine Phosphate/APAP | Meperidine HCl |
| Codeine/ASA | Methadone HCl |
| Codeine Sulfate | Morphine Sulfate IR |
| Codeine/APAP/Caffeine/Butalbital | Oxycodone HCl IR |
| Codeine/ASA/Caffeine/Butalbital | Oxycodone/APAP |
| Codeine/Carisoprodol/ASA | Oxycodone ASA |
| Dihydrocodeine/APAP/Caffeine | Oxycodone/Ibuprofen |
| Fentanyl Ciltrate Buccal | Oxymorphone |
| Pentazocine/APAP | Tramadol HCl  |
| Pentazocine/Naloxone | Tramadol HCl/APAP |

**NOTE:** Concurrent prescriptions for opioid analgesics with buprenorphine agents may only be overridden when issued by the same physician.

**Long-Acting Opiate Agents**

|  |  |
| --- | --- |
| Fentanyl Transdermal  | Oxycodone HCl CR |
| Morphine Sulfate CR | Oxymorphone ER |

**Proton Pump Inhibitors**

|  |  |
| --- | --- |
| Esomerprazole  | Omeprazole/Soduim Bicarbonate |
| Lansoprazole  | Pantoprazole |
| Omeprazole | Rabeprazole  |

**Sulfonylureas**

A pharmacy claim for a sulfonylurea will deny if there is an active claim on the beneficiary’s file for another sulfonylurea.

The Department may add drugs to these lists as new drugs appear on the market.

**NOTE:** Refer to Section 37.5.8 - Claim Submission and Processing Payments for override information as well as the *POS User Guide* accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing information.

**Drug/Drug Interaction**

There may be some situations where adverse interactions could potentially occur between two drugs. In these instances the UniDUR system denies one or both of these claims.

Prescriptions for nitrates will deny when there is an active prescription for Sildenafil (Revatio®) or Tadalafil (Adcirca®) on the beneficiary’s drug history file. Conversely, prescriptions for Sildenafil (Revatio®) and Tadalafil (Adcirca®) will deny when there is an active prescription for nitrates on the drug history file.

Upon consultation with the prescriber, the pharmacist may override this interaction. The pharmacist must document the reason the prescriber required the beneficiary to receive a nitrate and Sildenafil (Revatio®) or Tadalafil (Adcirca®). In addition, documentation of the reason for service code, professional service code and result of service code is required on the hardcopy prescription or in the pharmacy’s electronic record keeping system. These DUR codes are required for the claim submission.

**Unnecessary Drug Therapy**

**Selective Cox-2 Inhibitor**

Pharmacy claims for the selective COX-2 inhibitor, celecoxib (Celebrex®) will deny for “drug use not warranted” if they are not submitted with an appropriate diagnosis code and reason for treatment documented on the hard prescription.

The FDA issued a public health advisory which stated that use of a COX-2 selective agent may be associated with an increased risk of serious cardiovascular events, especially when it is used for long periods of time or in very high-risk settings (e.g. immediately after heart surgery).

The FDA made the following interim recommendations:

1. Practitioners prescribing Celecoxib (Celebrex®) should consider this emerging information when weighing the benefits against risks for individual patients. Patients who are at a high risk of gastrointestinal (GI) bleeding, have a history of intolerance to non-selective NSAIDs or are not doing well on non-selective NSAIDs may be appropriate candidates for COX-2 selective agents; and
2. Individual patient risk for cardiovascular events and other risks commonly associated with NSAIDs should be taken into account for each prescribing situation.

As a result of this public health advisory and to help ensure the safety and well-being of Medicaid beneficiaries, the prescribing practitioner must include:

1. The condition being treated with the COX-2 selective agent by indicating the diagnosis code of the treated condition on all new prescriptions written for a COX-2 selective agent; and
2. The reason a COX-2 selective agent is used rather than a non-selective NSAID (e.g. treatment failure or history of a GI bleed).

The diagnosis code and the rationale for the choice of a COX-2 selective agent must be documented on the hardcopy prescription or in the pharmacy’s electronic record keeping system after consultation with the prescriber. The diagnosis code and the rationale may be submitted as an attachment to the original prescription via facsimile.

A prescription written for a COX-2 selective agent for a Medicaid beneficiary will only process without an override when the following conditions are met:

1. A diagnosis code indicating the reason for treatment is documented and submitted; and
2. When one of the following conditions exists:
	1. Beneficiary has current prescription for H2 receptor antagonist;
	2. Beneficiary has current prescription for proton pump inhibitor;
	3. Beneficiary has current prescription for warfarin;
	4. Beneficiary has current prescriptions indicating chronic use of oral steroids; or
	5. Beneficiary is 60 years of age or older.

If, in the professional judgment of the prescriber, a determination is made which necessitates therapy with a COX-2 selective agent, the pharmacist may override this edit. The pharmacy provider must supply the reason for service code, professional service code and result of service code with the POS submission of the claim and have the information recorded on the hardcopy prescription or in the pharmacy’s electronic record keeping system.

**NOTE:** Refer to Section 37.5.8 - Claim Submission and Processing Payments for override information as well as the *POS User Guide* accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing information.

**Maximum Dosage**

**Atypical Antipsychotic Agents**

Pharmacy claims for doses of antipsychotic agents which exceed the maximum recommended doses will deny.

**NOTE**: Refer to Antipsychotic Agents of this section for the age limits and dosage schedules for antipsychotic agents.

The prescriber may choose to override an age or dosage limit for an antipsychotic medication. Overrides for antipsychotic medications can be addressed by the provider contacting the RxPA Unit. When the pharmacist cannot reach the prescriber or the RxPA Unit is closed, the pharmacist, using their professional judgment, may deem the filling of the antipsychotic prescription to be an “emergency.”  In these emergency cases, the pharmacist must indicate “Emergency Prescription” on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system and override the age or dosage limit.

**Suspending Agents**

Pharmacy claims for the following select suspending agents are reimbursable:

|  |  |
| --- | --- |
| **Generic Name** | **Trade Name1** |
| Compounding Vehicle Suspension No. 19 | Mx-Sol Blend; Ora Blend |
| Compound Vehicle Suspension SF No. 20 | Ora Plus |
| Compounding Vehicle No. 8 | Ora Sweet |
| Compound Vehicle Sugar Free No. 9 | Ora Sweet SF |

**Sedative Hypnotic Agents**

Pharmacyclaims which exceed the maximum daily dosage limit for selected sedative hypnotic agents will deny at POS.

The maximum daily doses for the selected sedative hypnotic agents are as follows:

| **Generic Name** | **Brand Name** | **Maximum Dose Per Day** |
| --- | --- | --- |
| Daridorexant | QuvivqTM | 50mg/day |
| Doxepin (sedative-hypnotic only) | Silenor® | 6 mg/day |
| Estazolam | Prosom® | 2 mg/day |
| Eszopiclone | Lunesta® | 3 mg/day |
| Flurazepam | Dalmane® | 30 mg/day |
| Lemborexant | Dayvigo® | 10mg/day |
| Quazepam | Doral® | 15 mg/day |
| Ramelteon | Rozerem® | 8 mg/day |
| Suvorexant | Belsomra® | 20mg/day |
| Tasimelteon | Heltioz® | 20mg/day |
| Temazepam | Restoril® | 30 mg/day |
| Triazolam | Halcion® | 0.5 mg/day |
| Zaleplon | Sonata® | 20 mg/day |
| Zolpidem IR tablet | Ambien® | 10 mg/day |
| Zolpidem SL tablet | Edluar® | 10 mg/day |
| Zolpidem oral spray | Zolpimist® | 10 mg (2sprays)/day |
| Zolpidem ER tablet | Ambien CR® | 12.5 mg/day |
| Zolpidem SL tablet | Intermezzo® | 1.75mg/day (female) |
| Zolpidem SL tablet | Intermezzo® | 3.5 mg/day (male) |

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)or by visiting

Section 37.5.1 for detailed billing instructions and override procedures.

Pharmacy claims for the following sedative hypnotics will be subject to thequantity limits listed in the chart below:

| **Generic Name (Brand Name Example)** | **Naïve 7-day supply per rolling 30 days1** | **Chronic Use 15-day supply per 30 rolling days2** |
| --- | --- | --- |
| Daridorexant (Quviviq™) | 7 tablets | 15 tablets |
| Doxepin Tablet (Silenor®) | 7 tablets | 15 tablets |
| Estazolam Tablet (ProSom®) | 7 tablets | 15 tablets |
| Eszopiclone Tablet (Lunesta®) | 7 tablets | 15 tablets |
| Flurazepam Capsule (Dalmane®) | 7 capsules | 15 capsules |
| Lemborexant (Dayvigo®) | 7 tablets | 15 tablets |
| Ramelteon Tablet (Rozerem®) | 7 tablets | 15 tablets |
| Suvorexant Tablet (Belsomra®) | 7 tablets | 15 tablets |
| Temazepam Capsule (Restoril®) | 7 capsules | 15 capsules |
| Triazolam Tablet (Halcion®) | 7 tablets | 15 tablets |
| Zaleplon Capsule (Sonata®) | 7 capsules | 15 capsules |
| Zolpidem IR (Ambien®) | 7 tablets | 15 tablets |
| Zolpidem ER (Ambien CR®) | 7 tablets | 15 tablets |
| Zolpidem Sublingual (Edluar®; Intermezzo®) | 7 tablets | 15 tablets |

1 Oral sedative hypnotics for a naïve beneficiary have a 7 day supply per rolling 30 days.

 Naïve is defined as having no paid claims for a sedative hypnotic in the previous 60

 days.

2 Oral sedative hypnotics for chronic use have a 15 day supply per rolling 30 days.

 Chronic use is defined as having a paid claim for a sedative hypnotic in the previous 60

 days.

**Additional information for oral sedative hypnotics:**

1. Pharmacy claims for all sedative/hypnotic agents (except dexmedetomidine, tasimelteon capsule and zolpidem tartrate oral spray) are limited to:
	1. A quantity of 7 per rolling 30 days for beneficiaries who have no sedative/hypnotic pharmacy claims in the previous 60-day period;
	2. A quantity of 15 per rolling 30 days for beneficiaries who have any sedative/hypnotic pharmacy claim in the previous 60-day period; and
	3. Tasimelteon (Hetlioz LQ™) is limited to a maximum quantity of 158 ml per 31 days.

**Exclusions for quantity limit edits for oral sedative hypnotics:**

1. Pharmacy claims submitted with an ICD-10-CM diagnosis code of palliative care (Z51.5) in **NCPDP field 424-DO** will bypass the quantity limit; and
2. Pharmacy claims submitted for tasimelteon capsule (Hetlioz®) and zolpidem tartrate oral spray (ZolpiMist®) are excluded.

Sedative hypnotics are monitored at POS for duplication of therapy with other sedative/hypnotic agents.

**Tapentadol (Nucynta®)**

When the cumulative daily dosage for Tapentadol (Nucynta®) exceeds the maximum daily dosage of 700mg per day, the claim will deny.

If the prescribing practitioner chooses to exceed the maximum daily dosage, the prescribing practitioner must provide the reason why the daily dosage limit needs to be exceeded. The pharmacist may override the dosage limit after consultation with the prescriber. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic record keeping system the prescriber’s reason why the daily dosage limit needs to be exceeded. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system the reason for service code, professional service code and result of service code with the POS submission.

**Agents containing Tramadol**

Pharmacy claims for doses of agents containing Tramadol which exceed the maximum recommended doses will deny.

The maximum daily doses for agents containing Tramadol are as follows:

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Maximum****Dose per Day** | **Age** |
| Tramadol Immediate Release | 400mg/day | <76 years |
| Tramadol Immediate Release | 300mg/day | >75 years |
| Tramadol Sustained Release | 300mg/day |  |
| Tramadol/Acetaminophen | 8 tablets/day |  |

If the prescribing practitioner chooses to exceed the maximum daily dosage, the prescribing practitioner must provide the reason why the daily dosage limit needs to be exceeded. The \*\*\*pharmacist may override the dosage limit after consultation with the prescriber. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic record keeping system the prescriber’s reason why the daily dosage limit needs to be exceeded. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic record keeping system the reason for service code, professional service code and result of service code with the POS submission.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\_User\_Manual\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)or by visiting

Section 37.5.1 for detailed billing instructions and override procedures.

**Tramadol/Celecoxib (Seglentis®)**

Pharmacy claims for tramadol/celecoxib (Seglentis®) will have the following POS edits:

1. Age limit;
2. Concurrent Use;
3. Drug-Drug Interaction;
4. Maximum Daily Dose;

Pharmacy claims for botulinum toxins will be subject to the following:

1. Quantity Limit; and
2. Diagnosis Code Requirement.
3. Quantity limit; and
4. Therapeutic Duplication.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Botulinum Toxins: Abobotulimumtoxin A (Dysport**®), **OnabotulinumtoxinA (Botox®), IncobotulinumtoxinA (Xeomin®), RimabotulinumtoxinB (Myobloc®)**

Pharmacy claims for botulinum toxins will be subject to the following:

1. Quantity Limit; and
2. Diagnosis Code Requirement.

**Quantity Limit**

Pharmacy claims for botulimum toxins have the following quantity limits.

|  |  |
| --- | --- |
| **Generic (Brand Example)** | **Quantity Limit per 84-Day Period** |
| IncobotulinumtoxinA (Xeomin®) | 400 units |
| OnabotulinumtoxinA (Botox®) | 600 units[Six (6) 100-unit vials OR Three (3) 200-unit vials] |

**Diagnosis Code Requirement**

Prescriptions for onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) require an appropriate diagnosis code documented on the hard copy prescription by either the prescriber or pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis code is required for the claim submission.

**Acceptable Diagnosis Codes for OnabotulinumtoxinA (Botox®)**

| **ICD-10-CM Diagnosis Code(s)** | **Description** |
| --- | --- |
| L74.510 | Axillary Hyperhidrosis |
| G24.5 | Blepharospasm |
| G24.3 | Cervical Dystonia |
| G43.7\* | Chronic Migraine (Prophylaxis) |
| N32.81 | Overactive Bladder |
| H49\*, H50\*, H51\* | Strabismus |
| G35 | Upper or Lower Limb Spasticity Associated with Multiple Sclerosis (Relapsing) |
| G80.0, G80.1, G80.2, G80.4, G80.8, G80.9 | Upper or Lower Limb Spasticity Associated with Cerebral Palsy |
| G81.1\* | Upper or Lower Limb Spasticity Associated with Spastic Hemiplegia  |
| G82.53 | Upper or Lower Limb Spasticity Associated with Complete Quadriplegia |
| G82.54 | Upper or Lower Limb Spasticity Associated with Incomplete Quadriplegia  |
| G83.0 | Upper Limb Spasticity Associated with Diplegia of Upper Limb |
| G83.1\*, G83.2\*, G83.3\* | Spasticity Associated with Monoplegia of Upper or Lower Limb |
| I69.•31, I69.•32, I69.•33, I69.•34, I69.•39, I69.•41, I69.•42, I69.•43, I69.•44, I69.•49 | Spasticity Associated with Monoplegia of Upper or Lower Limb due to Late Effects Cerebrovascular Disease  |
| S06.1\*, S06.2\*, S06.3\*, S06.4\*, S06.5\*, S06.6\*, S06.8\*, S06.9\* | Upper or Lower Limb Spasticity Associated with Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury) |
| S14.0\*, S14.1•5\*, S14.1•6\*, S14.1•7\* | Upper or Lower Limb Spasticity Associated with Spinal Cord Injury without Evidence of Spinal Bone Injury  |
| N36.44, N31.9 | Urinary Incontinence (Detrusor Overactivity Associated with Neurological Disease) |

\* - any number or letter or combination of UP TO FOUR numbers and letters of a valid ICD-10-CM diagnosis code

• - any ONE number or letter of a valid ICD-10-CM diagnosis code

**Acceptable Diagnosis Codes for IncobotulinumtoxinA (Xeomin®)**

| **ICD-10-CM Diagnosis Code(s)** | **Description** |
| --- | --- |
| G24.5 | Blepharospasm |
| G24.3 | Cervical Dystonia |
| K11.7 | Chronic Sialorrhea |
| G35 | Upper Limb Spasticity (ULS) Associated with Multiple Sclerosis (Relapsing) |
| G80.0, G80.1, G80.2, G80.4, G80.8, G80.9 | Upper Limb Spasticity (ULS) Associated with Cerebral Palsy |
| G81.1\* | Upper Limb Spasticity (ULS) Associated with Spastic Hemiplegia |
| G82.53 | Upper Limb Spasticity (ULS) Associated with C5-C7 Complete Quadriplegia |
| G82.54 | Upper Limb Spasticity (ULS) Associated with C5-C7 Incomplete Quadriplegia |
| G83.0 | Upper Limb Spasticity (ULS) Associated with Diplegia of Upper Limb |
| I69.31, I69.32, I69.33, I69.34, I69.39 | Upper Limb Spasticity (ULS) Associated with Monoplegia of Upper Limb due to Late Effects of Cerebrovascular Disease |
| I69.51, I69.52, I69.53, I69.54, I69.59 | Upper Limb Spasticity (ULS) Associated with Hemiplegia due to Late Effects of Cerebrovascular Disease |
| S06.1\*, S06.2\*, S06.3\*, S06.4\*, S06.5\*, S06.6\*, S06.8\*, S06.9\* | Upper Limb Spasticity (ULS) Associated with Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury) |
| G83.2\* | Upper Limb Spasticity (ULS) Associated with Monoplegia of Upper Limb |
| S14.0\*, S14.15, S14.16, S14.17 | Upper Limb Spasticity (ULS) Associated with Spinal Cord Injury without Evidence of Spinal Bone Injury (C5-C7) |

\* - any number or letter or combination of UP TO FOUR numbers and letters of a valid ICD-10-CM diagnosis code

• - any ONE number or letter of a valid ICD-10-CM diagnosis code

**Acceptable Diagnosis Codes for RimabotulinumtoxinB (Myobloc®)**

| **ICD-10-CM Diagnosis Code(s)** | **Description** |
| --- | --- |
| K11.7 | Chronic sialorrhea |

**Lidocaine Patches (Lidoderm®)**

Pharmacy claims for lidocaine patches (Lidoderm®) have a quantity limit of 30 patches every rolling 30 days.

Select lidocaine patches (Lidoderm®) and lidocaine patch kits may require PA or clinical authorization.

**Lofexidine (Lucemyra®)**

Pharmacy claims for lofexidine (Lucemyra®) are subject to the following:

1. Age limit;
2. Maximum Daily Dose;
3. Quantity Limit; and
4. Diagnosis Code Requirement.

Pharmacy claims for lofexidine (Lucemyra®) will deny for beneficiaries 17 years or younger.

Lofexidine (Lucemyra®) pharmacy claims are subject to a maximum daily dose of 2.88 mg (16 tablets) per day.

Pharmacy claims for lofexidine (Lucemyra®) tablets are limited to a 14-day supply (224 tablets) per 6-month period (180 days).

Lofexidine (Lucemyra®) pharmacy claims have the following diagnosis code requirement.

|  |  |  |
| --- | --- | --- |
| **Generic** – **Brand Example** | **Diagnosis Description** | **ICD-10-CM Diagnosis Code(s)** |
| Lofexidine – Lucemyra® | Opioid abuse with withdrawal | F11.13 |
| Opioid dependence with withdrawal | F11.23 |
| Opioid use, unspecified with withdrawal | F11.93 |

**Midazolam (Nayzilam®)**

Pharmacy claims for midazolam (Nayzilam ®) have a quantity limit.

|  |  |
| --- | --- |
| **Generic (Brand Example)**  | **Quantity Limit**  |
| Midazolam (Nayzilam®)  | 5 boxes (10 doses) per 30 days  |

**Naltrexone Tablets**

Naltrexone tablets are subject to the following:

1. Age limit;
2. Diagnosis code requirement;
3. Drug-Drug Interaction; and
4. Therapeutic Duplication.

Pharmacy claims for naltrexone tablets will deny for beneficiaries 17 years or younger.

Pharmacy claims for naltrexone tablets have the following diagnosis code requirement.

|  |  |  |
| --- | --- | --- |
| **Generic Name** | **Diagnosis Description** | **ICD-10-CM Diagnosis Code(s)** |
| Naltrexone Tablets | Opioid dependence | F11.2\* |
| Alcohol dependence  | F10.2\* |
| \* – any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD–10–CM diagnosis code |

Pharmacy claims for naltrexone tablets will deny at POS with a drug-drug interaction when there is an active claim on the beneficiary’s file for an opioid or buprenorphine-containing product. Pharmacy claims for opioids or buprenorphine-containing products will deny with a drug-drug interaction when there is an active claim on the beneficiary’s file for naltrexone tablet.

Incoming pharmacy claims for any naltrexone agent will deny for therapeutic duplication when the beneficiary has an active prescription on file for any other naltrexone agent.

**Naltrexone Injection (Vivitrol®)**

Pharmacy claims for naltrexone injection (Vivitrol® are subject to the following for reimbursement:

1. Diagnosis code requirement;
2. Age Limit;
3. Quantity Limit; and
4. Drug-Drug Interaction.

**Diagnosis Code Requirement**

The acceptable diagnosis code(s) for naltrexone injection (Vivitrol®) are listed below:

|  |  |  |
| --- | --- | --- |
| **Medication** | **Diagnosis Description** | **ICD-10-CM****Diagnosis** **Code** |
| Naltrexone Injection (Vivitrol®) | Alcohol Dependence | F10.2\* |
| Opioid Dependence | F11.2\* |

\* any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Age Limit**

Pharmacy claims for naltrexone injection (Vivitrol®) have a minimum age requirement of 18 years old and older.

**Quantity Limit**

Pharmacy claims for naltrexone injection (Vivitrol®) have a quantity limit of 1 unit (380mg/vial dose kit) per 28 rolling days.

**Drug-Drug Interaction**

Pharmacy claims for naltrexone injection (Vivitrol®) prescriptions will deny if there is an active claim on the beneficiary’s file for an opioid. Pharmacy claims for opioid prescriptions will deny if there is an active claim on the beneficiary’s file for naltrexone injection (Vivitrol®).

**Opioids**

Pharmacy claims for opioids may be subject to the following:

1. Age limit;
2. Concurrent Use;
3. Drug-Drug interaction;
4. Diagnosis code;
5. Maximum Daily Dose;
6. Morphine Milligram Equivalent;
7. PA;
8. Prior Use;
9. Quantity Limit; and
10. Therapeutic Duplication.

**Age Limit**

Pharmacy claims for narcotic analgesics are limited to use in beneficiaries within agent-specific age ranges.

Codeine single-ingredient products are limited to use in beneficiaries who are at least 18 years of age. Codeine combination products are limited to use in beneficiaries who are at least 12 years of age.

Tramadol (tablets/solution) and tramadol combination products are limited to use in beneficiaries who are at least 12 years old.\*

\**Use of tramadol products for beneficiaries 12 to less than 18 years of age will require authorization*.

**Concurrent Use**

Concurrent use of opioid analgesics and benzodiazepines is monitored in the POS system.

Pharmacy claims for an opioid analgesic will deny when the beneficiary has an active prescription (a prescription in which the days’ supply has not expired) for a benzodiazepine.

**Drug-Drug-Interaction**

Pharmacy claims for any opioid (including buprenorphine-containing products) will deny for drug-drug interaction when the beneficiary has an active prescription (a prescription in which the days’ supply has not expired) for naltrexone tablets or naltrexone extended-release injectable suspension (Vivitrol®) and vice versa.

**Diagnosis Code Requirement**

Pharmacy claims for all Schedule II opioid prescriptions must be submitted with a valid diagnosis code.

Pharmacy claims for fentanyl buccal and sublingual agents must be submitted with a cancer-related diagnosis code (C00.\*-C96.\*).

\* *Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code*

**Maximum Daily Dose**

Pharmacy claims for select narcotic analgesics are limited to a maximum daily dose.

Buprenorphine buccal film (Belbuca®) is limited to a maximum daily dose of 1800mcg/24hr.

Buprenorphine transdermal (Butrans®) is limited to a maximum daily dose of 480mcg/24hr (20mcg/hr). Each patch is intended to be worn for seven days.

Morphine sulfate ER (Avinza®) is limited to a maximum daily dose of 1600mg/day.

Tapentadol immediate-release formulation is limited to a maximum daily dose of 700mg per day.

Tapentadol extended-release formulation is limited to a maximum daily dose of 500mg per day.

Tramadol immediate-release tablets and oral solution are limited to a maximum daily dose based on age:

* 1. 400mg/day for beneficiaries who are younger than 76 years of age; and
	2. 300mg/day for beneficiaries who are older than 75 years of age.

Tramadol/acetaminophen is limited to a maximum daily dose of 8 tablets per day.

Tramadol/celecoxib is limited to a maximum daily dose of 4 tablets per day.

Tramadol sustained-release is limited to a maximum daily dose of 300mg/day.

**Morphine Milligram Equivalent**

The cumulative daily morphine milligram equivalent (MME) for all active opioid prescriptions will be limited to a maximum of 90 MME per day.

**Prior Authorization**

Pharmacy claims for select opioids require a PA.

**Prior Use**

Pharmacy claims for long-acting opioids verifies that there has been at least one short-acting or long-acting opioid claim within the previous 90-day period before a long-acting opioid claim will process at POS.

**Quantity Limit**

|  |
| --- |
| **Short-Acting Quantity Limits by Generic**  |
| **No Opioid Claim in Previous 90 days** | **Opioid Claim in Previous 90 days** |
| **Generic** | **7-day Quantity Limit** | **Generic** | **30-day Quantity Limit** |
| Codeine/Acetaminophen | 28 units | Codeine/Acetaminophen | Not Addressed |
| Benzhydrocodone/Acetaminophen | 28 units | Benzhydrocodone/Acetaminophen | 45 units |
| Fentanyl Buccal/Sublingual  | Not Addressed | Fentanyl Buccal/Sublingual  | 120 units |
| Hydrocodone/Acetaminophen  | 28 units | Hydrocodone/Acetaminophen  | 45 units |
| Hydrocodone/Ibuprofen  | 28 units | Hydrocodone/Ibuprofen  | 30 units |
| Hydromorphone  | 28 units | Hydromorphone  | 45 units |
| Meperidine  | 28 units | Meperidine  | 45 units |
| Morphine | 28 units | Morphine  | 45 units |
| Oxycodone  | 28 units | Oxycodone  | 45 units total |
| Oxycodone/Acetaminophen  | Oxycodone/Acetaminophen  |
| Oxymorphone  | 28 units | Oxymorphone  | 45 units |
| Tapentadol  | 28 units | Tapentadol  | 45 units |
| Tramadol  | 28 units | Tramadol  | 45 units |
| Tramadol/Acetaminophen  | 28 units | Tramadol/Acetaminophen | 40 units |
| Tramadol/Celecoxib | 28 units | Tramadol/Celecoxib | 45 units |
| **Short-Acting Opioids: Butalbital** |
| Short-acting opioids, butalbital-containing agents have a quantity limit of 30 units per 30 days. |
| **Oral Opioid Liquid Formulation Quantity Limits if No Opioid Claim in Previous 90 days** |
| All oral opioid liquid products have a quantity limit of 6 ounces (180ml) or a 7-day supply (whichever is less) if there is no opioid claim in the previous 90 days. |
| **Long-Acting 30-day Quantity Limits by Generic (Brand Example)** |
| Fentanyl Patch (Duragesic®) 12mcg/hr, 25mcg/hr, 37.5mcg/hr, 50mcg/hr | 10 units |
| Fentanyl Patch (Duragesic®) 62.5mcg/hr, 75mcg/hr, 87.5mcg/hr, 100mcg/hr | 20 units |
| Hydromorphone (Exalgo®)  | 30 units |
| Hydrocodone (Zohydro ER®)  | 60 units |
| Hydrocodone (Hysingla ER®)  | 30 units |
| Morphine (Avinza®)  | 30 units |
| Morphine (Kadian®)  | 30 units |
| Morphine (MS Contin®)  | 60 units |
| Oxycodone (Oxycontin®)  | 60 units |
| Oxycodone (Xtampza ER®)  | 60 units |
| Oxymorphone (Opana ER®)  | 60 units |
| Tapentadol (Nucynta ER®)  | 60 units |
| Tramadol ER (Conzip®)  | 30 units |

**Therapeutic Duplication**

Opioids are monitored at POS for duplication of therapy with each other and with buprenorphine-containing agents.

Opioids are monitored at POS for duplication of therapy with each other (short-acting narcotics with other short-acting narcotics).

Opioids are monitored at POS for duplication of therapy with each other (long-acting narcotics with other long-acting narcotics).

Pharmacy claims for an opioid analgesic for beneficiaries with an active prescription (a prescription in which the days’ supply has not expired) for buprenorphine-containing agents will deny.

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

**Opioid Dependence Agents**

Prescriptions for opioid dependence agents are subject to the following:

1. Age requirement;
2. Concurrent use;
3. Drug-drug interaction;
4. Diagnosis code;
5. Maximum Daily Dose; and
6. Therapeutic Duplication.

Select opioid dependence agents will have the age requirement listed in the chart.

|  |  |
| --- | --- |
| Generic (Brand Example) | Minimum Age |
| Buprenorphine (Brixadi™, Sublocade®) | 18 years |
| Buprenorphine SL | 16 years |
| Buprenorphine/Naloxone (Suboxone®, Zubsolv® | 16 years |
| Lofexidine (Lucemyra®) | 18 years |
| Nalmefene (Opvee®) | 12 years |
| Naltrexone Extended-Release Injectable Suspension (Vivitrol®) | 18 years |
| Naltrexone Tablet | 18 years |

Opioid dependence agents are monitored for concurrent use with other agents.

1. Incoming pharmacy claims for an opioid analgesic will deny when the beneficiary has an active prescription (a prescription in which the days’ supply has not expired) for an opiate dependence agent; and
2. Incoming pharmacy claims for a benzodiazepine will deny when the beneficiary has an active prescription (a prescription in which the days’ supply has not expired) for an opiate dependence agent.

Pharmacy claims for naltrexone tablets or naltrexone extended-release injectable suspension (Vivitrol®) will deny for drug-drug interaction when the beneficiary has an active prescription (a prescription in which the days’ supply has not expired) for any opioid (including buprenorphine-containing products) and vice versa

Pharmacy claims for select opioid dependence agents must be submitted with an appropriate diagnosis code.

1. Pharmacy claims for all buprenorphine opiate dependence agents (single-ingredient and combination) must be submitted with a diagnosis code for opioid dependence (F11.2\*);
2. Pharmacy claims for lofexidine (Lucemyra®) must be submitted with a diagnosis code for ONE of the following:
3. Opioid abuse with withdrawal – F11.13;

1. Opioid dependence with withdrawal – F11.23; and
2. Opioid use, unspecified with withdrawal – F11.93.
3. Pharmacy claims for naltrexone tablets or naltrexone extended-release injectable suspension (Vivitrol®) must be submitted with either a diagnosis code for opioid dependence (F11.2\*) or alcohol dependence (F10.2\*).

\* *Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code*

Oral buprenorphine agents (single-ingredient and combination) are limited to a maximum daily dose of 24mg per day of buprenorphine or buprenorphine equivalent.

The quantity limits for select opioid dependence agents are listed in the following chart.

|  |  |
| --- | --- |
| **Generic Name (Brand Example)** | **Quantity Limit** |
| Buprenorphine Extended-Release Injection Weekly (Brixadi™) 8mg, 16mg, 24mg or 32mg | 4 units/21 days |
| Buprenorphine Extended-Release Injection Monthly (Brixadi™) 64mg, 96mg or 128mg | 1 unit/21 days |
| Buprenorphine Extended-Release Injection (Sublocade®) | 1 unit/26 days |
| Buprenorphine SL Tablet 2mg | 2 units/day |
| Buprenorphine SL Tablet 8mg | 3 units/day |
| Buprenorphine/Naloxone 2mg/0.5mg SL Tab (Suboxone®) | 2 units/day |
| Buprenorphine/Naloxone 2mg/0.5mg SL Film (Suboxone®) | 1 unit/day |
| Buprenorphine/Naloxone 4mg/1mg SL Film (Suboxone®) | 1 unit/day |
| Buprenorphine/Naloxone 8mg/2mg SL Film/Tab (Suboxone®) | 3 units/day |
| Buprenorphine/Naloxone 12mg/3mg SL Film (Suboxone®) | 2 units/day |
| Buprenorphine/Naloxone SL Tablet 0.7mg/0.18mg (Zubsolv®) | 1 unit/day |
| Buprenorphine/Naloxone SL Tablet 1.4mg/0.36mg (Zubsolv®) | 1 unit/day |
| Buprenorphine/Naloxone SL Tablet 2.9mg/0.71mg (Zubsolv®) | 1 unit/day |
| Buprenorphine/Naloxone SL Tablet 5.7mg/1.4mg (Zubsolv®) | 3 units/day |
| Buprenorphine/Naloxone SL Tablet 8.6mg/2.1mg (Zubsolv®) | 2 units/day |
| Buprenorphine/Naloxone SL Tablet 11.4mg/2.9mg (Zubsolv®) | 1 unit/day |
| Nalmefene (Opvee®) | 4 units/30 days |
| Naloxone Nasal Spray (Narcan®)\* | 4 units/30 days |
| Naloxone Nasal Spray (Kloxxado™)\* | 4 units/30 days |
| Naloxone Injectable Solution Cartridge/Vial (1ml) 0.4mg/ml\*  | 4 units/30 days |
| Naloxone Injectable Solution Syringe 1mg/ml\* | 4 units/30 days |
| Naloxone Injectable Solution (5ml, 10ml, 20ml) 1mg/ml\* | 1 unit/30 days |
| Naloxone Injectable Solution (10ml) 0.4mg/ml\*  | 1 unit/30 days |
| Naloxone Injectable Solution (Zimhi™)\* | 4 syringes (2ml)/30 days |
| Naltrexone Extended-Release Injectable Suspension (Vivitrol®) | 1 unit/28 days |

**NOTE:** Oral buprenorphine agents (single-ingredient and combination) are limited to a maximum daily dose of 24mg per day of buprenorphine or buprenorphine equivalent.

Opiate dependent agents are monitored at the pharmacy POS for duplication of therapy with each other.

1. Incoming prescriptions for buprenorphine or buprenorphine/naloxone agents will deny when the beneficiary has an active prescription (a prescription in which the days’ supply has not expired) for any buprenorphine or buprenorphine/naloxone agent; and

1. Incoming prescriptions for any naltrexone agent will deny when the beneficiary has an active prescription for any other naltrexone agent.

**Serotonin Agents (Triptans)**

Pharmacy claims for quantities of Serotonin agents (Triptans) which are in excess of the quantity limit will deny. Quantity limits are cumulative and are based on a rolling 30 day period. Unless otherwise specified, quantity limits apply to all strengths of an agent.

Quantity limits for Serotonin agents (Triptans) are as follows:

| **Generic Name** | **Dosage Form** | **Quantity Limit per 30 Rolling Days** |
| --- | --- | --- |
| Almotriptan Maleate | Tablet | 12 units |
| Eletriptan HBr | Tablet | 6 units |
| Frovatriptan Succinate | Tablet | 9 units |
| Naratriptan HCl | Tablet | 9 units |
| Rizatriptan Benzoate | Tablet, Tablet rapid dissolve | 12 units |
| Sumatriptan Succinate(Nasal) | Exhaler Powder | 1 kit\*(package size = 16) |
| Sumatriptan Succinate/ Naproxen Na | Tablet | 9 units |
| Sumatriptan Succinate | Tablet | 9 units |
| Zolmitriptan | Tablet, Tablet rapid dissolve | 6 units |

If the prescribing practitioner chooses to exceed the quantity limit, the prescribing practitioner must provide the reason why the quantity limit needs to be exceeded. The pharmacist may override the quantity limit after consulting with the prescriber. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic record keeping system the prescriber’s reason why the quantity limit needs to be exceeded. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic record keeping system the reason for service code, professional service code and result of service code with the POS submission.

**Spironolactone**

Pharmacy claims for spironolactone require a valid diagnosis code submitted for beneficiaries who are younger than 18 years of age. Pharmacy claims which are submitted with a diagnosis code associated with gender dysphoria or gender reassignment (F64\*, Z87.890) will deny.

\* – any number or letter or combination of **UP TO 4** numbers and letters of an assigned ICD–10–CM diagnosis code

**NOTE:** Refer to the Diagnosis Code Policy Chart at: [www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf](http://www.ldh.la.gov/assets/medicaid/PharmPC/9.23.24/Louisiana.Medicaid.ICD-10.Chart.pdf)

**Quantity Limitations**

Prescriptions payable under the Medicaid Program are limited as follows.

**Maximum Allowable Quantities**

The maximum quantity payable is either a one month’s supply or 100 unit doses, whichever is greater.

**Maintenance Medication**

Pharmacy claims for select maintenance medications will have a 90-day allowance at POS. A 90-day supply is allowed on maintenance drugs after a beneficiary has been on the same drug and strength for 60 days.

**Dispensing Fee for Select Maintenance Medications**

An educational edit will alert pharmacies when they are submitting pharmacy claims for maintenance medications that are not dispensed in at least a 30 day supply If a Generic/Brand product and strength has been dispensed for at least 60 days, and the current pharmacy claim is for the same Generic/Brand product and strength and is **NOT** dispensed in a 30 day supply, then an educational alert will be sent. The dispensing fee will not be reimbursed. The pharmacy will still be reimbursed for the ingredient cost on each dispensing.

Override procedures are available. Upon consultation with the prescriber to verify the necessity of the short fill (quantity less than 30 days’ supply), the pharmacist may override the claim and be reimbursed the dispensing fee.

The quarterly FFS Maintenance Medication List can be found at the following link: <https://ldh.la.gov/assets/docs/BayouHealth/Pharmacy/MaintenanceMedications.pdf>

**Coverage and Limitations for Long-Term Care Beneficiaries**

**Quantities for Long-Term Care Beneficiaries**

Providers shall dispense a one month’s supply, unless the prescribing provider specifies a smaller quantity for medical reasons, to beneficiaries in long-term care facilities. Dispensing a smaller quantity should only be done in exceptional cases.

Specific quantity limitations for maintenance medications and prn prescriptions are as follows:

1. “Maintenance” medications are those used to treat chronic conditions or illnesses (see Maintenance Medication section above for quantity limits); and
2. “PRN” prescriptions are those prescriptions that patients utilize on an “as needed” basis. For “prn” prescriptions, thirty units or a 10-day supply shall be supplied, unless otherwise specified by the prescriber.

The beneficiary profile should be periodically reviewed to determine if the “prn” order has become a “maintenance” one. In that event, refer to the “maintenance” drug policy. Otherwise, if every six months, a quantity of the “prn” medication remains unused by the resident, the profile should be reevaluated to determine the necessity of the order as well as the quantity of the prescribed medication. Should the prescriber authorize an additional “prn” medication, then the subsequent dispensed quantity shall be reduced to an amount equal to the utilization of the prior six-month period.

Pharmacies are providing twenty-four hours coverage to the long-term care facilities. Prescription reorders should not be made until a three-day supply remains.

**Co-Payment Exemption**

Long-term care beneficiaries (residing in a nursing facility or ICF/IID) are exempt from co-payments and monthly prescriptions limits.

**NOTE:** Refer to Chapters 26: Intermediate Care Facilities for Individuals with Intellectual Disabilities and 34 – Nursing Facilities of the *Medicaid Services Manual* for detailed information regarding beneficiaries in LTC facilities.

**Over-the-Counter Drugs**

LTC facilities are responsible for providing all OTC drugs to Medicaid beneficiaries. OTC drugs are part of the per diem for LTC beneficiaries.

**Over the Counter Drugs for Preventive Care**

Select OTC agents for preventive care will be reimbursed when:

1. The prescribing practitioner issues the beneficiary a prescription for the preventive care OTC agent; and
2. The beneficiary meets the criteria to obtain the preventive care OTC agent.

| **OTC Drug** | **Medicaid Beneficiary** | **Preventive Care** |
| --- | --- | --- |
| Aspirin 81 mg | Women greater than 12 years of age Men greater than 44 years of age | Cardiovascular disease, colorectal cancer, and preeclampsia prevention |
| Folic Acid 0.4mg and 0.8mg | Women ages 12-54 | Pregnancy planning |
| Vitamin D 400 IU | Women and men greater than 64 years of age | Fall prevention |

**Age Restriction**

Pharmacy claims submitted for beneficiaries outside of the age limits listed above will deny at POS.

**Days’ Supply**

Quantities of 100 units with 100 days’ supply will be allowed to process for payment.

**Copayment**

Pharmacy claims for the select preventive care OTC agents listed above will be exempt from copayment.

Coverage for aspirin 81 mg will be continued for beneficiaries greater than 79 years old; however, these pharmacy claims will be subject to copayment.

**Diabetic Supplies**

Medicaid will not reimburse pharmacies for claims for diabetic supplies when an individual resides in a long-term care facility.

**NOTE:** Refer to “Drugs with Special Payment Criteria/Limitations; Diabetic Testing Supplies” in this section for detailed information.

**Nebulizer Medications**

Medicaid will reimburse pharmacies for the nebulizer medications for those individuals who reside in a long-term care facility who do not have Medicare.

**Medicare Skilled Nursing Facilities**

When a resident of a skilled nursing facility is in Medicare payment status, payment for prescription medications is the responsibility of the facility, as prescription services are included in the per diem paid by Medicare.

**Emergency Kits**

All drugs dispensed from an emergency kit shall be billed to the Medicaid Program indicating the date of service that coincides with the date of administration.

**Outpatient Drugs Covered by Medicare Part B**

Medicare Part B covers oral anticancer drugs, antiemetics, diabetic supplies, glucometers, antihemophilia factor products, oral immunosuppressive drugs, nebulizer medication and some other medications. Providers must be enrolled as Medicare suppliers and must bill Medicare first if the beneficiary receives Medicare benefits. Medicaid will pay any applicable deductibles and coinsurances.

**NOTE:** Refer to Section 37.5.7 Medicare Prescription Drug Coverage for detailed information on drugs covered by Medicare Part B.

**Drug Services for Hospice Beneficiaries**

“Hospice” is a concept that extends a process of care to terminally ill patients.

Hospice is a program of palliative (control of pain and symptoms) and supportive services that provides physical, psychological, social and spiritual care for dying persons and their families. Hospice care concentrates on assuring the quality of the terminal patient’s remaining life rather than on trying to prolong the length of that life.

For Medicare/Medicaid patients who have elected hospice, services covered in the beneficiary’s plan of care should not be billed to Medicaid. These services are covered in the hospice reimbursement.

To ensure the correct billing of drug services, it is imperative that the hospice provider communicate with the pharmacist to verify which drugs are related to the terminal illness (billed to the hospice) and which drugs are not related to the terminal illness (billed to Medicaid). The hospice shall assume that the distinction in billing drugs is understood by enrolled pharmacists who render services to the Medicaid beneficiaries who have elected hospice.

**The pharmacy provider shall bill Louisiana Medicaid for out-patient pharmacy claims only for those drugs unrelated to the terminal illness.**

Recoupment of drug claims erroneously paid to a pharmacy provider through Medicaid for those Medicaid beneficiaries who have elected hospice will be performed as they are identified. Any provider of services to a hospice beneficiary needs to clear with the hospice provider that the billed service is not included in the beneficiary’s plan of care. Erroneous payment will be recouped as identified.

**NOTE:** Refer to Chapter 24 - Hospice of the *Medicaid Services Manual* for detailed information.

**GENERAL PROGRAM INFORMATION**

The Pharmacy Program within the LDH, Bureau of Health Services Financing (BHSF) covers all FDA approved legend drugs that meet the Omnibus Budget Reconciliation Act (OBRA) ‘90 and OBRA ‘93 criteria with a few exceptions. The Pharmacy Program determines the reimbursement methodology for both the drug ingredient cost and the maximum allowable overhead cost (dispensing fee) for covered drugs.

The Pharmacy Program is responsible for the following components:

1. Policy;
2. Program development and implementation;
3. Network development;
4. Program coverage;
5. PDL development and implementation and PA for certain therapeutic classes;
6. Federal upper limit (FUL) for multiple source drugs;
7. Claims management;
8. Annual provider recertification;
9. Clinical interventions;
10. Prospective and retrospective DUR;
11. Federal and state supplemental pharmaceutical manufacturer rebates;
12. Pharmacy provider desk audits;
13. Beneficiary Lock-In program;
14. Provider help desk;
15. Beneficiary help desk;
16. Provider relations; and
17. Provider education for prescribers and pharmacists.

The Pharmacy Program:

1. Initiates policy development;
2. Implements new policies and clarifies existing pharmacy policies, which include the services associated with outpatient drugs and Medicare/Medicaid pharmacy claims crossovers;
3. Approves all new drugs added to program coverage; and
4. Establishes any limitations on reimbursement or coverage in accordance with the federally approved reimbursement methodology.

The Pharmacy Program directs an extensive network of pharmacy providers and is also responsible for the integrity of several subsystems, including the drug file component of reference subsystem, the DUR subsystem and the drug portion of the Surveillance Utilization Review Subsystem (SURS).

**Medicaid Management Information System**

The Medicaid Management Information System (MMIS) is a computerized claims processing and information system designed to manage the Medicaid Program’s expenditures through effective claims processing and utilization control.

LDH contracts with a FI who operates the federally approved MMIS which is consistent with the Centers for Medicare and Medicaid Services (CMS) and LDH requirements.

The FI is contracted to provide the following pharmacy-related services:

1. Pharmacy claim processing through an on-line, real-time POS system;
2. Coordination of the federally mandated Omnibus Budget Reconciliation Act of 1990 DUR Board activities;
3. Retrospective DUR (LaDUR);
4. Prospective DUR (UniDUR);
5. Educational articles - *Provider Update* newsletter article;
6. Lock-In Program;
7. DUR Board coordination;
8. PDL and PA system;
9. Monthly prescription limit system; and
10. Electronic Data Inquiry/Clinical Drug Inquiry System (e-CDI).